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A B S T R A C T
Background
Alpha-glucosidase inhibitors such as acarbose or miglitol, have the potential to improve glycemic control in type 2 diabetes mellitus. The
true value of these agents, especially in relation to diabetes related mortality and morbidity, has never been investigated in a systematic
literature review and meta-analysis.
Objectives
To assess the effects of alpha-glucosidase inhibitors in patients with type 2 diabetes mellitus.
Search methods
We searched The Cochrane Library, MEDLINE, EMBASE, Current Contents, LILACS, databases of ongoing trials, reference lists of
reviews on the topic of alpha-glucosidase inhibitors and we contacted experts and manufacturers for additional trials.
Selection criteria
Randomised controlled trials of at least 12 weeks duration comparing alpha-glucosidase inhibitor monotherapy in patients with type
2 diabetes with any other intervention and that included at least one of the following outcomes: mortality, morbidity, quality of life,
glycemic control, lipids, insulin levels, body weight, adverse events.
Data collection and analysis
Two reviewers read all abstracts, assessed quality and extracted data independently. Discrepancies were resolved by consensus or by the
judgement of a third reviewer. A statistician checked all extracted data entrance in the database. We attempted to contact all authors
for data clarification.
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Main results
We included 41 trials (8130 participants), 30 investigated acarbose, sevenmiglitol, one trial voglibose and three trials compared different
alpha-glucosidase inhibitors. Study duration was 24 weeks in most cases and only two studies lasted amply longer than one year. We
found only few data on mortality, morbidity and quality of life. Acarbose had a clear effect on glycemic control compared to placebo:
glycated haemoglobin -0.8% (95% confidence interval -0.9 to -0.7), fasting blood glucose -1.1 mmol/L (95% confidence interval -1.4
to -0.9), post-load blood glucose -2.3 mmol/L (95% confidence interval -2.7 to -1.9). The effect on glycated haemoglobin by acarbose
was not dose-dependent. We found a decreasing effect on post-load insulin and no clinically relevant effects on lipids or body weight.
Adverse effects were mostly of gastro-intestinal origin and dose dependent. Compared to sulphonylurea, acarbose decreased fasting and
post-load insulin levels by -24.8 pmol/L (95% confidence interval -43.3 to -6.3) and -133.2 pmol/L (95% confidence interval -184.5
to -81.8) respectively and acarbose caused more adverse effects.
Authors’ conclusions
It remains unclear whether alpha-glucosidase inhibitors influence mortality or morbidity in patients with type 2 diabetes. Conversely,
they have a significant effect on glycemic control and insulin levels, but no statistically significant effect on lipids and body weight.
These effects are less sure when alpha-glucosidase inhibitors are used for a longer duration. Acarbose dosages higher than 50 mg TID
offer no additional effect on glycated hemoglobin but more adverse effects instead. Compared to sulphonylurea, alpha-glucosidase
inhibitors lower fasting and post-load insulin levels and have an inferior profile regarding glycemic control and adverse effects.
P L A I N L A N G U A G E S U M M A R Y
Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Alpha-glucosidase inhibitors may be used for patients with type 2 diabetes. They delay the absorbance of carbohydrates (’complex
form of sugar’) in the gut. In this review we present data from meta-analyses that show (among other things) a decrease in glycated
haemoglobin, fasting and post-load blood glucose and post-load insulin. But we found no evidence for an effect on mortality or
morbidity. We found clues that with higher dosages the effect on glycated haemoglobin, in contrast to post-load blood glucose, remains
the same. This might be because a lower compliance due to increasing side-effects.
B A C K G R O U N D
Description of the condition
Diabetes mellitus is a metabolic disorder resulting from a defect in
insulin secretion, insulin action, or both. As a result there is a dis-
turbance of carbohydrate, fat and protein metabolism. Long-term
complications of diabetes mellitus include retinopathy, nephropa-
thy, neuropathy and increased risk of cardiovascular disease. For
a detailed overview of diabetes mellitus, please see under ’Ad-
ditional information’ of the Metabolic and Endocrine Disorders
Group in The Cochrane Library (see ’About the Cochrane Col-
laboration’, ’Collaborative Review Groups’, ’Cochrane Metabolic
and Endocrine Disorders Group’). For an explanation of method-
ological terms, see the main Glossary in The Cochrane Library.
Description of the intervention
Currently, four alpha-glucosidase inhibitors exist: acarbose, migli-
tol, voglibose and emiglitate. Of these, acarbose is by far the most
prescribed drug. In most guidelines it is not a drug of first choice
but used as an addition to other drugs for type 2 diabetes when
treatment goals are not met, or in case of contra-indications for
other medications (EDPG 1999; Rutten 2000). The price of acar-
bose and miglitol is approximately $72 per month for 100 mg
tablets, three times daily.
Because of its lowering effect on the postprandial elevation of in-
sulin levels, a beneficial effect on body weight is to be expected.
Further, a positive effect on hypertriglyceridaemia has been re-
ported (Reaven 1990).
Recently, alpha-glucosidase inhibitors have been put in a new light
as a result of a study on the efficacy of acarbose in patients with im-
paired glucose tolerance (IGT) (Chiasson 2002; Chiasson 2003).
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This study showed that acarbose could prevent or delay the de-
velopment of IGT into type 2 diabetes. Moreover, it showed a re-
duced risk of cardiovascular disease and hypertension in the acar-
bose treated group, but the conclusions of this study are heavily
debated (Kaiser 2004).
Adverse effects of the intervention
Abdominal discomfort like flatulence, diarrhoea and stomachache
are the most frequently occurring adverse effects of alpha-glucosi-
dase inhibitors. Because of their specific working mechanism hy-
poglycaemic adverse events do not occur. They do not increase
insulin output potentially leading to hypoglycaemia.
Existing evidence
Systematic reviews
Some reviews have been published recently on the topic of acar-
bose (Breuer 2003; Laube 2002) and miglitol (Campbell 2000;
Scott 2000), these reviews were not performed systematically with
respect to one or more of the following items: literature search, in-
clusion criteria of studies and quality assessment. In none of these
reviews a meta-analysis was performed.
A recentmeta-analysis of seven trialswith acarbose in the treatment
of type 2 diabetes suggested a significant decrease in the occurrence
of myocardial infarction (Hazard ratio 0.32, 95%CI 0.14 to 0.80)
(Hanefeld 2004). However, we do not support the conclusions
of this meta-analysis because the study was subject to publication
bias, heterogeneity, detection bias and confounding (Van de Laar
2004b).
RCTs
Several randomised clinical trials evaluating the efficacy of alpha-
glucosidase inhibitors as monotherapy or as a combination with
other agents have been published. Most of these evaluated the
efficacy of acarbose.Onemajor trial reported a decrease in glycated
haemoglobin of 0.6%when acarbose was given as sole therapy and
compared to placebo (Coniff 1995).
Another large (n = 1946) randomised clinical trial, per-
formed within the United Kingdom Prospective Diabetes Study
(UKPDS), investigated acarbose versus placebo given in addition
to diet, (combined) oral antidiabeticmedication or insulin therapy
(Holman 1999). At the three-years endpoint, 39% of the patients
in the acarbose group and 58% in the placebo group were still tak-
ing the study medication. The intention-to-treat analysis showed,
that compared with placebo during three years, acarbose lowered
glycated haemoglobin by 0.2% (P = 0.003). When only the pro-
portion of patients that continued to take the study medication
was considered, this difference was 0.5%. The clinical relevance
of this finding remains unclear, especially when considering that
even in the per-protocol analysis for most patients using acarbose
glycated haemoglobin remained higher than 8.0%. Further, data
on other important outcomes like morbidity and mortality are not
available from this study. Adverse effects were mostly of gastro-
intestinal origin (flatulence, stomachache) and were reported to
resolve after a short while.
How the intervention might work
Alpha-glucosidase inhibitors are reversible inhibitors of alpha-glu-
cosidase, an enzyme present in the brush border of the small in-
testine. Alpha-glucosidase inhibitors delay absorption of complex
carbohydrates and thus inhibit postprandial glucose peaks thereby
leading to decreased postprandial insulin levels.
Why it is important to do this review
The scope of the current review was to assess the value of
monotherapywith alpha-glucosidase inhibitors in the treatment of
type 2 diabetes mellitus with respect to patient-oriented outcomes
such as morbidity, mortality and quality of life. Further we inves-
tigated the value of alpha-glucosidase inhibitors with respect to
parameters related to glucose and lipid metabolism, body weight
and adverse events. We sought studies that compared alpha-glu-
cosidase inhibitors with placebo or any other intervention. In the
future, the review will be regularly updated to include relevant
new trials.
O B J E C T I V E S
To assess the effects of alpha-glucosidase inhibitors primarily on
mortality, morbidity and quality of life in patients with type 2 di-
abetes mellitus, and secondly, the effects on parameters represent-
ing glucose and lipid metabolism (that is glycated haemoglobin,
glucose, insulin and cholesterol).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only randomised controlled trials with a minimum duration of
three months were eligible for inclusion in this review. Because
the common adverse effects of alpha-glucosidase inhibitors make
true blinding difficult, both blinded and non-blinded studies were
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included. We included studies published in any language and all
identified trials, published or unpublished, were investigated.
Types of participants
Patients with existing or newly diagnosed type 2 diabetes mellitus.
Changes in diagnostic criteria (ADA 1997; ADA 1999; NDDG
1979; WHO 1980; WHO 1985; WHO 1998) may have pro-
duced variability in the clinical characteristics of the patients in-
cluded as well as in the results obtained. These differences will be
considered and explored in a sensitivity analysis.
Types of interventions
Monotherapy with alpha-glucosidase inhibitors (acarbose, migli-
tol, voglibose, emiglitate) compared with any other intervention:
• placebo;
• sulphonylurea (for example, glibenclamide);
• thiazolidinedione (for example, pioglitazone);
• meglitinide (for example, nateglinide);
• biguanide (for example, metformin);
• insulin;
• any other pharmacological intervention;
• a non-pharmacological intervention (for example, diet
therapy).
Types of outcome measures
Primary outcomes
• mortality: diabetes-related mortality (death from
myocardial infarction, stroke, renal disease, or sudden death,
death from hyperosmolar nonketotic coma), total mortality;
• diabetes-related complications: vascular complications
(angina pectoris, myocardial infarction, stroke, peripheral
vascular disease, amputation), neuropathy, retinopathy,
nephropathy, erectile dysfunction, hyperosmolar nonketotic
dysregulation;
• quality of life, assessed with a validated instrument.
Secondary outcomes
• glycaemic control: glycated haemoglobin levels, fasting and
post-load blood glucose levels;
• plasma lipids (triglycerides, total-, high-density lipoprotein
(HDL)- and low-density lipoprotein (LDL)-cholesterol);
• fasting and post-load insulin and C-peptide levels;
• body weight (or body mass index);
• adverse effects (i.e. diarrhoea, stomachache, flatulence).
Specific patient co-variates thought to be effect modifiers
• compliance
Timing of outcome measurement
We assessed a possible influence of treatment duration in a sensi-
tivity analysis.
Search methods for identification of studies
Electronic searches
We used the following sources for the identification of trials:
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (2003, issue 3);
• MEDLINE (up to April 2003) using the search terms listed
below and combined with the MEDLINE search strategy for
randomised controlled trials from the Cochrane Metabolic and
Endocrine Disorders Group (see review group search strategy),
without language restriction;
• EMBASE (up to April 2003);
• LILACS (www.bireme.br/bvs/I/ibd.htm) from up to April
2003;
• Current Contents (up to December 2003).
• Handsearching: checking references of existing reviews,
checking abstract books and poster displays on congresses or
meetings attended by the first author. The Internet was searches
non-systematically by using different combinations of
(brand)names for alpha-glucosidase inhibitors.
Databases of ongoing trials (latest access April 2003):
• Current Controlled Trials (http://www.controlled-
trials.com - with links to other databases of ongoing trials);
• UK National Research Register (http://www.update-
software.com/National/nrr-frame.html);
• USA - CenterWatch Clinical Trials Listing Service (http://
www.CenterWatch.com/);
• USA - National Institutes of Health (http://
clinicalstudies.info.nih.gov/).
All records from each database that seemed eligible after assessing
the title and/or abstract were imported to a bibliographic database,
Reference Manager (Version 10, ISI ResearchSoft), checked for
duplicates and merged into one core database.
The described search strategy has been used for MEDLINE. For
use with EMBASE and Current Contents this strategy was slightly
adapted because these databases were only available with differ-
ent browsers. The necessary alterations in search string were done
in such a way that the search became more sensitive (that is
yielded a higher number of ’hits’). In CENTRAL, LILACS and
the databases of ongoing trials we searched with the various text
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words for the alpha-glucosidase inhibitors and their brand names.
For the detailed search strategy see Appendix 1.
Searching other resources
Authors of relevant identified studies and other experts were con-
tacted by mail in order to obtain additional references, unpub-
lished trials, and ongoing trials or to obtain missing data not re-
ported in the original trials. Similarly, manufacturers and patent
holders (Bayer AG, Sanofi-Synthelabo, Pfizer, Takeda) were con-
tacted in order to retrieve information on alpha-glucosidase in-
hibitors trials, published and unpublished.
We searched reference lists of relevant trials and alpha-glucosidase
inhibitor reviews and selected possible references that were not
already in our database.
Data collection and analysis
Selection of studies
Two reviewers (FVDL and PL) independently checked the titles,
abstract sections and keywords of every record retrieved. Full ar-
ticles were retrieved for further assessment when the information
given suggested that the study: 1) included patients with diabetes
mellitus, 2) compared alpha-glucosidase inhibitors with placebo
or any other active intervention, 3) assessed one or more relevant
predefined clinical outcomemeasure, 4) used random allocation to
the comparison groups. In case of any doubt regarding these crite-
ria from the information given in the title and abstract, the full ar-
ticle was retrieved for clarification. Interrater agreement for study
selection was measured using the kappa statistic (Cohen 1960).
Differences in opinion were resolved by a third party (EVDL) and
when resolving the disagreement was not possible, the article was
added to those ’awaiting assessment’ and the authors were con-
tacted for clarification. If the authors provided no clarification, the
review group editorial base was consulted.
Data extraction and management
Two reviewers extracted data on intervention and outcomes inde-
pendently, using a pre-tested data extraction form that was adapted
from a standard form provided by the review group. The data ex-
traction form included the following items:
• general information: author, type of publication (including
the existence of duplicate or multiple publications), year of
publication, language, country were the study was conducted,
setting (general practice, hospital or outpatient / rural, city,
developed / developing world / single or multi-centre), the stated
aim of the study published, sponsor(s), ethics approval;
• study characteristics: parallel or cross-over, type of control
groups (placebo, other medication etc.), existence of run-in and/
or wash-out period, description of possible carry-over effect (for
cross-over studies), method, type and quality of randomisation,
method and quality of allocation concealment, method and
quality of blinding, information about handling of drop-outs,
withdrawals and losses to follow-up, numbers of and reasons for
drop-out, existence of possible sub-groups, method of assessment
of compliance;
• participants: description of diagnostic criteria for type 2
diabetes mellitus, inclusion and exclusion criteria,
• interventions: specification of a possible reinforcement of
diet therapy, the nature, dose and regimen (including: fixed or
titrated dose, step-up dosage scheme) of alpha-glucosidase
inhibitor(s) and control interventions, duration of intervention
and follow-up;
• baseline characteristics and measurements: numbers of
patients, sex, age, ethnicity, socio-economic status and duration
of diabetes, existence of significant differences at baseline,
baseline glycated haemoglobin, fasting and post-load blood
glucose, plasma lipids (triglycerides, total-, HDL- and LDL-
cholesterol), height, weight and body mass index (BMI), fasting
and post-load insulin and C-peptide (standard deviations if
applicable), specifications (including reference ranges) of all
laboratory measurements, type of post-load test, time between
fasting and post-load measurements, centralisation of laboratory
measurements;
• outcomes: total and disease specific deaths and morbidity,
quality of life (including method of assessment), mean changes
(standard deviation, SD) of the following values: glycated
haemoglobin, fasting and post-load blood glucose, lipids, fasting
and post-load insulin / C-peptide, body weight, BMI, occurrence
of adverse events (total and gastro-intestinal), compliance.
When more than one publication was available from a study, all
articles were abstracted and scores separately and the collected data
was synthesized. In case of contradictorily findings, the author was
contacted for clarification.
Differences in data extractionwere resolved by consensus, referring
back to the original article. If necessary, information was sought
from the authors of the original studies.
If necessary, data were also extracted from graphical figures: two
reviewers (FVDL and PL) calculated the data independently and
if both outcomes were not similar, a third reviewer (EVDL) recal-
culated the data. A statistician checked all extracted data for errors,
after transfer to the database.
Assessment of risk of bias in included studies
The two reviewers assessed each trial independently. Possible dis-
agreement was resolved with consensus, or with consultation of a
third reviewer (EVDL) in case of disagreement. In particular, the
following quality criteria were assessed:
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Minimisation of selection bias
• Randomisation procedure: the randomisation procedures
were scored adequate if the resulting sequences were
unpredictable (that is computer generated schemes, tables of
random numbers, coin tossing).
• Allocation concealment: allocation concealment was scored
adequate if participating patients and investigators could not
foresee the assignment (that is by central randomisation remote
from trial site, sequentially numbered and sealed radio-opaque
envelopes).
Minimisation of performance bias
• Method of blinding: blinding was considered adequate if
the two (or more) interventions were similar in size, colour and
shape or when a double-dummy method was applied. Because of
the sometimes-obvious adverse effects of alpha-glucosidase
inhibitors, true blinding was difficult. For trials that reported
blinding of patients for medications, we also investigated
whether blinding was checked; for example by asking patient and
investigator afterwards about the medication they suspected to
be supplied.
Minimisation of attrition bias
• Handling of drop-outs: handling of drop-outs was
considered adequate if studies gave a complete description of all
patients failing to participate until the end of the trial and if the
data were analysed on intention-to-treat (ITT) basis, that means
with all randomised patients included.
• Quantity of dropouts: overall dropout rate less than 15%
was considered adequate.
• Selective dropout: a difference in dropout rate the in main
treatment groups less than 10% was considered adequate.
Minimisation of detection bias
• Method of blinding outcome-assessment: this item was
considered less relevant for studies with laboratory data or death
as main outcomes or if the (blinded) investigator was also
outcome assessor. If applicable, outcome assessment was
considered adequate if the outcome assessors were completely
blind for the intervention.
We explored the influence of individual quality criteria in a sensi-
tivity analysis (see under ’sensitivity analyses’).
Based on these criteria, studies were broadly subdivided into the
following three categories adapted from the Cochrane Handbook
criteria (see Cochrane Handbook):
A - All quality criteria met (1. adequate randomisation and alloca-
tion concealment, 2. adequate blinding, 3. adequate ITT analysis
and/or both drop-out rate less than 15% and selective drop-out
less than 10%): low risk of bias.
B - One or more quality criteria only partially met (1. adequate
randomisation or adequate allocation concealment, 2. mentioning
of blinding but exact method unclear, 3. inadequate/unclear ITT
analysis but drop-out less than 15% or selective drop-out less than
10%): moderate risk of bias.
C - One or more quality criteria not met (1. inadequate randomi-
sation and allocation concealment, 2. inadequate or no blinding,
3. inadequate ITT and drop-out rate equal to or more than 15%
and selective drop-out equal to or more than 10%): high risk of
bias.
This adapted classification was also used as the basis of a sensitivity
analysis.
Data synthesis
Data were summarised statistically if available and of sufficient
quality. The table of comparison was first divided in all possible
comparisons (that is acarbose versus placebo / voglibose versus
sulphonylurea), then sub-divided into all possible outcomes (that
is death, glycated haemoglobin adverse events) and finally, within
the outcomes sub-groups were made for the different dosages.
Outcomes were calculated per sub-group and for all sub-groups
together.
Dichotomous data were expressed as odds ratios (OR), but in
some cases the relative risk (RR) was also calculated in addition to
the OR since its interpretation is easier, especially if the outcome
was a negative event, for example death. We calculated the risk
difference (RD) andwe converted the RD into the number needed
to treat (NNT) or the number needed to harm (NNH) taking
into account the time of follow-up.
Continuous data were expressed as weighted mean differences
(WMD) and an overallWMDwas calculated. The actual measure
of effect of all continuous variables were the differences from base-
line to endpoint. The standard deviations of these differences were
essential for the data to be included in the meta-analysis. When
the standard deviation (SD) of the difference was not reported we
first asked the authors to provide these data. If the SDs were not
provided we estimated the SD of the difference with the following
formula:
SDpaireddifference = ??(SD1)2 + (SD2)2 - 2 x r x SD1 x SD2].
SDpaireddifference = standard deviation of the difference (pre- /
post-treatment)
SD1 = Standard deviation of the pre-treatment value, SD2 = Stan-
dard deviation of the post-treatment value, r = correlation coeffi-
cient. We used a conservative correlation coefficient of 0.4.
Overall results were calculated based on the random effects model.
Heterogeneity was statistically tested by using the Z score and
the Chi square statistic with significance set at P < 0.10. Possible
sources of heterogeneity were assessed by subgroup, sensitivity and
meta-regression analyses as described below. Small study bias was
tested for using the funnel plot or other corrective analytical meth-
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ods depending on the number of clinical trials included in the
systematic review (Begg 1994; Egger 1997; Hedges 1992). Quan-
tification of the effect of heterogeneity will be assessed by means
of I squared, ranging from 0-100% including its 95% confidence
interval (Higgins 2002). I squared demonstrates the percentage of
total variation across studies due to heterogeneity and will be used
to judge the consistency of evidence.
The analyseswere donewith the computer programRevManAnal-
yses 1.0.2 in Review Manager 4.2.3 (2003, The Cochrane Col-
laboration).
Subgroup analysis and investigation of heterogeneity
Significant main outcome measures were explored by subgroup
analyses in order to explore differences in effect as follows:
• glycated haemoglobin level at baseline (subdividing into
three groups: less than 7%, 7 to 9%, more than 9%);
• age (based on mean age of total randomised group);
• gender (subdivided in two groups, based on data: less than
45% female, equal or more than 45% female);
• body mass index (BMI) (Normal: male less than 27, female
less than 25; overweight: male 27 to 30, female 25 to 30; obese:
more than 30);
• different kind of diets or exercise schedules used;
• duration of intervention (less than 24 weeks, 24 weeks,
more than 24 weeks);
Sensitivity analysis
The sensitivity of the analysis for a number of factors was deter-
mined by comparing the results of the meta-analysis for studies
with and without certain characteristics. Data from a minimum
of five studies had to be available for both groups to be considered.
The following factors were investigated:
• comparing published and unpublished studies;
• comparing studies with and without (or with unknown)
quality characteristics: adequate randomisation, adequate
allocation concealment, adequate method of blinding, adequate
ITT analyses. Further, comparing studies with an overall drop-
out rate equal to or more than 15% and less than 15%,
difference of drop-out rates less than 10% and equal to or more
than 10% between the main treatment groups. In addition, the
overall score for quality based on the adapted Cochrane criteria
was used so that studies with score A and B were compared with
studies with C;
• repeating the analysis excluding trials using the following
filters: diagnostic criteria, language of publication, source of
funding (industry versus other or no sponsoring) or country;
• repeating the analyses using different measures of effect size
(relative risk, risk difference) and different statistical models
(fixed and random effects models);
Meta-regression analyses
We used meta-regression analyses (in SAS proc MIXED, version
8.0) to explore the influence of characteristics of study population
and study design on the outcomes.We studied the dependent vari-
ables glycated haemoglobin, fasting and post-load glucose, fasting
and post-load insulin, total cholesterol, triglycerides and adverse
effects. The independent variables were similar to the pre-defined
sub-groups (baseline glycated haemoglobin, age, gender, baseline
BMI, and duration of treatment). In addition we studied duration
of diabetes at baseline, the use of a fixed dose and the use of a
step-up dosage regimen. The weight of each trial was equal to the
inverse sum of the within trial variance and the residual between
trial variance, in order to perform a random effects analysis. To
gain sufficient power, data from at least 10 studies had to be avail-
able to calculate results from the meta-regression.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
Trials identified
For details see Figure 1
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Figure 1. Flow chart of study selection
* CENTRAL: 262 records were retrieved and assessed on the basis
of title and/or abstract (Issue 3 2003), 59 records were initially
included. Ten records were excluded after the full article had been
read. So 49 records were finally included in the review.
*MEDLINE: 328 records found (April 2003), 43 records initially
included, 34 records finally included in the review.
* Embase: 567 records found (April 2003), 50 records initially
included, 40 records finally included in the review.
* Current Contents (December 2003): 260 records found, 27
records initially included, 23 records finally included in the review.
* LILACS: 13 records found, one records initially but excluded
after further scrutiny.
Experts: We obtained 14 references as a result of correspondence
with experts: seven references after a general mailing to 27 ex-
perts with a request for additional references (six out of 27 forms
were returned), and another seven references as a result of contacts
which we established searching formissing or additional data. Two
references were already in our possession (one study performed by
our group but that was not published at that time (Van de Laar
2004a) and an article referring to two trials (Fölsch 1990, using
data from Hoffmann 1990 and Spengler 1992).
We included nine (out of these 16) references in the final review.
Manufacturers: Bayer, the developer of acarbose and miglitol, sent
us 23 references, 17 were initially included and 16 were finally in-
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cluded in the review. The developer and patent holder of voglibose
(Takeda) and the patent holders of miglitol (Pfizer and Sanofi-
Synthelabo) did not reply to our letters.
Handsearch: 22 possibly eligible references were found by hand-
searching (checking references of existing reviews, browsing on
the internet, posters on congresses etc.). Seventeen references were
initially included, of which 14 references were finally included in
the review.
Databases of ongoing trials (see table Characteristics of ongoing
trials): in addition three studies were identified as ongoing studies
in trial registers. All attempts to retrieve reports or data from these
studies, failed so far.
Interrater agreement
Interrater kappa for agreement on inclusion, calculated on basis
of the first 852 titles and / or abstracts read by the two reviewers
(FVDL and PL) was good: 0.74 (95% confidence interval 0.67 to
0.81). All differences in opinion were resolved by consensus.
Missing data
Because none of the articles contained all the study data we re-
quired for the quality assessment and meta-analyses, we attempted
to contact all corresponding authors. For one study we could not
retrieve contact information (Hillebrand 1987). For 22 out of 41
studies we received additional data about design, quality and/or
outcomes. For 12 studies the authors delegated the reply to repre-
sentatives of Bayer Germany, USA or Italy because the data-files
were kept by this firm. Studies for which we received additional
data are indicated in the table ’Characteristics of included studies’
and the reference list (published and unpublished data).
Measurement of post-load blood glucose, insulin and c-
peptide
There are several methods to determine the patients’ response to a
glucose load. The ’load’ may consist of simple glucose (like in an
oral Glucose Tolerance Test, oGTT), a standardised or ad libitum
meal, or a standardised portion of carbohydrates. Studies may also
differ in the time-interval used for the test and if the study drug
was given prior to the test. We assessed all those differences and
described them in a table (Table 1). Most studies used some form
of test-meal with carbohydrates, except for two studies which used
an OGTT (Hotta 1993; Van de Laar 2004a). In two studies the
type of test was unclear (Hillebrand 1987; Rybka 1999).
For two studies, the only post-load measurement was at a 2-hours
interval (Hotta 1993; Pagano 1995) and six studies reported both
one and two hour values (Chiasson 2001; Coniff 1994; Coniff
1995; Coniff 1995b; Kawamori 2003; Santeusanio 1993), all
other studies that measured post-load values for glucose, insulin
and/or C-peptide used an 1-hour interval. Therefore, we chose
to report the 1-hour values for post-load glucose, insulin and C-
peptide, and to use the 2-hour outcomes if 1-hour data were not
available. As a sensitivity analysis, we repeated the analysis with the
opposite method: using the 2-hour values, and the 1-hour values
for studies that did not report 2-hour measurements.
Included studies
Fourty-one studieswith 8130participants, described in 69 articles,
abstracts, posters or unpublished documents were finally included
in the review. Details are given in the Table of included studies.
Thirty-five studies were published as journal articles, three studies
as abstract only (Campbell 1998; Hillebrand 1987; Rybka 1999)
and two studies were found by their poster presentation (Holmes
2001; Kawamori 2003), one study done by our own group was
accepted for publication during the review process (Van de Laar
2004a).
Four studies were performed in general practice, for one study
the patients were recruited in general practice but all study related
activities were done in so-called ’study-centres’ (Drent 2002), pa-
tients from 34 studies were characterised as ’outpatients’ and for
two studies the setting was not reported.
Thirty-nine studies had a parallel design and two were crossover
studies (Gentile 1999,Hillebrand1987). Thirty-three studieswere
double-blinded, five studies were not blinded and three studies
with three treatment groups were not blinded with respect to one
treatment arm (metformin and glibenclamide).
Nineteen studies compared acarbose with placebo, four of which
compared two or more doses with placebo. Eleven studies com-
pared acarbose with other anti-diabetic medication and in most
cases also with placebo. Miglitol was studied in comparison with
placebo in three studies, one of which with four different dosages.
In four studies miglitol was compared with other anti-diabetic
medication (and placebo eventually). Two three-arm studies com-
pared acarbose with miglitol and placebo (one study) or gliben-
clamide (one study). One study compared miglitol and voglibose
(and placebo) and one trial studied voglibose versus diet and gly-
buride (a sulphonylurea). We found no studies with emiglitate.
Study durationwas 24weeks (21 studies), 16weeks (seven studies),
one year (four studies), 12 weeks (four studies), three years (two
studies), 30 weeks, 36 weeks or 56 weeks (all one study).
Two studies reported data on mortality (Coniff 1995; Johnston
1998) and one crossover study reported that no patients had died
(Gentile 1999). Two studies reported data on morbidity (Holman
1999; Johnston 1998) and one study reported quality of life as an
outcome (Meneilly 2000), but none of these data were primary
efficacy measures.
Excluded studies
Fifteen studies were excluded after reading the full article (see
Figure 1). The most common reason was that patients used anti-
diabetic medication in addition to the study medication. See table
’Charcteristics of excluded studies’ for further details.
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Risk of bias in included studies
For details on risk of bias see Figure 2.
Figure 2. Risk of bias data
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Methodological quality
With respect to selection bias 11 studies had both an adequate
randomisation and allocation concealment. The risk of attrition
bias was low in 14 studies: one study had adequate ITT; one study
had both adequate ITT analysis and low total / selective drop-out
(less than 15% total drop-out, less than 10% difference between
groups); 12 studies had low total / selective drop-out. Blinding
(performance bias) was adequate in 22 studies.
The overall quality was roughly assessed on a three point scale
according to the Cochrane handbook: five studies scored A (low
risk of bias) and five studies B (moderate risk of bias). The other
31 studies scored C (high risk of bias).
Missing data
In a number of cases it was reported that certain outcomes (that is
fasting blood glucose, triglycerides) were investigated, but the re-
sults were not or insufficiently reported (that is standard deviations
missing). This was especially striking for a study with acarbose,
that was of long duration and with a large number of participants
(Campbell 1998). Data from this trial could not be used because
the main outcome measure was the time until patients with good
control on diet alone needed additional medication. Data from a
large study of long duration investigating miglitol could not be
used as no measures of variance were reported for the main out-
comes (that are standard deviations) (Johnston 1998). Our writ-
ten request for these data, has not been answered so far.
One large study (603 participants) comparing miglitol and acar-
bose was published as an abstract only (Rybka 1999). Attempts to
contact the author failed so far.
Effects of interventions
Heterogeneity
Statistical tests for heterogeneity yielded statistically significant
results inmany cases. Studies were homogenouswith respect to the
fact that all participants were described as having type 2 diabetes
and that they used the test drug as mono therapy for at least three
months. But studies could differ with respect to country (and
thus dietary habits), age, severity and duration of diabetes. These
possible sources for heterogeneity were investigated in the sub-
group and meta-regression analyses.
Mortality, morbidity, quality of life
Three studies reported the occurrence of death (Coniff 1995;
Holman 1999; Johnston 1998). No statistically or clinically sig-
nificant differences in outcomes were found.
One 3-year study reported data on morbidity as relative risks
(Holman 1999). The relative risk for acarbose users compared
with placebo for “any diabetes-related end point” was 1.0 (95%
confidence interval 0.8 to 1.2) and for microvascular disease 0.9
(95% confidence interval 0.6 to 1.4). The outcome for the sub-
group actually receiving acarbose monotherapy was not reported.
One 56-weeks study that compared 25 mg and 50 mg TID migli-
tol with glyburide and placebo, reported the number of cardiovas-
cular events in the table of adverse effects (Johnston 1998). The
percentage of occurrence of any cardiovascular event was 19%,
17%, 22% and 29% for miglitol 25 mg TID, miglitol 50 mg
TID, placebo and glyburide respectively. Statistical significance
was reached for the comparison miglitol 50 mg and glyburide.
Glycemic control
Glycated haemoglobin, alpha-glucosidase inhibitors versus
placebo
alpha-glucosidase inhibitors had a clear beneficial effect on
glycemic control compared to placebo. Glycated haemoglobin was
considered the primary measurement in most studies. The results
of themeta-analysis for overall effect of alpha-glucosidase inhibitor
on glycated haemoglobin compared to placebo was -0.8% (95%
confidence interval -0.9 to -0.6, 28 comparisons) for acarbose and
-0.7% (95% confidence interval -0.9 to -0.4, seven comparisons)
for miglitol. For voglibose, data from only one comparison were
available: -0.5% (95% confidence interval -0.6 to -0.3). We did
not see a clear dose dependency of the effect on glycated haemo-
globin with respect to acarbose. Effect sizes for the subgroups for
dosage 25 mg (n = 1 study), 50 mg (n = 2), 100 mg (n = 17), 200
mg (n = 4) and 300 mg (n = 2) TID were -0.5%, -0.9%, -0.8%,
-0.8% and -0.8% respectively.
Formiglitol, there seemed tobe a dose dependent effect on glycated
haemoglobin, but data from only seven comparisons, of which
four originating from the same multi-arm study (Drent 2002),
were available.
Fasting and post-load blood glucose, alpha-glucosidase
inhibitors versus placebo
We also found a beneficial effect on fasting blood glucose for acar-
bose compared to placebo in a meta-analysis with 28 comparisons:
-1.1 mmol/L (95% confidence interval -1.4 to -0.8). For migli-
tol and voglibose two and one comparisons were available in the
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meta-analysis with fasting blood glucose as outcome. These anal-
yses resulted in a mean decrease in fasting blood glucose of -0.5
mmol/L (miglitol, 95% confidence interval -0.9 to -0.2) and -0.6
mmol/L (voglibose, 95% confidence interval -1.0 to -0.2).
The influence on (1-hour) post-load blood glucose was more pro-
found. Overall effect on post-load blood glucose was -2.3 mmol/L
(95% confidence interval -2.7 to -1.9, 22 comparisons). The sub-
groups for dosage showed a dose dependent pattern. For miglitol
and voglibose only very limited data were available: miglitol -2.7
mmol/L 95% confidence interval -5.5 to 0.1, two comparisons),
voglibose -2.4 mmol/L (95% -3.0 to -1.8, one comparison).
In contrast to the effect on glycated haemoglobin, the forest plots
for the comparison acarbose versus placebo and the outcome fast-
ing and post-load blood glucose suggested a dose dependency of
the treatment effect.
Because not all studies used similar methods for the measurement
of post-load blood glucose we repeated the analyses replacing 1-
hour post-load data by 2-hour values (if available). We found no
differences in that analysis compared with the meta-analysis in
which we primarily used the 1-hour values.
Alpha-glucosidase inhibitors versus other medication
Studies that compared an alpha-glucosidase inhibitor with other
interventions than placebo were scarce. Pooling of results was only
possible for the comparison acarbose with sulphonylurea, as data
from eight comparisons were available. For other comparisons,
pooling was not possible because of lack of studies (metformin
and nateglinide, both one study). The overall comparison acarbose
versus sulphonylureas yielded a non-significant trend for sulpho-
nylureas with respect to glycated haemoglobin (0.4%, 95% confi-
dence interval -0.0 to 0.8). The results in the subgroup ’Acarbose
100 mg TID versus Glibenclamide 3.5 mg TID’ were not consis-
tent with the other comparisons (overall test for heterogeneity p <
0.00001). Leaving the entire sub-group out of the analysis would
give an overall effect of 0.6% (95% confidence interval 0.3 to 1.0)
in favour of sulphonylurea with a non-significant chi-square test
for heterogeneity (p = 0.15). In the comparison acarbose versus
sulphonylurea one study seemed tobe anoutlier (Kovacevic 1997),
but the results of that study were again in line with the compar-
isons with other sulphonylurea. For most comparisons acarbose
versus sulphonylurea, acarbose was given as a fixed dose and the
sulphonylurea individually adjusted, mostly sub-maximal.
The result for fasting blood glucose showed a similar pattern: su-
periority for sulphonylurea except for the subgroup ’Acarbose 100
mg TID vs. Glibenclamide 3.5mg TID’. Overall effect 0.7mmol/
L (95% confidence interval 0.2 to 1.2) in favour of sulphonylurea.
Without the deviating sub-group: 1.2 mmol/L (95% confidence
interval 0.6 to 1.8) in favour of sulphonylurea.
The outcome post-load blood glucose yielded no statistically sig-
nificant differences between acarbose and sulphonylurea.
Results from studies not included in the meta-analyses
In a four-arm study comparing miglitol 25 mg TID, miglitol 50
mg TID, glyburide maximum 20 mg QD or placebo, glycated
haemoglobin decreased by 0.5%, 0.4%, 0.9% and 0.0% respec-
tively (Johnston 1998). Similarly fasting blood glucose decreased
by 0.7 mmol/L, 1.1 mmol/L, 1.7 mmol/L and 0.1 mmol/L and
one hour post-load blood glucose decreased by 2.4 mmol/L, 3.2
mmol/L, 1.8 mmol/L and 0.0 mmol/L respectively.
One study with 603 participants and of 24 weeks duration (Rybka
1999) reported a placebo subtracted decrease of glycated haemo-
globin of 0.4%, 0.5% and 0.4% respectively for miglitol 50 mg
TID, miglitol 100 mg TID and acarbose 100 mg TID.
Plasma lipids
We found no effects of acarbose compared to placebo on total,
HDL- and LDL-cholesterol. There was no statistically significant
effect on triglycerides: -0.1 mmol/L (21 comparisons, 95% confi-
dence interval -0.2 to 0.0). With respect to the comparison with
sulphonylurea no statistically significant differences were found.
Very few comparisons (arcabose versus metformin etc.) were avail-
able.
Fasting and post-load insulin and C-peptide
The 25 studies that assessed pancreatic function mostly used in-
sulin levels for this purpose.We found that acarbose hadno statisti-
cally significant effect on fasting insulin levels compared to placebo
and a non-statistically significant decreasing effect on post-load
insulin levels (fasting insulin: -1 pmol/L (15 comparisons, 95%
confidence interval -8 to 7), post-load insulin: -41 pmol/L (13
comparisons, 95% confidence interval -61 to -19)). For miglitol
and voglibose only a limited number of comparisons were avail-
able and no statistically significant differences were found.
Compared to sulphonylurea, acarbose had a statistically significant
decreasing effect on fasting insulin (seven comparisons, -25 pmol/
L, 95% confidence interval -43 to -6) and post-load insulin as well
(seven comparisons, -133 pmol/L, 95% confidence interval -185
to -82). Only one study compared miglitol with a sulphonylurea
and found an opposite result: fasting insulin 28 pmol/L increase
compared to sulphonylurea (Pagano 1995). Post-load insulin was
not measured in that study.
Body weight and body mass index (BMI)
Compared to placebo, alpha-glucosidase inhibitors had minimal
effects on body weight. There were no statistically significant dif-
ferences for body weight in the meta-analysis for acarbose versus
placebo, but BMI decreased slightly in favour of acarbose: -0.2 kg/
m2 (13 comparisons, 95% confidence interval -0.3 to -0.1).
The reported advantage for alpha-glucosidase inhibitors on body
weight compared to sulphonylurea could not be confirmed: no
significant differences were found.
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Adverse events
Most studies reported the total number of adverse events and al-
though it became clear from most reports that by far the most
adverse effects were of gastro-intestinal origin, the number of pa-
tients with gastro-intestinal adverse effects were rarely reported
exactly.
Compared to placebo, patients treated with acarbose reported sig-
nificantly more adverse effects: OR 3.4 (or relative risk 1.4) (23
comparisons, 95% confidence interval 3.4 to 4.4). There was a
dose dependent increase in adverse effects in the range 25 mg
TID to 200 mg TID. When the sub-group for studies that ap-
plied a fixed dosage scheme (in contrast to studies with an indi-
vidually titrated dose) was considered, the dose dependency was
more clear: ORs for adverse events were 1.6, 2.9, 4.1, 7.0 and 8.3
for the dosages 25, 50, 100, 200 and 300 mg TID respectively.
Most studies reported that the adverse events mainly consisted of
gastro-intestinal symptoms. The meta-analysis on gastro-intesti-
nal adverse events yielded a similar result: OR 3.30 (or relative
risk 1.8) (four comparisons, 95% confidence interval 2.2 to 4.7).
The comparison miglitol versus placebo resulted in similar figures:
all adverse events OR 4.0 (seven comparisons, 95% confidence
interval 1.7 to 9.5).
Compared to sulphonylurea, patients treated with acarbose had
more adverse effects: OR 4.0 (seven comparisons, 95% confidence
interval 2.0 to 7.8). Only two studies provided data for the com-
parison miglitol versus sulphonylurea: OR 1.3 (95% confidence
interval 0.7 to 2.4).
Sensitivity analyses
We compared outcomes of meta-analyses between studies with
and without certain characteristics. The results were considered
of possible interest when the 95% confidence intervals of the two
groups in the analysis (for example results from studies with ad-
equate randomisation versus inadequate randomisation) did not
overlap, or when one group yielded a statistically significant result
whereas the other did not. At least five studies had to be in each
groups to be considered, this was only the case for the comparison
acarbose versus placebo.
Unpublished versus published studies
By the time the analyses were done, one study that was initially in-
cluded as unpublished study was published (Van de Laar 2004a).
All other studies were published in some form. Some studies were
published otherwise than as a journal article: letter-to-the-edi-
tor (Calle-Pascual 1996) or congress abstract (Campbell 1998,
Hillebrand 1987, Holmes 2001, Kawamori 2003, Rybka 1999).
Because data from three of these studies could not be included in
the meta-analysis, sensitivity analysis was not possible.
Methodological quality criteria
Randomisation: studies with inadequate or unclear randomisation
showed a beneficial effect of acarbose on total cholesterol: -0.3
(95% CI -0.5 to -0.0) versus 0.0 (95% CI -0.1 to 0.1) for stud-
ies with adequate randomisation. No other differences between
studies with adequate and inadequate/unclear randomisation were
found.
Allocation concealment: the studies with adequate allocation con-
cealment showed a slightly more profound effect on glycaemic
control although not statistically significant: glycated haemoglo-
bin -0.8% (adequate allocation concealment) versus -0.7 (not ad-
equate or unclear).
Blinding: we found no differences between studies with no or
inadequate blinding and studies with adequate blinding.
ITT adequate: only two studies were considered to have done ad-
equate ITT analyses, therefore sensitivity analyses were not possi-
ble.
Total dropout rate: studies with a total dropout rate less than 15%
showed a beneficial effect on post-load insulin levels compared to
studies with a total dropout rate equal to or more than 15%: -52
(95% confidence interval -77 to -29) versus -18 (95% confidence
interval -55 to 19). No other differences between studies with high
or low drop-out rates were found.
Selective drop-out (difference in drop-out between treatment
groups): we found no differences between studies with selective
dropout rate less than 10% or equal to or more than 10%.
Overall quality: studies with a overall quality A or B (high) showed
a beneficial effect on post-load insulin levels compared to studies
with an overall quality score of C (low): -46 (95% confidence
interval -64 to -29) versus -8 (95% confidence interval -68 to 52).
No other differences were found.
Other
Diagnostic criteria
Eight studies referred to the WHO criteria from 1985 (WHO
1985), three studies to the criteria from theNationalDiabetesData
group 1979 (NDDG 1979), two studies referred toWHO criteria
of unknown data, one study referred to both ADA guidelines from
1997 (ADA 1997) and WHO guidelines from 1987 (unknown
origin, no reference given), one study used the so-called UKPDS
protocol (Holman 1999) and one study referred to diagnostic cri-
teria of the Japan Diabetes Society. Twenty-five studies did not re-
fer to specific diagnostic criteria of type 2 diabetes. Although most
studies referred diagnostic criteria (that is fasting blood glucose
more than 7.8 mmol/L), it was often not clear whether these cri-
teria were used for the trial selection or for the original diagnosis.
Sensitivity analysis was not possible with these data.
13Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Language of publication
For most included studies the primary publication was in English,
with exception of one study in Russian (Dedov 1995) and one in
the Italian language (Gentile 1999). Thus, sensitivity analysis was
not performed.
Source of funding
For one study the authors made clear that it was not sponsored
(Calle-Pascual 1996), two study were sponsored by fundings other
than a pharmaceutical company (Gentile 1999, Haffner 1997),
for five studies possible sponsoring was not specified and all other
studieswere sponsored by a pharmaceutical company. Accordingly,
sensitivity analysis was not performed.
Country
Twenty-five studies were conducted in Europe (including one Rus-
sian study), nine studies in the USA or Canada, six studies in Asia
(including one Turkish study) and one study was performed in
New Zealand and Australia.
European studies versus non-European studies: studies that were
conducted in Europe showed a tendency towards a greater effect
on glycated haemoglobin (-0.9%, 95% confidence interval -1.0 to
-0.7) compared to non-European studies (-0.7%, 95% confidence
interval -0.8 to -0.5). On the other hand, the effect on post-load
blood glucose was significantly less than for the non-European
studies: -1.9 mmol/L (95% confidence interval -2.2 to -1.5) for
the European studies versus -3.3 mmol/L (95% CI -4.2 to -2.3)
for the non-European studies. These differences could not be fully
explained when the Asian studies were excluded from the analyses.
We also compared the Asian studies with non-Asian studies sep-
arately because of the high carbohydrate food habits in Asia. The
analyses with Asian studies only yielded a lower effect on glycated
haemoglobin compared with the analyses with non-Asian studies
(-0.5% versus -0.8%) but in the Asian group only three compar-
isons were available.
Different statistical models
We repeated the analyses for all outcomes using a fixed effects
model. This yielded similar results with only two exceptions: 1) the
effect on fasting insulin levels in the comparison acarbose versus
placebo was statistically significant with a fixed effects model (5
pmol/L in favour of placebo, 95% confidence interval 1 to 10)
2) the effect on body weight in the comparison acarbose versus
sulphonylureawas statistically significantwith a fixed effectsmodel
(-1.4 in favour of acarbose, 95% confidence interval -1.9 to -0.9).
Sub-group analyses (tables available on request)
• subgroups baseline glycated haemoglobin: Subgroup 1a
(acarbose - placebo), Subgroup 1b (tables available on request)
(acarbose - sulphonylurea). The effects on glycated haemoglobin
and post-load insulin tended to be more profound with higher
baseline glycated haemoglobin;
• subgroups gender: Subgroup 2a, Subgroup 2b (tables
available on request). No significant differences between studies
with less and more or equal than 45% female participants were
observed;
• subgroups baseline BMI: Subgroup 3a, Subgroup 3b (tables
available on request). No significant differences between studies
in patients with different mean baseline BMI values were
observed;
• subgroups study duration: Subgroup 4a, Subgroup 4b
(tables available on request). We found a tendency towards a
lower effect in studies that lasted longer than 24 weeks. The
effect on glycated haemoglobin was -0.8%, -0.8% and -0.5% for
studies less than 24, 24 and more than 24 weeks respectively.
However only three studies were included in the latter (more
than 24 weeks) categorie.
In addition to the pre-defined sub-groups, we also investigated the
following subgroups: different duration of diabetes (mean dura-
tion of diabetes less or equal/more than 55 months), groups with
a step-up dose regimen versus studies that administered the full
dose at once and studies that used a fixed dosage scheme versus
studies with an individually titrated scheme.
• subgroups mean duration of diabetes: Subgroup 5a,
Subgroup 5b (tables available on request). No significant
differences between studies in patients with a mean duration of
diabetes less or equal/more 55 months were observed;
• subgroups step-up dosage versus no step-up dosages: Studies
investigating acarbose versus placebo that used a step-up dosing
schedule, tended to result in less effect on glycated haemoglobin,
fasting and post-load blood glucose than studies that gave the
full dose at once. On the other hand, the latter studies reported
more adverse effects. The 95% confidence intervals for fasting
blood glucose and adverse effects in both groups did not overlap
indicating statistical significance (Subgroup 6a).
This effect was also found in the comparison acarbose versus
sulphonylurea. (Subgroup 6b) (tables available on request)
• subgroups fixed dose versus individually titrated: Subgroup
7a, Subgroup 7b (tables available on request). Studies that used a
fixed dose showed more profound effect on glycated
haemoglobin (-0.8% versus -0.5%) with no different effect on
fasting blood glucose.
Meta-regression analyses (tables available on request)
For the comparison acarbose versus placebo, sufficient data were
available to perform meta-regression analyses.
Glycated haemoglobin: regression coefficient for mean baseline
glycated Hb was -0.12, indicating a decrease in outcome value
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of 0.12% per 1% increase of baseline glycated Hb. The use of a
fixed dosage yielded a regression coefficient of -0.32 (95% CI -
0.69 to 0.04) and a step-up dosage scheme regression coefficient of
0.36 (95% CI 0.06 to 0.66), thus having an increasing influence
on glycated haemoglobin (Metaregression 1, table available on
request).
Fasting blood glucose: use of a step-up dosages scheme had a dete-
riorating effect on the outcome: correlation coefficient 0.62 (95%
CI 0.05 to 1.19) (Metaregression 2, table available on request).
Post-load blood glucose: no statistically significant effects were
found (Metaregression 3, table available on request).
Total cholesterol: no statistically significant effects were found
(Metaregression 4, table available on request).
Triglycerides: no statistically significant effects were found
(Metaregression 5, table available on request).
Fasting insulin: no statistically significant effects were found
(Metaregression 6, table available on request).
Post-load insulin: no statistically significant effects were found
(Metaregression 7, table available on request)
Body weight: no statistically significant effects were found
(Metaregression 8, table available on request).
Total adverse effects: The use of a step-up dosing scheme had
a statistically significant decreasing effect on the occurrence of
adverse effects (regression coefficient 0.50, 95% CI 0.29 to 0.88)
(Metaregression 9, table available on request).
D I S C U S S I O N
Summary of main results
In this systematic review, we found no statistically significant ef-
fect for an effect of alpha-glucosidase inhibitors onmortality, mor-
bidity and quality of life in patients with type 2 diabetes mel-
litus. Compared to placebo, alpha-glucosidase inhibitors reduce
glycated hemoglobin (0.8% acarbose, 0.7% miglitol), fasting and
postprandial blood glucose (acarbose: fasting glucose 1.1 mmol/
L, post-load blood glucose 2.3 mmol/L) and post-load insulin.
We found no clinically relevant effects on plasma lipids and body
weight. We found no dose dependency for the effect on glycated
haemoglobin for acarbose. alpha-glucosidase inhibitors caused sig-
nificant more adverse effects, especially of gastro-intestinal origin.
It should be noted that the data of the largest and longest studies
could not be used for meta-analyses. Compared to sulphonylurea
alpha-glucosidase inhibitors were inferior with respect to glycemic
control and adverse effects, the extent of this effect differed with
the sulphonylurea used. On the contrary, alpha-glucosidase in-
hibitors had a decreasing effect on fasting and post-load insulin
levels compared to sulphonylurea. Of the three alpha-glucosidase
inhibitors investigated, acarbose,miglitol and voglibose,most data
and best outcomes were obtained for acarbose.
Overall completeness and applicability of
evidence
The results from this review are relevant for physicians dealingwith
patients with type 2 diabetes and for the developers of treatment
guidelines. Data of beneficial effects onmortality or complications
from diabetes mellitus are not available at the moment. Alpha-
glucosidase-inhibitors inhibit post-pranidal glucose peaks thereby
leading to decreased post-load insulin levels. Further, alpha-glu-
cosidase inhibitors lower post-load insulin levels, especially when
compared to sulphonylurea. There are no additional advantages
with respect to the lipid profile or body weight. Most evidence
is available for acarbose, which has also the best results for most
outcomes. The importance of these findings and the exact place
of alpha-glucosidase inhibitors in the treatment of type 2 diabetes
mellitus, has to be judged in view of other evidence regarding the
clinical importance of (post-load) hyperglycaemia and hyperin-
sulinaemia.
This review investigated alpha-glucosidase inhibitors asmonother-
apy. Although, from a theoretical point of view, it seems logical
that alpha-glucosidase inhibitors offer similar potentials in addi-
tion to other antidiabetic therapies, this cannot be concluded from
this review. Evidence for the possible efficacy for alpha-glucosidase
inhibitors as add-on therapy might be derived from a systematic
review that is currently going on (Navarro 2003).
Potential biases in the review process
This is the first high-quality systematic review and meta-analysis
on the topic of alpha-glucosidase inhibitors. It offers an up-to-date
and most complete overview of all randomised trials concerning
alpha-glucosidase inhibitor monotherapy, because it is the result
of an extensive search, including grey literature and unpublished
studies. In addition, maximum efforts have been done tominimise
missing or incomplete data by attempting to contact all authors.
This has been successful in 22 out of 41 cases.
Although we included a high number of studies, the data are re-
markably consistent and heterogeneity is limited. Statistical tests
for heterogeneity are less reliable when a high number of studies
are involved and further scrutiny by sub-group analysis and meta-
regression analysis yielded few possible sources for heterogeneity.
The use of a fixed dose (instead of an individually titrated dosage)
may cause a more profound effect with respect to glycemic control
but causes also more adverse effects. The same applies to giving
the full dose at once, instead of using a step-up scheme.
Although this review presents a possibly confusing amount of data
and figures, we feel that completeness is one of the strengths of
a Cochrane systematic review. The way we presented these data,
subdivided in types of alpha-glucosidase inhibitor, controls and
outcome measures, makes it possible for the reader to find what-
ever specific piece of information on alpha-glucosidase inhibitor
monotherapy he or she needs.
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This review will be regularly updated, leaving the possibility open
to add information or to correct possible errors. In fact, this is a
plea for anyone who is aware of such additional data or errors in
the data presented here, to report this to the authors.
Our main research question was not answered with the trials we
included in this review so far. Only few studies reported data on
morbidity and mortality on a reliable and consistent way. It is not
likely that in the (near) future a randomised trial of long enough
duration will be conducted with acarbose monotherapy to inves-
tigate mortality and morbidity. This raises the question whether
our review, with its strict inclusion criteria and high demands for
outcome data, overshoots themark.Maybe with broader inclusion
criteria, that is inclusion of (high quality) observational studies, we
would have gained data to study a possible influence on mortality
and morbidity. The use of observational data does not necessarily
lead to biased outcomes (Concato 2000). Still, we feel that for
the evaluation of medical interventions, well designed randomised
trials are the first choice. To improve systematic reviews in the
future, we strongly plea for the integration of outcome measures
such as death or morbidity into all trials that evaluate medical
interventions for patients with chronic diseases. Even if the trial
is underpowered for that outcome, the data might always be of
value for a meta-analysis. The question of including observational
studies in a future update of this review is still open to us.
Despite an exhaustive and thorough search, including requests to
experts and manufacturers, we still cannot rule out publication
bias. For the three trials that we found in a database for ongoing
trials, we were not able to reveal outcome data or additional infor-
mation about the design despite the fact that one trial ended six
years ago (Whitby 1998) and the others in 2003 (Holman 2003;
Sa-adu 2003). Another clue for possible publication bias was that
we, despite maximum efforts to retrieve unpublished data, discov-
ered three previously unpublished studies coincidentally (Bayer
2003; Bayer 2003a; Campbell 1998) that were used for a study on
a congress poster (Hanefeld 2003). Altogether, we still think that
the overall risk for publication bias is limited because the funnel
plots do not point at small study bias and because of the exhaustive
search. Still, we welcome unpublished data for future updates.
Not all papers reported outcomes in a way that could contribute to
meta-analyses. This problemwas partially solved by asking authors
for additional data, imputing the standard deviation of the mean
difference (see under methods, data analysis) or using data from
graphical figures. As an example, data from only four of the 32
studies investigating glycated haemoglobin in relation to the use
of acarbose, suited for use in the meta-analysis directly; for twelve
studies additional data had to be obtained from the authors to
complete all blanks; for twelve studies we had to calculate the SD
of the mean difference from the baseline and endpoint SDs and
for four studies the data could not be used at all. Unfortunately,
one of those four studies was of long duration (3 years) and had
a high number of participants (Campbell 1998). In summary, we
used the most precise data in about half of the cases (16 out of 32)
and we had to use less precise figures in 12 out of 32 cases. Because
we used a conservative correlation coefficient of 0.4, this will most
probably have made the confidence interval larger. The influence
of the missing data from the largest studies was discussed under
’existing literature’.
Only nine out of the 41 studies lasted longer than 24 weeks, and
only two studies were amply longer than one year (Holman 1999;
Campbell 1998). For one of those two studies data could not be
included in the meta-analyses (Campbell 1998). The importance
of long-term studies is evident, especially for a chronic disease such
as type 2 diabetes. In the subgroup analysed for study duration, we
found clues that the effect of alpha-glucosidase inhibitors decrease
with time, This was mostly due to the UKPDS study un which
a decrease of only 0.2% was found after three years of treatment
(Holman 1999). Therefore, we feel that the results from our study
should be interpreted with caution when applied to the long-term
treatment with alpha-glucosidase inhibitors of patients with type
2 diabetes.
Research funded by pharmaceutical companies is more likely to
produce results favouring the tested drug; this is often due to in-
appropriate comparators or small study bias (Lexchin 2003). In
this review at least 33 studies were sponsored by a pharmaceuti-
cal company, including one study in which the sponsor was the
producer of the comparison drug (Holmes 2001). We suppose
that this will cause a slight overestimation of the results, especially
concerning the studies that compare alpha-glucosidase inhibitors
with other medication. In fact, this is probable in the compari-
son acarbose versus sulphonylurea (glycated haemoglobin) where
acarbose is dosed in a fixed way and the comparison drugs are
individually adjusted (Coniff 1995; Hoffmann 1990; Hoffmann
1994; Kovacevic 1997; Rosenthal 2002; Salman 2001) or very low
dosed (Haffner 1997). In one study both treatment arms used an
individually adjusted dosage scheme (Van de Laar 2004a). For the
comparison with placebo the influence of this ’bias by sponsor-
ing’ is less sure as it would be similar to publication bias like we
discussed before.
Agreements and disagreements with other
studies or reviews
Although this is the first systematic review concerning alpha-glu-
cosidase inhibitormonotherapy, some reviews have beenpublished
recently about acarbose (Breuer 2003; Laube 2002) or miglitol
(Campbell 2000; Scott 2000). The quality of those reviews is lim-
ited: selection criteria for the studies were insufficiently specified
and there was no mention of the criteria used to assess the validity
of individual trials. Further, these reviews did not present explicit
methods on data extraction, assessment of heterogeneity or sub-
group analyses. Both reviews on acarbose referred also to a ’meta-
analysis’ of older date (Lebovitz 1998), which calculated the mean
outcomes on glycemic control for 13 studies, using outcomes for
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single treatment arms (baseline minus endpoint) as well as placebo
extracted outcomes in a non-transparent way.
Our results are roughly in line with the previous reviews with re-
spect to the overall effect on glycemic control compared toplacebo,
but there are relevant differences and additional findings. First, we
found no dose-dependency of acarbose on glycated haemoglobin
in the meta-analysis. Remarkably, the effect on fasting and post-
load blood glucose appeared to be dose dependent. This discrep-
ancy might be explained by a better compliance of patients that
were using the lower dosages, because higher dosages induce more
adverse effects. Prior to their visit to the study centre, it is more
likely that patients took their study medication and thus achieving
good fasting and post-load glucose values. Only for glycated hae-
moglobin, the effect of low compliance will show up. Secondly,
we could not find relevant effects on lipid levels, especially triglyc-
erides. Thirdly, we also could not confirm the optimistic view on
adverse effects reported in the previous reviews. Twenty out of 41
included studies were subject to a skewed drop-out pattern (? 10%
difference per treatment group) and 25 studies had a total drop-
out rate that was ? 15%, in most cases this was caused by adverse
effects. Finally, the previous reviews are optimistic about the glu-
cose lowering capacities of alpha-glucosidase inhibitors compared
to other agents such as sulphonylurea. We confirm a clear benefi-
cial effect with respect to fasting and post-load insulin levels. But
overall, the effects on glycemic control are inferior to sulphony-
lurea. For glycated haemoglobin this is not statistically significant,
but most studies that compare acarbose with sulphonylurea use
inappropriate comparators (that is too low dose for sulphonylurea
or using an individually titrated dosage versus a fixed dosage).
Therefore, we feel that a conclusion that sulphonylurea have su-
perior glucose lowering properties, is justified. In addition, alpha-
glucosidase inhibitors cause more adverse effects.
The three-years trial performed within the UKPDS (Holman
1999) was one of the main studies included in the review. The
effects regarding glycated hemoglobin obtained in this trial alone
(a decrease of 0.2%) are considerably less profound than those
from the meta-analysis. This discrepancy with the results from the
meta-analysis, point in the direction of a possible overestimation
of the effect in the long (three years) term.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In patients with type 2 diabetes, alpha-glucosidase inhibitor
monotherapy inhibit post-prandial glucose peaks thereby leading
to decreased post-load insulin levels. There are no advantages with
respect to lipid metabolism or body weight. Compared to sulpho-
nylurea, alpha-glucosidase inhibitors have less favourable effects
with respect to glycemic control and adverse effects but they lower
fasting and post-load insulin levels compared to sulphonylurea.
For all outcomes, the largest evidence base exists for acarbose.
Implications for research
New studies that investigate alpha-glucosidase inhibitors on proxy
indicators such as glycaemic control, lipids, insulin, body weight
would be redundant. Large randomised controlled trials of long
duration that investigate mortality, morbidity and quality of life
as primary endpoints are necessary. In addition studies comparing
alpha-glucosidase inhibitors with other glucose lowering agents
(especially metformin and thiazilodines) are of use. When these
trials are not available, inclusion of well-designed observational
studies in this review may be considered.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Braun 1996







NUMBER: randomised: AGI 80, CONTROL 72, analysed: AGI 42, CONTROL 44
SEX (F/M): AGI 16/26, CONTROL 20/24
AGE (YEARS (MEAN)): analysed patients: AGI 60, CONTROL 61
DURATION OF DIABETES (MONTHS (MEAN)): analysed patients: AGI 16, CONTROL 17
Interventions Dietary reinforcement: unclear
AGI: acarbose, week 1-2 50 mg TID, week 3-24 100 mg TID
CONTROL: placebo TID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: total cholesterol, HDL-cholesterol, triglycerides
6. Insulin levels: ND
7. Weight: body weight
8. Adverse effects: yes
Notes Sponsor: oharmaceutical
Author contacted: chief of department replied, data not in file, original authors were no longer working
there
Study retrieved: CENTRAL, EMBASE, manufacturer
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Buchanan 1988






NUMBER: randomised 28, analysed 20 (AGI 9, CONTROL 11)
SEX (F/M): AGI 3/6, CONTROL 3/8
AGE (YEARS (MEAN, SD)): analysed patients: AGI 60,1 (6,8), CONTROL 57,6 (8,2)
DURATION OF DIABETES (MONTHS (MEAN, SD)): analysed patients: AGI 44,9 (28,6), CON-
TROL 50,6 (30,1)
Interventions Dietary reinforcement: unclear; high complex carbohydrates / low-fat diet generally advised
AGI: acarbose, week 0-2 50 mg TID, week 3-8 100 mg TID, week 9-12: 200-100-100 mg, week 13-16
200-100-200 mg, in case of adverse effects patients were instructed to reduce the dosage of acarbose to
that which could be tolerated.
CONTROL: placebo TID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1), fasting blood glucose
5. Lipids: total cholesterol, triglycerides
6. Insulin levels: ND
7. Weight: body weight
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: co-author replied but could not give detailed answers
Study retrieved: CENTRAL, MEDLINE, EMBASE
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Calle-Pascual 1996






NUMBER: randomised AGI 20, control 20; dropout AGI 3/20, control 4/20
SEX: data missing
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Calle-Pascual 1996 (Continued)
AGE: data missing
DURATION OF DIABETES: data missing
Interventions Dietary reinforcement: yes, patients included in a behaviour modification program
AGI: acarbose, week 1-4 50 mg TID, week 5-16 100 mg TID
CONTROL: placebo
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting blood glucose
5. Lipids: total- and HDL-cholesterol, triglycerides
6. Insulin levels: fasting insulin
7. Weight: bodyweight, BMI
8. Adverse effects: yes
Notes Sponsor: not sponsored
Author contacted: additional data on design, quality and outcomes send by author
Study retrieved: CENTRAL, MEDLINE, EMBASE
Short report, published as letter to the editor
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Campbell 1998







NUMBER: randomised: 789 (baseline data: AGI 236, CONTROL1 254, CONTROL2 243)
SEX (F/M): AGI 87/150, CONTROL1 98/156, CONTROL2 71/172
AGE (YEARS (MEAN)): AGI 62, CONTROL1 62, CONTROL2 62
DURATION OFDIABETES (MONTHS (MEAN)): AGI 34.7, CONTROL1 37.8, CONTROL2 41.
6
Interventions Dietary reinforcement: unclear
AGI: acarbose 100 MG TID
CONTROL1: placebo
CONTROL2: acarbose 50 mg TID
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Campbell 1998 (Continued)
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c)
5. Lipids: ND
6. Insulin levels: ND
7. Weight: ND
8. Adverse effects: yes
Notes Sponsor: Pharmaceutical
Author contacted: addtional data on design, quality and outcomes via manufacturer. The sparse outcome
data of insufficient quality to be included in meta-analysis
Study retrieved: handsearch
Published as an abstract only. Patients were followed-up and an interim analysis was planned when the
HbA1c progressed to >= 8.0 on two consecutive visits or > 10.6% at any time. Therefore the results are
not suitable for meta-analysis
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Chan 1998




Participants COUNTRIES: China, Taiwan, Hong Kong, Philippines, Korea, Singapore, Malaysia
SETTING: outpatient
NUMBER: randomised AGI 63, CONTROL 63, analysed AGI 59, CONTROL 62
SEX (F/M): AGI 31/32, CONTROL 31/32
AGE (YEARS (MEAN, SD)): randomised patients: AGI 52,8 (10,2), CONTROL 54,0 (10,0)
DURATION OF DIABETES (MONTHS (MEAN, SD)): randomised patients: AGI 32,4 (42), CON-
TROL 25,2 (40,8)
Interventions Dietary reinforcement: unclear
AGI: acarbose, week 1-4 50 mg TID, week 5-24 100 mg TID
CONTROL: placebo TID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: total-, HDL- & LDL-cholesterol, triglycerides
6. Insulin levels: fasting & post-load insulin
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Chan 1998 (Continued)
7. Weight: body weight, BMI
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: no reply
Study retrieved: CENTRAL, MEDLINE, EMBASE, Current Contents
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Chiasson 1994






NUMBER: 354 patients randomised, 77 treated with diet alone; 67 (of 77) analysed
SEX (F/M): 29/48
AGE (YEARS (MEAN, SD)): all randomised patients in diet-only group 57,2 (9.7)
DURATION OF DIABETES (MONTHS (MEAN, SD)): all randomised patients in diet-only group
62,4 (63,6)
Interventions Dietary reinforcement: yes, according to Canadian Association Nutritional guidelines (1993)
AGI: acarbose 50, 100 or 200 mg TID, dose adjusted according to blood glucose values and / or tolerance,
main target to achieve a postprandial blood glucose < 12 mmol/l
CONTROL: placebo
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & 90 minutes post-load blood glucose
5. Lipids: ND
6. Insulin levels: ND
7. Weight: ND
8. Adverse effects: ND
Notes Sponsor: pharmaceutical
Author contacted: author requested us to send questions again, no reply since
Study retrieved: CENTRAL, MEDLINE, EMBASE, Current Contents, manufacturer, handsearch
For this review the reported data from the ’diet only’ subgroup is used
Risk of bias
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Chiasson 1994 (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Chiasson 2001






NUMBER: total: randomised 324, analysed 318; AGI 82, CONTROL1 83, CONTROL2 83, CON-
TROL3 76
SEX (F/M): AGI 18/64, CONTROL1 27/56, CONTROL2 22/61, CONTROL3 17/59
AGE (YEARS (MEAN, SD)): AGI 57,3 (9,0), CONTROL1 57,7 (9,9), CONTROLl2 57,9 (8,6),
CONTROL3 58,9 (7,9)
DURATION OF DIABETES (MONTHS (MEAN, SD)): AGI 62,4 (56,4), CONTROL1 61,2 (58,8)
, CONTROL2 90,0 (88,8), CONTROL3 73,2 (66,0)
Interventions Dietary reinforcement: yes, ’well-balanced weight-reducing diet’ (reference Diabetes Care 1994, 17(5)
490-519)
AGI: miglitol, week 1-4 25 mg TID, week 5-12 50 mg TID, week 13-36 100 mg TID
CONTROL1: placebo
CONTROL2: metformin 500 mg TID
CONTROL4: combination of miglitol 100 mg TID and metformin 500 mg TID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: ND
6. Insulin levels: fasting & post-load insulin
7. Weight: body weight
8. Adverse effects: any AE, gastrointestinal AE
Notes Sponsor: pharmaceutical
Author contacted: author requested us to send questions again, no reply since (4 months)
Study retrieved: CENTRAL, MEDLINE, EMBASE, Current Contents
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Coniff 1994






NUMBER: randomised: AGI 105, CONTROL 107; analysed: AGI 91, CONTROL 98
SEX (F/M): analysed group: AGI 50/41, CONTROL 45/53
AGE (YEARS (MEAN, SD)): analysed group: AGI 56,0 (9,5), CONTROL 55,6 (9,9)
DURATION OF DIABETES (MONTHS (MEDIAN, RANGE)): analysed group: AGI 48 (6-396),
CONTROL 36 (6-252)
Interventions Dietary reinforcement: yes, standard diabetic diet containing at least 50% carbohydrates
AGI: acarbose titrated to a maximum of 300 mg TID: dose in- or decreased according to fasting blood
glucose and tolerance (cut-off point fasting blood glucose > 11.1 mmol/l)
CONTROL: placebo TID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of Life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: triglycerides, total-, HDL- & LDL-cholesterol
6. Insulin levels: ND
7. Weight: body weight
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: additional data on design, quality and outcomes via manufacturer
Study retrieved: CENTRAL, MEDLINE, EMBASE, manufacturer, handsearch
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Coniff 1995






NUMBER: randomised: AGI 76, CONTROL1 72, CONTROL2 72, CONTROL3 70; analysed: AGI
67, CONTROL1 62, CONTROL2 66, CONTROL3 60
SEX (F/M): analysed group: AGI 41/26, CONTROL1 30/32, CONTROL2 29/37, CONTROL3 29/
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Coniff 1995 (Continued)
31
AGE (YEARS (MEAN)): analysed group: AGI 56,2, CONTROL1 56,3, CONTROL2 55,4, CON-
TROL3 55,7
DURATION OF DIABETES (MONTHS (MEAN, SD)):
Interventions Dietary reinforcement: yes, standard diabetic diet with 50% energy as carbohydrates
AGI: acarbose 200 mg TID
CONTROL1: placebo
CONTROL2: tolbutamide, individually adjusted in steps of 250 mg TID, maximum dose unclear
CONTROL4: acarbose & tolbutamide combination (data not used in this review)
Outcomes 1. Mortality: yes
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: triglycerides, total-, HDL- & LDL-cholesterol
6. Insulin levels: fasting & post-load insulin
7. Weight: body weight
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: additional data on design, quality and outcomes via manufacturer
Study retrieved: CCRCT, Medline, Embase, manufacturer
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Coniff 1995b






NUMBER: randomised: AGI 73, CONTROL1 73, CONTROL2 72, CONTROL3 72; analysed: AGI
58, CONTROL1 64, CONTROL2 54, CONTROL3 53
SEX (F/M): analysed group: AGI 28/30, CONTROL1 27/37, CONTROL2 22/32, CONTROL3 22/
31
AGE (YEARS (MEAN)): analysed group: AGI 55, CONTROL1 54, CONTROL2 56, CONTROL3
54
DURATIONOFDIABETES (MONTHS (MEAN)): analysed group: AGI 72, CONTROL1 60, CON-
TROL2 60, CONTROL3 60
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Coniff 1995b (Continued)
Interventions Dietary reinforcement: yes, weight stable ADA diet (1979): 50% carbohydrate, 30% fat, 20% protein
AGI: acarbose 100 mg TID
CONTROL1: placebo TID
CONTROL2: acarbose, week 1-2 100 mg TID, week 3-16 200 mg TID
CONTROL3: acarbose, week 1-2 100 mg TID, week 3-4 200 mg TID, week 5-16 300 mg TID
Outcomes 1. Mortality: ND
2. Diabetes Related Complications: ND
3. Quality of Life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: total cholesterol, triglycerides
6. Insulin levels: fasting & post-load insulin levels
7. Weight: body weight
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: additional data on design, quality and outcomes via manufacturer
Study retrieved: CENTRAL, MEDLINE, EMBASE, manufacturer
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Dedov 1995






NUMBER: randomised 180 patients, analysed 155 (AGI 82, CONTROL 73). Baseline values are given
for 161 patients
SEX (F/M): baseline group AGI 50/33, CONTROL 50/28
AGE (YEARS (MEAN, SD)): baseline group AGI 52,6 (9,5), CONTROL 49,2 (9,5)
DURATION OF DIABETES: ND
Interventions Dietary reinforcement: unclear
AGI: acarbose, week 1-2 50 mg TID, week 3-24 wk 100 mg TID
CONTROL: placebo TID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1), fasting & post-load blood glucose
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Dedov 1995 (Continued)
5. Lipids: ND
6. Insulin levels: ND
7. Weight: body weight
8. Adverse effects: yes
Notes Sponsor: not specified
Author contacted: no reply
Study retrieved: CENTRAL, EMBASE
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Delgado 2002






NUMBER: AGI 9, CONTROL 8
SEX (F/M): AGI 3/6, CONTROL 3/5
AGE: ND
DURATION OF DIABETES (MONTHS (MEAN, SD)): all patients 26 (6)
Interventions Dietary reinforcement: yes, for details article referred to article in French (Journeés de diabétologie Hôtel
Dieu 1998: 51-69)
AGI: acarbose, week 1-2 50 mg once daily, week 3-16 50 mg BID
CONTROL1: placebo BID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: total cholesterol, HDL-cholesterol, triglycerides
6. Insulin levels: Reaven’s triple test
7. Weight: body weight, BMI
8. Adverse effects: ND
Notes Sponsor: Not specified
Author contacted: no reply
Study retrieved: CENTRAL, MEDLINE, EMBASE, Current Contents, handsearch
Study mainly about insulin insulin resistance & secretion
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Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Drent 2002




Participants COUNTRY: The Netherlands
SETTING: patients recruited in general practice, study performed in ’study centres’
NUMBER: 599 enrolled, 468 randomised, 384 analysed (AGI 71, CONTROL1 87, CONTROL2 84,
CONTROL3 58, CONTROL4 84)
SEX (F/M): AGI 34/37, CONTROL1 38/49, CONTROL2 37/47, CONTROL3 21/37, CONTROL4
43/41
AGI (YEARS (MEAN, SD)): AGI 63 (11), CONTROL1 63 (11), CONTROL2 63 (9), CONTROL3
64 (10), CONTROL4 64 (10)
DURATION OF DIABETES (MONTHS (MEAN)): AGI 36, CONTROL1 30, CONTROL2 48,
CONTROL3 46, CONTROL4 41.5
Interventions Dietary reinforcement: when patients were not using diet, advice was given during screening period, ADA/
EASD guidelines, at least 40% carbohydrates
AGI: miglitol, week 1-2 50 mg TID, week 3-24 100 mg TID
CONTROL1: placebo TID
CONTROL2: miglitol 50 mg TID
CONTROL3: miglitol, week 1-2 100 mg TID, week 3-24 200 mg TID
CONTROL4: miglitol 25 mg TID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: “blood lipids”
6. Insulin levels: fasting & post-load insulin
7. Weight: weight & BMI
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: additional data on design, quality and outcomes send by author
Study retrieved: CENTRAL, MEDLINE, EMBASE, Current Contents (2nd reference via author)
Risk of bias
Item Authors’ judgement Description
35Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Drent 2002 (Continued)
Allocation concealment? Yes A - Adequate
Fischer 1998




Participants COUNTRY: Germany, Austria, Croatia, Hungary, Italy
SETTING: outpatient
NUMBER: randomised 495, analysed 420 (AGI 25 mg 86, AGI 50 mg 88, AGI 100 mg 78, AGI 200
mg 87, CONTROL 81)
SEX (F/M): AGI 25 mg 40/46, AGI 50 mg 45/43, AGI 100 mg 32/46, AGI 200 mg 43/44, CONTROL
38/43
AGE (YEARS (MEAN, SD)): analysed group: AGI 25 mg 58,5 (8,4), AGI 50 mg 55,5 (9,6), AGI 100
mg 56,8 (9,4), AGI 200 mg 59,4 (8,6), CONTROL 52,7 (8,7)
DURATION OF DIABETES (MONTHS (MEDIAN)): AGI 25 mg 26, AGI 50 mg 20, AGI 100 mg
17, AGI 200 mg 21, CONTROL 24
Interventions Dietary reinforcement: yes, ADA nutritional recommendations 1986
AGI: acarbose divided in 4 groups: 25 mg, 50 mg, 100 mg (week 1-2 50 mg TID) and 200 mg TID
(week 1-2 100 mg TID)
CONTROL: placebo TID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting blood glucose
5. Lipids: ND
6. Insulin levels: ND
7. Weight: body weight
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: additional data on design, quality and outcomes via manufacturer
Study retrieved: CENTRAL, MEDLINE, EMBASE, Current Contents, manufacturer
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Gentile 1999
Methods DESIGN: cross-over study
RANDOMISATION PROCEDURE: unclear
BLINDING: double-blind






DURATION OF DIABETES (MONTHS (MEAN, SD)): 110,4 (49,2)
Interventions Dietary reinforcement: unclear, general advice 60% carbohydrates, 20-22% fat, 18-20% protein
AGI: acarbose, week 1 50 mg TID, week 2-12 100 mg TID
CONTROL: placebo
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin, fasting blood glucose
5. Lipids: ND
6. Insulin levels: ND
7. Weight: ND
8. Adverse effects: yes
Notes Sponsor: “Fundi MURST”, not clear whether this is a pharmaceutical sponsor
Author contacted: no reply
Study retrieved: CENTRAL, MEDLINE, EMBASE
This study is done with patients suffering from non-alcoholic liver cirrhosis
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Haffner 1997






NUMBER: 77 patients randomised and analysed (AGI 25, CONTROL1 25, CONTROL2 27)
SEX (F/M): AGI 6/19, CONTROL1 8/17, CONTROL2 11/16
AGI (YEARS (MEAN, SD)): AGI 59.4 (28), CONTROL1 58.6 (31.5), CONTROL2 58.1 (36.4)
DURATION OF DIABETES (MONTHS (MEAN, SD)): AGI 94.0 (59.9), CONTROL1 77.3 (53.5)
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Haffner 1997 (Continued)
, CONTROL2 69.5 (49.9)
Interventions Dietary reinforcement: yes, body weight stable, 15% protein, 35% fat, 50% carbohydrates
AGI: acarbose 100 mg TID
CONTROL1: placebo TID
CONTROL2: glibenclamide 1 mg TID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: triglycerides, total & HDL-cholesterol
6. Insulin levels: fasting & post-load insulin
7. Weight: weight & BMI
8. Adverse effects: ND
Notes Sponsor: non-industry (National Heart Lung and Blood Institute)
Author contacted: no reply
Study retrieved: CENTRAL, MEDLINE, EMBASE, Current Contents, handsearch
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Hanefeld 1991






NUMBER: randomised 100, analysed 94; AGI 47, CONTROL 47
SEX (F/M): AGI 24/23, CONTROL 22/25
AGE (YEARS (MEAN)): analysed patients AGI 60, CONTROL 59
DURATION OF DIABETES (MONTHS (MEAN)): analysed patients AGI 70, CONTROL 49
Interventions Dietary reinforcement: yes, specification diet unclear.
AGI: acarbose 100 mg TID
CONTROL: placebo
Outcomes 1. Mortality: ND
2. Diabetes related Complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1), fasting & 1 hour post-load blood glucose
5. Lipids: triglycerides, total- and HDL-cholesterol
38Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hanefeld 1991 (Continued)
6. Insulin levels: fasting & 1 hour post-load insulin
7. Weight: body weight
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: additional data on design, quality and outcomes via manufacturer
Study retrieved: CENTRAL, MEDLINE, EMBASE, manufacturer
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Hillebrand 1987
Methods DESIGN: cross-over study
RANDOMISATION PROCEDURE: unclear
BLINDING: double-blind






DURATION OF DIABETES (MONTHS (MEAN, SD)): 110,4 (49,2)
Interventions Dietary reinforcement: unclear
AGI: acarbose 200 mg BID
CONTROL1: miglitol 200 mg BID
CONTROL2: glibenclamide 7 mg once daily
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1), fasting & post-load blood glucose
5. Lipids: ND
6. Insulin levels: ND
7. Weight: ND
8. Adverse effects: yes
Notes Sponsor: not specified
Author contacted: authors could not be retrieved
Study retrieved: handsearch
Published as abstract only.
Risk of bias
39Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hillebrand 1987 (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Hoffmann 1990






NUMBER: 95 patients included; AGI 48, CONTROL 47
SEX (F/M): AGI 30/18, CONTROL 26/21
AGE (YEARS (MEAN, SD)): AGI 61.8 (5.6), CONTROL 61.2 (5.5)
DURATION OF DIABETES (MONTHS (MEAN (SD)): AGI 22.4 (16.2), CONTROL 30.7 (29.2)
Interventions Dietary reinforcement: yes, normocaloric diet of 1500 kcal with 120 g carbohydrates, 50 g protein, 55 g
fat
AGI: acarbose, week 1-4 50 mg TID, week 5-25 100 mg TID (for one patient dose reduced to 100 mg
BID)
CONTROL: glibenclamide 3,5 mg administered individually 1-3 times per day
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1), fasting & post-load blood glucose
5. Lipids: triglycerides, total-, HDL and LDL-cholesterol
6. Insulin levels: ND
7. Weight: body weight, Broca index
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: additional data on design, quality and outcomes via manufacturer
Study retrieved: CENTRAL, experts
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Hoffmann 1994
Methods DESIGN: parallel study
RANDOMISATION PROCEDURE: adequate




NUMBER: 96 patients randomised, 85 analysed for efficacy (AGI 28, control1 30, control2 27)
SEX (F/M): AGI 15/13, CONTROL1 18/12, CONTROL2 14/13
AGE (YEARS (MEAN, SD)): analysed patients: AGI 58,8 (6,9), CONTROL1 56,9 (6,7), CONTROL2
59,9 (5,7)
DURATION OF DIABETES (MONTHS (MEAN, SD)): analysed patients: AGI 12,7 (10,8), CON-
TROL1 12,1 (10,8), CONTROL2 17,6 (13,1)
Interventions Dietary reinforcement: yes, 50% carbohydrates, 35% fat, 15% protein
AGI: acarbose 100 mg TID
CONTROL1: placebo TID
CONTROL2: glibenclamide 3,5 mg administered individually 1-3 times per day
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: triglycerides, total- and HDL-cholesterol
6. Insulin levels: fasting & post-load insulin
7. Weight: body weight, BMI
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: additional data on design, quality and outcomes via manufacturer
Study retrieved: CENTRAL, MEDLINE, EMBASE, manufacturer
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Hoffmann 1997
Methods DESIGN: parallel study
RANDOMISATION PROCEDURE: adequate




NUMBER: 96 patients randomised; 94 analysed for efficacy (AGI 31, CONTROL1 32, CONTROL2
31)
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SEX (F/M): AGI 25/6, CONTROL1 20/12, CONTROL2 17/14
AGE (YEARS (MEAN, SD)): analysed patients: AGI 58,9 (9,4), CONTROL1 60,2 (8,6), CONTROL2
55,9 (7,8)
DURATION OF DIABETES (MONTHS (MEAN, SD)): analysed patients: AGI 36,9 (27,2), CON-
TROL1 43,2 (33,9), CONTROL2 25,0 (17,4)
Interventions Dietary reinforcement: yes, 50% carbohydrates, 35% fat, 15% protein
AGI: acarbose 100 mg TID
CONTROL1: placebo TID
CONTROL2: metformin 850 mg BID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting post-load blood glucose
5. Lipids: triglycerides, total-, HDL- & LDL-cholesterol
6. Insulin levels: fasting & post-load insulin
7. Weight: body weight
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: additional data on design, quality and outcomes via manufacturer
Study retrieved: CENTRAL, MEDLINE, EMBASE, Current Contents, manufacturer
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Holman 1999





SETTING: outpatient, part of the United Kingdom Prospective Diabetes Study
NUMBER: 1946 patients randomised, total 1624 analysed (intention-to-treat): diet only group ran-
domised 256, diet only group analysed (HbA1c) AGI 83, CONTROL 107.
SEX (F/M): AGI 36/84, CONTROL 38/98
AGE (YEARS (MEAN, SD)): AGI 60.0 (8.2), CONTROL 60.9 (9.0)
DURATION OF DIABETES (MONTHS (MEAN, SD)): AGI 82.6 (33.3), CONTROL 91.3 (34.9)
Interventions Dietary reinforcement: no (dietary advice according to UKPDS protocol)
AGI: acarbose, 50 mg once, BID & TID at two-week intervals; 4 months after start dosage increased in 3
weeks period with 50 mg per step to 100 mg TID. In case of side effects patients were allowed to reduce
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Outcomes 1. Mortality: yes
2. Diabetes related complications: yes
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c)
5. Lipids: ND
6. Insulin levels: ND
7. Weight: body weight, BMI
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: additional data on design, quality and outcomes send by authors
Study retrieved: CENTRAL, MEDLINE, EMBASE, Current Contents, Manufacturer
For this review the reported data from the ’diet only’ subgroup is used
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Holmes 2001




Participants COUNTRY: Germany, France and Spain
SETTING: outpatient
NUMBER: 260 patients entered run-in period, 179 randomised (AGI 92, CONTROL 87). analysed (for
HbA1c) AGI 90, CONTROL 85
SEX (F/M): randomised group AGI 33/59; CONTROL 30/57
AGE (YEARS (MEAN, SD)): randomised patients AGI 60,6 (10.2); CONTROL 64.3 (10.4)
DURATION OF DIABETES (MONTHS (MEAN (SD)): randomised patients AGI 53.9 (62.4 or 64.
4 ); CONTROL 63.4 (66.5)
Interventions Dietary reinforcement: no (”patients continued with their normal dietary habits’)
AGI: acarbose, week 0-4 50 mg TID, week 4-8 100 mg TID, in case of side-effects to be reduced to 50
mg
CONTROL: nateglinide 120 mg TID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting blood glucose
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5. Lipids: ND
6. Insulin levels: ND
7. Weight: body weight
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: additional data on design, quality and outcomes send by author
Study retrieved: handsearch
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Hotta 1993






NUMBER: randomised: AGI 20, CONTROL 20, analysed: AGI 16, CONTROL 15, (baseline values
given for 37 patients)
SEX (F/M): AGI 5/14, CONTROL 4/14
AGE (YEARS (MEAN)): AGI 49,8, CONTROL 47,9
DURATION OF DIABETES (MONTHS (MEAN)): AGI 55,2, CONTROL 57,6
Interventions Dietary reinforcement: yes, specification unclear
AGI: acarbose 100 mg TID
CONTROL: placebo TID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: total- & HDL-cholesterol, triglycerides
6. Insulin levels: ND
7. Weight: body weight
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: additional data on design, quality and outcomes send by author
Study retrieved: CENTRAL, MEDLINE, EMBASE, manufacturer, (2nd reference via author)
Risk of bias
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Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Johnston 1998






NUMBER: randomised: AGI 102, CONTROL1 104, CONTROL2 104, CONTROL3 101, analysed:
AGI 85, CONTROL1 95, CONTROL2 92, CONTROL3 92
SEX (F/M): analysed patients: AGIN24/61, CONTROL1 35/60, CONTROL2 33/59, CONTROL3
26/66
AGE (YEARS (MEAN, SD)): analysed group: AGI 67,8 (5,5), CONTROL1 67,2 (5,8), CONTROL2
67,7 (5,8), CONTROL3 68,5 (5,8)
DURATION OF DIABETES (MONTHS (MEAN, SD)): AGI 81,6 (88,8), CONTROL1 90 (93,6),
CONTROL2 86,4 (92,4), CONTROL3 84 (92,4)
Interventions Dietary reinforcement: yes, ADA approved diet >= 50% carbohydrates
AGI: miglitol 50 mg TID
CONTROL1: miglitol 25 mg TID
CONTROL2: glyburide 20 mg once daily, step up & individually titrated: every 2 weeks increase: 2,5/
5/7,5/10/15/20 mg
CONTROL4: placebo TID and once daily
Outcomes 1. Mortality: yes
2. Diabetes related complications: yes
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: triglycerides
6. Insulin levels: fasting & post-load insulin
7. Weight: BMI
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: Bayer replied that the data from this study was transferred to Pfizer. Pfizer didn’t reply
to our requests do far.
Study retrieved: CENTRAL, MEDLINE, EMBASE, Current Contents
Risk of bias
Item Authors’ judgement Description
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Allocation concealment? Unclear B - Unclear
Johnston 1998a
Methods DESIGN: parallel study
RANDOMISATION PROCEDURE: unclear
BLINDING: double-blind
DURATION: 52 weeks, main outcomes measured at 26 weeks
Participants COUNTRY: USA
SETTING: outpatient
NUMBER: total randomised: AGI 254, CONTROL 131, diet only group 55 (AGI), 14 (CONTROL);
analysed: AGI 19, CONTROL 10
SEX: no data for diet only group
AGE: no data for diet only group
DURATION OF DIABETES: no data for diet only group
Interventions Dietary reinforcement: yes, at least 50% carbohydrates, intended to maintain weight
AGI: miglitol 50 mg: when tolerant the patient increased the dose to 100/150/200 TID at wk 13/26 and
39 respectively. Backtitration allowed (in case of intolerance).
CONTROL: placebo TID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c)
5. Lipids: no data for diet only group
6. Insulin levels: no data for diet only group
7. Weight: no data for diet only group
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: Bayer replied that the data from this study was transferred to Pfizer. Pfizer didn’t reply
to our requests so far.
Study retrieved: CENTRAL, MEDLINE, EMBASE, Current Contents
Both patients using diet only and patients receiving additional sulphonylurea therapy were included in
this study
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Methods DESIGN: parallel study
RANDOMISATION PROCEDURE: unclear
BLINDING: double-blind
DURATION: 52 weeks, primary efficacy criterion measured at 28 weeks
Participants COUNTRY: USA
SETTING: outpatient
NUMBER: total randomised: AGI 229, CONTROL 116; valid for efficacy diet only group: AGI 32,
CONTROL 13; analysed for HbA1c: AGI 30, CONTROL 9
SEX (F/M): diet only group valid for efficacy: AGI 12/20, CONTROL 7/6
AGE (YEARS (MEAN, SD)): diet only group valid for efficacy: AGI 57,3 (10,2), CONTROL 54,9 (12,
6)
DURATION OF DIABETES (MONTHS (MEAN, SD)): diet only group valid for efficacy: AGI 57,6
(95,0), CONTROL 30 (38,9)
Interventions Dietary reinforcement: yes, overweight patients received counselling to produce gradual (1 lb./week)
weight loss
AGI: miglitol, week 1-12 50 mg TID, week 12-52 100 mg TID. In case of intolerance to be decreased to
50 mg
CONTROL: placebo TID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c)
5. Lipids: no data for diet only group
6. Insulin levels: no data for diet only group
7. Weight: no data for diet only group
8. Adverse effects: no data for diet only group
Notes Sponsor: pharmaceutical
Author contacted: Bayer replied that the data from this study was transferred to Pfizer. Pfizer didn’t reply
to our requests so far.
Study retrieved: CENTRAL, MEDLINE, EMBASE, Current Contents
Study among African-American patients. Both patients using diet only and patients receiving additional
sulphonylurea therapy were included in this study
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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NUMBER: 445 patients enrolled, efficacy data for 396 patients (AGI1 158, AGI2 154, CONTROL 84)
SEX: Data missing
AGE: Data missing
DURATION OF DIABETES: Data missing
Interventions Dietary reinforcement: unclear
AGI1: miglitol 50 mg TID
AGI2: voglibose 0.2 mg TID
CONTROL: placebo
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: ND
6. Insulin levels: post-load insulin
7. Weight: ND
8. Adverse effects: yes
Notes Sponsor: not specified
Author contacted: no additional data before study was published as journal article
Study retrieved: handsearch
Data extracted from a congress abstract and a copy of a poster presentation. Authors refused to give more
data before this study was published
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Kovacevic 1997
Methods DESIGN: parallel study
RANDOMISATION PROCEDURE: unclear




NUMBER: randomised: AGI 34, CONTROL1 34, CONTROL2 34; analysed AGI 33, CONTROL1
31, CONTROL2 33
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SEX (F/M): total group 55/47; analysed AGI 16/17, CONTROL1 18/13, CONTROL2 20/13
AGE (YEARS (MEAN, SD)): total group 57,5 (8,1), analysed AGI 58.42 (7.76), CONTROL1 59.35
(8.61), CONTROL2 54.73 (7.80)
DURATION OF DIABETES (MONTHS (MEAN)): total group 54
Interventions Dietary reinforcement: yes, 40-50% carbohydrates, 35-40% fat, 15% protein
AGI: acarbose 100 mg TID
CONTROL1: placebo TID
CONTROL2: glibenclamide 3.5 mg adjusted individually, maximum TID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood-glucose
5. Lipids: tot cholesterol, HDL and triglycerides
6. Insulin levels: fasting & post-load insulin
7. Weight: BMI
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: additional data on design, quality and outcomes send by author
Study retrieved: CENTRAL, EMBASE, manufacturer
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Meneilly 2000






NUMBER: AGI 93, CONTROL 99
SEX (F/M): AGI 28/65, CONTROL 39/60
AGE (YEARS (MEAN, SD)): AGI 69.7 (4,8), CONTROL 70.3 (5,0)
DURATION OF DIABETES (MONTHS (MEAN, SD)): AGI 69,6 (81,6), CONTROL 57,6 (60)
Interventions Dietary reinforcement: yes, advised tomaintain diet to ensure that calorie intake was consistent throughout
the study
AGI: acarbose, week 1: 50 mg once daily, week 2: 50 mg BID, week 3: 50 mg TID, week 4-52 titrated
upward to 100 mg TID when post-load blood glucose > 12 mmol/l, downtitrated in case of intolerance.
CONTROL: placebo TID
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Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: SF 36 & Boyer quality of life rating instrument
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: ND
6. Insulin levels: fasting & post-load insulin
7. Weight: body weight
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: no reply
Study retrieved: CENTRAL, MEDLINE, EMBASE, Current Contents, manufacturer, handsearch
Study conducted in older patients
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Pagano 1995






NUMBER: 100 patients randomised, 96 patients completed study: AGI 49, CONTROL 47. Primary
efficacy data for 90 patients
SEX (F/M): AGI 16/33, CONTROL 23/24
AGE (YEARS (MEAN, SD)): patients that completed study: AGI 57 (8.4), CONTROL 59 (7.5)
DURATION OF DIABETES (MONTHS (MEAN, SD)): patients that completed study: AGI 60 (48.
3), CONTROL 84 (64.4)
Interventions Dietary reinforcement: yes, 30 kcal per Kg of ideal body weight per day (60% carbohydrates, 25% fat,
15% protein, 30g dietary fibres)
AGI: miglitol, week 1-6 50 mg TID, week 7-24 100 mg TID
CONTROL: glibenclamide week 1-6 2,5 mg BID, week 7-24 5 mg BID, 1 placebo tablet to ensure
blinding
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: total-, HDL-cholesterol, triglycerides
6. Insulin levels: fasting insulin
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7. Weight: body weight
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: additional data on design, quality and outcomes send by author
Study retrieved: CENTRAL, MEDLINE, EMBASE
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Rosenthal 2002






NUMBER: selected: AGI 39, CONTROL 37, analysed: AGI 32, CONTROL 31
SEX: data missing
AGE (YEARS (MEAN, SD)): AGI 57.4 (8.6), CONTROL 57.7 (10.5)
DURATION OF DIABETES (MONTHS (MEAN, SD)): AGI 20.2 (31.2), CONTROL 35.6 (44.8)
Interventions Dietary reinforcement: no
AGI: acarbose, 50 mg TID, uptitrated to 100 mg TID (exact scheme not reported)
CONTROL: glibenclamide, maximum 10.5 mg daily (7 mg - 0 - 3.5 mg), step-up scheme as long as
fasting blood glucose remained > 8.9 mmol/l
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood-glucose
5. Lipids: total cholesterol, HDL, triglycerides
6. Insulin levels: fasting & post-load insulin
7. Weight: body weight, BMI
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: additional data on design, quality and outcomes via manufacturer
Study retrieved: EMBASE, Current Contents, manufacturer, (2 additional references via authors)
Main outcome is blood pressure.
According to the statistical report, the changes for lipids are calculated with standardised values (using a
linear transformation to the interval [0,1] with respect to normal range), and therefore cannot be used for
the meta-analysis
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Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Rybka 1999




Participants COUNTRY: multiple European countries, not further specification
SETTING: unclear
NUMBER: 603 patients included
SEX: data missing
AGE: data missing
DURATION OF DIABETES: data missing
Interventions Dietary reinforcement: yes, specifications unclear
AGI: acarbose 100 mg TID
CONTROL1: placebo
CONTROL2: miglitol 50 mg TID
CONTROL3: miglitol 100 mg TID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: ND
6. Insulin levels: ND
7. Weight: body weight
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: no reply
Study retrieved: handsearch
Published as an abstract. A non-systematic review on miglitol cited this study also as an unpublished
document (Scott 2000). Bayer referred to Pfizer being the current owner of this data, but wen received
no reply from Pfizer so far
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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NUMBER: randomised 72; analysed: AGI 27, CONTROL 30
SEX (F/M): analysed patients: AGI 10/17, CONTROL 14/16
AGE (YEARS (MEAN, SD)): analysed group: AGI 52,6 (9,1), CONTROL 56,1 (8,7)
DURATIONOFDIABETES (MONTHS (MEAN, SD)): analysed group: AGI50,4 (40,8),CONTROL
56,4 (67,2)
Interventions Dietary reinforcement: patients under dietary recommendations for at least 3 months, controlled for diet
compliance before study inclusion
AGI: acarbose, week 1 to 4 every week 50 mg increase to 100 mg BID, week 4-24 100 mg TID, dose
reduced to 100 mg BID in case of adverse events
CONTROL: gliclazide maximum 80 mg BID, depending on degree of glycemic control; in general
maximum dose was not recommended
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic Control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: triglycerides, total-, HDL- & LDL-cholesterol
6. Insulin levels: fasting & post-load insulin, fasting & post-load C-peptide
7. Weight: body weight, BMI
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: additional data on design, quality and outcomes send by author
Study retrieved: CENTRAL, MEDLINE, EMBASE, Current Contents, manufacturer
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Santeusanio 1993






NUMBER: randomised: AGI 27, CONTROL1 29, CONTROL2 28; evaluated in ITT-analysis: AGI
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23, CONTROL1 23, CONTROL2 18
SEX (F/M): ITT: AGI 8/15, CONTROL1 7/16, CONTROL2 8/10
AGE (YEARS (MEAN, SD)): ITT: AGI 53,8 (11,0), CONTROL1 55,5 (11,5), CONTROL2 58,9 (9,
8)
DURATION OF DIABETES (MONTHS (MEAN, SD)): ITT: AGI 60,6 (57,6), CONTROL1 46,4
(51,6), CONTROL2 46,4 (36,0)
Interventions Dietary reinforcement: yes, iso-caloric diet to maintain stable body weight (50-55% carbohydrates, <30%
lipids, 15-20% protein and <10 g/1000 kcal as fibre)
AGI: acarbose m100 mg TID
CONTROL1: placebo TID
CONTROL2: acarbose 50 mg TID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: ND
6. Insulin levels: fasting & post-load insulin
7. Weight: ND
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: additional data on design, quality and outcomes via manufacturer
Study retrieved: CENTRAL, MEDLINE, EMBASE, Current Contents, manufacturer, handsearch
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Scott 1999




Participants COUNTRY: New Zealand / Australia
SETTING: outpatient
NUMBER: AGI 53, CONTROL 52
SEX (F/M): AGI 20/33, CONTROL 18/34
AGE (YEARS (MEAN, SD)): AGI 56 (9), CONTROL 57 (8)
DURATION OF DIABETES (MONTHS (MEAN, SD)): AGI 21 (15), CONTROL 26 (17)
Interventions Dietary reinforcement: yes, ’conforming to current recommendations for type 2 diabetes’
AGI: acarbose, week 1-2 50 mg TID, wk 3-16 100 mg TID, dose reduced to 50 mg TID in case of adverse
events
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CONTROL: placebo TID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting blood glucose
5. Lipids: triglycerides, total- and HDL-cholesterol
6. Insulin levels: fasting insulin
7. Weight: ND
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: author replied that he passed our queries through to Bayer Australia, but we received
no reply from Bayer Australia since.
Study retrieved: CENTRAL, MEDLINE, EMBASE, Current Contents
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Segal 1997




Participants COUNTRY: Germany, Austria, Israel, Czech Republic
SETTING: outpatient
NUMBER: randomised 201, ITT 186, PP 119 (AGI 40, CONTROL 37, CONTROL2 42)
SEX (F/M): PP: AGI 18/22, CONTROL1 14/23, CONTROL2 18/24
AGE (YEARS (MEAN)): PP: AGI 61, CONTROL1 56, CONTROL2 59
DURATION OF DIABETES (MONTHS (MEAN, SD)): ND
Interventions Dietary reinforcement: no
AGI: miglitol, week 1-4 50 mg TID, week 5-25 100 mg TID
CONTROL1: glibenclamide 3,5 mg once or twice daily
CONTROL2: placebo TID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load glucose
5. Lipids: ND
6. Insulin levels: ND
7. Weight: body weight
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8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: no reply
Study retrieved: CENTRAL, MEDLINE, EMBASE, Current Contents
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Spengler 1992






NUMBER: randomised 72, analysed: AGI 26, CONTROL 29
SEX (F/M): AGI 15/11, CONTROL 18/11
AGE (YEARS (MEAN, SD)): analysed: AGI 59 (5), CONTROL 60 (7)
DURATION OF DIABETES (MONTHS (MEDIAN)): analysed: AGI 12.0, CONTROL 8.4
Interventions Dietary reinforcement: unclear
AGI: acarbose, week 1-2 50 mg TID, week 3-24 100 mg TID
CONTROL: glibenclamide maximum 3,5 mg TID
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: ND
6. Insulin levels: ND
7. Weight: body weight
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: additional data on design, quality and outcomes via manufacturer
Study retrieved: CENTRAL, MEDLINE, EMBASE, experts (1 additional reference via author)
For all outcomes except body weight, geometric means are reported; true means not available from articles
and statistical reports
Risk of bias
Item Authors’ judgement Description
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Allocation concealment? Unclear B - Unclear
Takami 2002






NUMBER: Analysed: AGI 12, CONTROL1 11, CONTROL2 9
SEX (F/M): AGI 3/9, CONTROL1 4/7, CONTROL2 3/10
AGE (YEARS (MEAN, SD)): total group (n=36!) men 48,7 (8,3), women 55,0 (7,8)
DURATION OF DIABETES: Newly diagnosed patients
Interventions Dietary reinforcement: yes, 30 kcal/Kg of ideal body weight per day, 60% carbohydrate, 20% fat, 20%
protein
AGI: voglibose 0,3 mg TID
CONTROL1: diet therapy
CONTROL2: glyburide 1,25 mg once daily
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting bloodglucose
5. Lipids: Total & HDL-cholesterol, triglycerides
6. Insulin levels: fasting insulin
7. Weight: weight & BMI
8. Adverse effects: ND
Notes Sponsor: not specified
Author contacted: no reply
Study retrieved: CENTRAL, MEDLINE, Current Contents, handsearch
36 ’study subjects’, 32 randomised and 4 patients assigned to diet group after random phase to ’facilitate
analysis of correlations between the changes in abdominal adipose tissue and glycemic control with diet’
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
57Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Van de Laar 2004a
Methods DESIGN: Parallel studyRANDOMISATION PROCEDURE: adequateBLINDING: double-blindDU-
RATION: 30 weeks
Participants COUNTRY:TheNetherlandsSETTING: general practiceNUMBER: randomised: AGI 48, CONTROL
48, ITT: AGI 32, CONTROL 43SEX (F/M): ITT: AGI 16/16, CONTROL 20/23AGE (YEARS
(MEAN, SD)): ITT: AGI 58.6 (7.7), CONTROL 58.6 (7.1)DURATION OF DIABETES (MONTHS
(MEDIAN)): analysed: AGI 12.0, CONTROL 8.4
Interventions Dietary reinforcement: yes, advice tailored to individual food habits by dietician with access to current
recommendationsAGI: acarbose, maximum dosage schedule at week 0, 2, 4 and 6-30 was (mg): 50 - 0 -
0, 50 - 0 - 50, 50 - 50 - 50 and 100 - 100 - 100 respectivelyCONTROL: tolbutamide, maximum dosage
schedule at week 0, 2, 4 and 6-30 (mg) was 500 - 0 - 0, 500 - 0 - 500, 500 - 500 - 500 and 1000 - 500 -
500 respectively
Outcomes 1. Mortality: ND 2. Diabetes related complications: ND 3. Quality of Life: ND4. Glycaemic Control:
glycated haemoglobin (HbA1c), fasting & post-load blood glucose5. Lipids: triglycerides, total-, LDL- &
HDL-cholesterol6. Insulin levels: fasting & post-load insulin 7. Weight: BMI8. Adverse effects: yes
Notes Sponsor: pharmaceuticalAuthor contacted: data possessed by authors reviewStudy retrieved: expertsE-
quivalence study
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Zheng 1995






NUMBER: AGI 39, CONTROL 38
SEX (F/M): AGI 19/20, CONTROL 18/20
AGE (YEARS (MEAN, SD)): AGI 49.6 (6.9), CONTROL 49.0 (6.6)
DURATION OF DIABETES (MONTHS (MEAN, SD)): AGI 49.2 (33.6), CONTROL 50.4 (43.2)
Interventions Dietary reinforcement: unclear (’diet and level of activity had to remain stable)
AGI: acarbose, week 1-3 50 mg TID, wk 4-24 100 mg TID
CONTROL: placebo
Outcomes 1. Mortality: ND
2. Diabetes related complications: ND
3. Quality of life: ND
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Zheng 1995 (Continued)
4. Glycaemic control: glycated haemoglobin (HbA1c), fasting & post-load blood glucose
5. Lipids: triglycerides, total- and HDL-cholesterol
6. Insulin levels: fasting & post-load insulin
7. Weight: BMI
8. Adverse effects: yes
Notes Sponsor: pharmaceutical
Author contacted: no reply
Study retrieved: CENTRAL
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
BID = two times per day; BMI = body mass index; CENTRAL = Cochrane Central Register of Controlled Trials; HDL = high-density
lipoprotein; ITT = intention-to-treat analysis; LDL = low-density lipoprotein; ND = no reported data; PP = per protocol analysis;
TID = three times per day,
For interventions the maximum dosage is given
For outcomes: Outome measures that are reported are given
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bachmann 2003 Use of additional anti-diabetic medication
Bayer 2003 Use of additional anti-diabetic medication
Bayer 2003a Use of additional anti-diabetic medication, included patients with type 1 and type 2 diabetes
Coniff 1995a Falsely included on basis of Embase search (excluded from Medline search) acarbose given as additional
therapy (added to insulin therapy)
De Leiva 1993 Use of additional anti-diabetic medication, reported data does not allow subgroup analysis of AGI only
group
Escobar-Jimenez 1995 Use of additional anti-diabetic medication, reported data does not allow subgroup analysis of AGI only
group
Fujita 2001 Use of additional anti-diabetic medication, reported data does not allow subgroup analysis of AGI only
group
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(Continued)
Hasche 1999 Use of additional medication, reported data does not allow subgroup analysis of AGI only group
Holman 1991 Duration of AGI treatment < 12 wk (4 wk)
Ikeda 1998 Use of additional anti-diabetic medication, reported data does not allow subgroup analysis of AGI only
group
Jenney 1993 No randomisation; Acarbose not given as monotherapy
Rosak 2002 Study duration < 12 wk (1 day)
Rosenbaum 2002 Us of additional anti-diabetic medication, reported data does not allow subgroup analysis of AGI only group
Soonthornpun 1998 Use of additional anti-diabetic medication
Wang 2000 Patients with impaired glucose tolerance (in stead of type 2 diabetes mellitus)
Characteristics of ongoing studies [ordered by study ID]
Holman 2003
Trial name or title Early Diabetes Intervention Study (EDIT)
Methods
Participants Subjects were selected on the basis of two consecutive fasting plasma glucose values of 5.5 to 7.7 mmol/l.
They all underwent OGTTs at entry into the study but if the 2-h glucose was found to be in the diabetic
range (i.e. 11.1 or above) they were not excluded, provided that the fasting remained below 7.8 mmol/l
Interventions Acarbose (50mg TID), metformin (500mg TID) and placebo; Design: prospective, parallel group, double
blind, double dummy, randomised, factorial design, multicentre study; Duration 6 years
Outcomes Progression to frank diabetes; Glycaemic reduction
Starting date 01 / 04 / 1998; end date: 30 / 04 / 2003
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Holman 2003 (Continued)
Notes A subgroup of 106 patients had postprandial blood glucose in the diabetic range (> 11.1 mmol/l, but fasting
blood glucose < 7.8 mmol/l). Data from this sub-group might be possible included in the review
Sa-adu 2003
Trial name or title A one-year multicentre, international, randomised, double-blind comparison of
Mitiglinide (10to40mgTID) and Acarbose (50mgODto100mgTID) administered orally for the treatment
of elderly type 2 diabetic patients
Methods
Participants Elderly type 2 diabetic patients suboptimally controlled with diet alone
Interventions Mitiglinide (10 to 40mg TID) and Acarbose (50 mgOD to 100 mgTID); Design: comparative, randomised,
double blind, parallel group phase III
Outcomes HbA1c
Starting date 01 /12 / 2--1; end date: 01/ 06 / 2003
Contact information Prof Alan Sinclair, The University of Warwick; Dr Alfa Sa-adu









Notes Two e-mails to prof. Sinclair were not answered. Dr Sa-adu replied that he was not a contributor to this study
and that recruitment was taken to East European Countries
Whitby 1998
Trial name or title A long-term study to investigate the effects of acarbose (glucobay) in
preventing or delaying deterioration in glycaemic status in non-insulin diabetes
will controlled on diet alone.
Methods
Participants Non-insulin dependent diabetics, either newly diagnosed or well controlled on diet alone
Interventions Acarbose versus placebo
Outcomes Not specified
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Whitby 1998 (Continued)
Starting date 28 / 09 / 1993; end date: 31 / 07 / 1996








Telephone: 0121 554 3801






Notes Dr Ryder and dr. Whitby were contacted. Dr Ryder referred to prof. Holman as leading investigator, but
Professor Holman did not reply to our e-mails regarding questions about this study
TID = three times per day
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D A T A A N D A N A L Y S E S
Comparison 1. Acarbose versus placebo




participants Statistical method Effect size
1 Change in glycated haemoglobin
(%)
22 2831 Mean Difference (IV, Random, 95% CI) -0.77 [-0.90, -0.64]
1.1 Acarbose 25 mg TID 1 178 Mean Difference (IV, Random, 95% CI) -0.48 [-0.86, -0.10]
1.2 Acarbose 50 mg BID 1 17 Mean Difference (IV, Random, 95% CI) -0.1 [-2.31, 2.11]
1.3 Acarbose 50 mg TID 2 217 Mean Difference (IV, Random, 95% CI) -0.90 [-1.20, -0.59]
1.4 Acarbose 100 mg TID 17 1615 Mean Difference (IV, Random, 95% CI) -0.76 [-0.95, -0.56]
1.5 Acarbose 200-100-200 1 20 Mean Difference (IV, Random, 95% CI) -0.5 [-3.75, 2.75]
1.6 Acarbose 200 mg TID 4 486 Mean Difference (IV, Random, 95% CI) -0.77 [-1.00, -0.53]
1.7 Acarbose 300 mg TID 2 298 Mean Difference (IV, Random, 95% CI) -0.78 [-1.18, -0.38]
2 Change in fasting blood glucose
(mmol/l)
22 2838 Mean Difference (IV, Random, 95% CI) -1.09 [-1.36, -0.83]
2.1 Acarbose 25 mg TID 1 177 Mean Difference (IV, Random, 95% CI) -0.29 [-0.85, 0.27]
2.2 Acarbose 50 mg BID 2 57 Mean Difference (IV, Random, 95% CI) -0.73 [-2.64, 1.18]
2.3 Acarbose 50 mg TID 1 179 Mean Difference (IV, Random, 95% CI) -0.96 [-1.51, -0.41]
2.4 Acarbose 100 mg TID 17 1632 Mean Difference (IV, Random, 95% CI) -1.07 [-1.41, -0.72]
2.5 Acarbose 200-100-200 1 20 Mean Difference (IV, Random, 95% CI) 1.6 [-2.26, 5.46]
2.6 Acarbose 200 mg TID 4 478 Mean Difference (IV, Random, 95% CI) -1.49 [-1.92, -1.06]
2.7 Acarbose 300 mg TID 2 295 Mean Difference (IV, Random, 95% CI) -1.40 [-2.54, -0.27]
3 Change in post-load blood
glucose (mmol/l)
16 2238 Mean Difference (IV, Random, 95% CI) -2.32 [-2.73, -1.92]
3.1 Acarbose 25 mg TID 1 176 Mean Difference (IV, Random, 95% CI) -1.36 [-2.14, -0.58]
3.2 Acarbose 50 mg BID 1 17 Mean Difference (IV, Random, 95% CI) -1.8 [-3.23, -0.37]
3.3 Acarbose 50 mg TID 2 219 Mean Difference (IV, Random, 95% CI) -1.63 [-2.40, -0.87]
3.4 Acarbose 100 mg TID 13 1124 Mean Difference (IV, Random, 95% CI) -2.26 [-2.79, -1.73]
3.5 Acarbose 200 mg TID 3 411 Mean Difference (IV, Random, 95% CI) -2.78 [-3.72, -1.85]
3.6 Acarbose 300 mg TID 2 291 Mean Difference (IV, Random, 95% CI) -3.62 [-5.34, -1.89]
4 Change in total cholesterol
(mmol/l)
17 2133 Mean Difference (IV, Random, 95% CI) -0.00 [-0.10, 0.09]
4.1 Acarbose 25 mg TID 1 179 Mean Difference (IV, Random, 95% CI) 0.12 [-0.16, 0.40]
4.2 Acarbose 50 mg BID 1 17 Mean Difference (IV, Random, 95% CI) -0.3 [-1.39, 0.79]
4.3 Acarbose 50 mg TID 2 218 Mean Difference (IV, Random, 95% CI) 0.00 [-0.24, 0.25]
4.4 Acarbose 100 mg TID 13 999 Mean Difference (IV, Random, 95% CI) -0.10 [-0.30, 0.11]
4.5 Acarbose 200-100-200 1 20 Mean Difference (IV, Random, 95% CI) -0.30 [-1.62, 1.02]
4.6 Acarbose 200 mg TID 3 410 Mean Difference (IV, Random, 95% CI) -0.02 [-0.18, 0.14]
4.7 Acarbose 300 mg TID 2 290 Mean Difference (IV, Random, 95% CI) 0.03 [-0.16, 0.22]
5 Change in HDL-cholesterol
(mmol/l)
13 924 Mean Difference (IV, Random, 95% CI) -0.00 [-0.04, 0.04]
5.1 Acarbose 50 mg BID 1 17 Mean Difference (IV, Random, 95% CI) -0.10 [-0.39, 0.19]
5.2 Acarbose 50 mg TID 1 38 Mean Difference (IV, Random, 95% CI) -0.09 [-0.28, 0.10]
5.3 Acarbose 100 mg TID 10 608 Mean Difference (IV, Random, 95% CI) 0.01 [-0.06, 0.07]
5.4 Acarbose 200 mg TID 1 109 Mean Difference (IV, Random, 95% CI) 0.01 [-0.08, 0.10]
5.5 Acarbose 300 mg TID 1 152 Mean Difference (IV, Random, 95% CI) Not estimable
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6 Change in LDL-cholesterol
(mmol/l)
4 402 Mean Difference (IV, Random, 95% CI) -0.08 [-0.41, 0.25]
6.1 Acarbose 100 mg TID 2 184 Mean Difference (IV, Random, 95% CI) -0.42 [-1.63, 0.80]
6.2 Acarbose 200 mg TID 1 93 Mean Difference (IV, Random, 95% CI) 0.16 [-0.12, 0.44]
6.3 Acarbose 300 mg TID 1 125 Mean Difference (IV, Random, 95% CI) -0.04 [-0.26, 0.18]
7 Change in triglycerides (mmol/l) 15 1969 Mean Difference (IV, Random, 95% CI) -0.09 [-0.18, 0.00]
7.1 Acarbose 25 mg TID 1 179 Mean Difference (IV, Random, 95% CI) 0.22 [-0.22, 0.66]
7.2 Acarbose 50 mg BID 1 17 Mean Difference (IV, Random, 95% CI) -0.2 [-1.96, 1.56]
7.3 Acarbose 50 mg TID 2 217 Mean Difference (IV, Random, 95% CI) 0.05 [-0.22, 0.33]
7.4 Acarbose 100 mg TID 11 834 Mean Difference (IV, Random, 95% CI) Not estimable
7.5 Acarbose 200-100-200 1 20 Mean Difference (IV, Random, 95% CI) 0.4 [-0.85, 1.65]
7.6 Acarbose 200 mg TID 3 412 Mean Difference (IV, Random, 95% CI) -0.27 [-0.57, 0.02]
7.7 Acarbose 300 mg TID 2 290 Mean Difference (IV, Random, 95% CI) -0.06 [-0.25, 0.14]
8 Change in fasting insulin levels
(pmol/l)
12 1264 Mean Difference (IV, Random, 95% CI) -0.52 [-7.90, 6.86]
8.1 Acarbose 50 mg TID 1 24 Mean Difference (IV, Random, 95% CI) -3.50 [-25.47, 18.
47]
8.2 Acarbose 100 mg TID 11 882 Mean Difference (IV, Random, 95% CI) 0.07 [-8.60, 8.73]
8.3 Acarbose 200 mg TID 2 242 Mean Difference (IV, Random, 95% CI) 4.59 [-20.63, 29.82]
8.4 Acarbose 300 mg TID 1 116 Mean Difference (IV, Random, 95% CI) -16.35 [-43.24, 10.
54]
9 Change in post-load insulin
levels (pmol/l)
10 1050 Mean Difference (IV, Random, 95% CI) -40.82 [-60.64, -21.
01]
9.1 Acarbose 50 mg TID 1 24 Mean Difference (IV, Random, 95% CI) 40.8 [-90.43, 172.
03]
9.2 Acarbose 100 mg TID 9 673 Mean Difference (IV, Random, 95% CI) -45.83 [-71.68, -19.
98]
9.3 Acarbose 200 mg TID 2 239 Mean Difference (IV, Random, 95% CI) -15.46 [-58.62, 27.
69]
9.4 Acarbose 300 mg TID 1 114 Mean Difference (IV, Random, 95% CI) -62.4 [-113.24, -11.
56]
10 Change in fasting C-peptide
levels (nmol/l)
1 94 Mean Difference (IV, Random, 95% CI) -0.05 [-0.18, 0.08]
10.1 Acarbose 100 mg TID 1 94 Mean Difference (IV, Random, 95% CI) -0.05 [-0.18, 0.08]
11 Change in post-load C-peptide
levels (nmol/l)
1 94 Mean Difference (IV, Random, 95% CI) -0.10 [-0.34, 0.14]
11.1 Acarbose 100 mg TID 1 94 Mean Difference (IV, Random, 95% CI) -0.10 [-0.34, 0.14]
12 Change in body weight (Kg) 14 1451 Mean Difference (IV, Random, 95% CI) -0.13 [-0.46, 0.20]
12.1 Acarbose 50 mg BID 1 17 Mean Difference (IV, Random, 95% CI) 0.30 [-19.48, 20.08]
12.2 Acarbose 100 mg TID 10 864 Mean Difference (IV, Random, 95% CI) -0.09 [-0.61, 0.42]
12.3 Acarbose 200-100-200 1 20 Mean Difference (IV, Random, 95% CI) -0.90 [-9.94, 8.14]
12.4 Acarbose 200 mg TID 2 245 Mean Difference (IV, Random, 95% CI) -0.23 [-0.86, 0.39]
12.5 Acarbose 300 mg TID 2 305 Mean Difference (IV, Random, 95% CI) -0.08 [-0.67, 0.51]
13 Change in body mass index
(Kg/m2)
10 1430 Mean Difference (IV, Random, 95% CI) -0.17 [-0.25, -0.08]
13.1 Acarbose 25 mg TID 1 177 Mean Difference (IV, Random, 95% CI) -0.03 [-0.25, 0.19]
13.2 Acarbose 50 mg BID 1 17 Mean Difference (IV, Random, 95% CI) 0.10 [-6.61, 6.81]
13.3 Acarbose 50 mg TID 2 219 Mean Difference (IV, Random, 95% CI) -0.05 [-0.26, 0.17]
13.4 Acarbose 100 mg TID 9 842 Mean Difference (IV, Random, 95% CI) -0.25 [-0.37, -0.13]
13.5 Acarbose 200 mg TID 1 175 Mean Difference (IV, Random, 95% CI) -0.15 [-0.38, 0.08]
14 Total deaths 2 385 Odds Ratio (M-H, Random, 95% CI) 1.11 [0.29, 4.22]
14.1 Acarbose 100 mg TID 1 256 Odds Ratio (M-H, Random, 95% CI) 1.11 [0.29, 4.22]
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14.2 Acarbose 200 mg TID 1 129 Odds Ratio (M-H, Random, 95% CI) Not estimable
15 Disease related deaths 1 129 Odds Ratio (M-H, Random, 95% CI) Not estimable
15.1 Acarbose 200 mg TID 1 129 Odds Ratio (M-H, Random, 95% CI) Not estimable
16 Occurence of morbidity (total) 0 Odds Ratio (M-H, Random, 95% CI) Subtotals only
16.1 Acarbose 200 mg TID 0 0 Odds Ratio (M-H, Random, 95% CI) Not estimable
17 Occurence of morbidity
(disease specific)
0 Odds Ratio (M-H, Random, 95% CI) Subtotals only
17.1 Acarbose 200 mg TID 0 0 Odds Ratio (M-H, Random, 95% CI) Not estimable
18 Occurence of adverse effects 16 3819 Odds Ratio (M-H, Random, 95% CI) 3.37 [2.60, 4.36]
18.1 Acarbose 25 mg TID 1 199 Odds Ratio (M-H, Random, 95% CI) 1.59 [0.90, 2.83]
18.2 Acarbose 50 mg TID 3 775 Odds Ratio (M-H, Random, 95% CI) 2.11 [1.29, 3.47]
18.3 Acarbose 100 mg TID 14 2003 Odds Ratio (M-H, Random, 95% CI) 3.38 [2.53, 4.52]
18.4 Acarbose 200 mg TID 3 486 Odds Ratio (M-H, Random, 95% CI) 6.97 [4.01, 12.12]
18.5 Acarbose 300 mg TID 2 356 Odds Ratio (M-H, Random, 95% CI) 3.78 [1.38, 10.37]
19 Occurence of gastro-intestinal
adverse effects
3 1442 Odds Ratio (M-H, Random, 95% CI) 3.30 [2.31, 4.71]
19.1 Acarbose 50 mg TID 1 522 Odds Ratio (M-H, Random, 95% CI) 2.72 [1.91, 3.88]
19.2 Acarbose 100 mg TID 2 774 Odds Ratio (M-H, Random, 95% CI) 2.82 [2.08, 3.82]
19.3 Acarbose 200 mg TID 1 146 Odds Ratio (M-H, Random, 95% CI) 7.39 [3.51, 15.59]
20 Quality of life 0 0 Mean Difference (IV, Random, 95% CI) Not estimable
21 Change in post-load blood
glucose (mmol/l) (2-hours)
16 2243 Mean Difference (IV, Random, 95% CI) -2.27 [-2.67, -1.88]
21.1 Acarbose 25 mg TID 1 176 Mean Difference (IV, Random, 95% CI) -1.36 [-2.14, -0.58]
21.2 Acarbose 50 mg BID 1 17 Mean Difference (IV, Random, 95% CI) -1.8 [-3.23, -0.37]
21.3 Acarbose 50 mg TID 2 219 Mean Difference (IV, Random, 95% CI) -1.60 [-2.35, -0.84]
21.4 Acarbose 100 mg TID 13 1126 Mean Difference (IV, Random, 95% CI) -2.22 [-2.75, -1.70]
21.5 Acarbose 200 mg TID 3 411 Mean Difference (IV, Random, 95% CI) -2.83 [-3.78, -1.88]
21.6 Acarbose 300 mg TID 2 294 Mean Difference (IV, Random, 95% CI) -3.54 [-5.12, -1.96]
22 Change in post-load insulin
levels (pmol/l) (2-hours)
10 1057 Mean Difference (IV, Random, 95% CI) -38.83 [-58.77, -18.
89]
22.1 Acarbose 50 mg TID 1 24 Mean Difference (IV, Random, 95% CI) 55.9 [-76.79, 188.
59]
22.2 Acarbose 100 mg TID 9 675 Mean Difference (IV, Random, 95% CI) -45.71 [-69.57, -21.
85]
22.3 Acarbose 200 mg TID 2 242 Mean Difference (IV, Random, 95% CI) -6.29 [-61.94, 49.
36]
22.4 Acarbose 300 mg TID 1 116 Mean Difference (IV, Random, 95% CI) -39.47 [-109.73, 30.
79]
Comparison 2. Acarbose versus sulphonylurea (SU)




participants Statistical method Effect size
1 Change in glycated haemoglobin
(%)
8 596 Mean Difference (IV, Random, 95% CI) 0.38 [-0.02, 0.77]
1.1 Acarbose 100 mg TID
vs Tolbutamide 2000 mg in 3
dose
1 75 Mean Difference (IV, Random, 95% CI) 0.7 [0.18, 1.22]
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1.2 Acarbose 200 mg TID vs
Tolbutamide 1000 mg TID
1 133 Mean Difference (IV, Random, 95% CI) 0.39 [0.03, 0.75]
1.3 Acarbose 100 mg TID vs
Glibenclamide 1 mg TID
1 52 Mean Difference (IV, Random, 95% CI) 1.3 [0.57, 2.03]
1.4 Acarbose 100 mg TID vs
Glibenclamide 3,5 mg TID
4 279 Mean Difference (IV, Random, 95% CI) 0.07 [-0.43, 0.58]
1.5 Acarbose 100 mg TID vs
Gliclazide 80 mg BID
1 57 Mean Difference (IV, Random, 95% CI) 0.38 [-0.37, 1.13]
2 Change in fasting blood glucose
(mmol/l)
8 596 Mean Difference (IV, Random, 95% CI) 0.69 [0.16, 1.23]
2.1 Acarbose 100 mg TID
vs Tolbutamide 2000 mg in 3
dose
1 75 Mean Difference (IV, Random, 95% CI) 1.4 [0.34, 2.46]
2.2 Acarbose 200 mg TID vs
Tolbutamide 1000 mg TID
1 133 Mean Difference (IV, Random, 95% CI) 0.91 [-0.16, 1.98]
2.3 Acarbose 100 mg TID vs
Glibenclamide 1 mg TID
1 52 Mean Difference (IV, Random, 95% CI) 2.5 [0.69, 4.31]
2.4 Acarbose 100 mg TID vs
Glibenclamide 3,5 mg TID
4 279 Mean Difference (IV, Random, 95% CI) 0.20 [-0.29, 0.69]
2.5 Acarbose 100 mg TID vs
Gliclazide 80 mg BID
1 57 Mean Difference (IV, Random, 95% CI) 0.69 [-0.57, 1.95]
3 Change in post-load blood
glucose (mmol/l)
8 591 Mean Difference (IV, Random, 95% CI) -0.10 [-0.43, 0.22]
3.1 Acarbose 100 mg TID
vs Tolbutamide 2000 mg in 3
dose
1 70 Mean Difference (IV, Random, 95% CI) 1.00 [-0.66, 2.66]
3.2 Acarbose 200 mg TID vs
Tolbutamide 1000 mg TID
1 133 Mean Difference (IV, Random, 95% CI) 0.33 [-0.95, 1.61]
3.3 Acarbose 100 mg TID vs
Glibenclamide 1 mg TID
1 52 Mean Difference (IV, Random, 95% CI) 0.80 [-2.87, 4.47]
3.4 Acarbose 100 mg TID vs
Glibenclamide 3,5 mg TID
4 279 Mean Difference (IV, Random, 95% CI) -0.15 [-0.46, 0.16]
3.5 Acarbose 100 mg TID vs
Gliclazide 80 mg BID
1 57 Mean Difference (IV, Random, 95% CI) -1.57 [-3.36, 0.22]
4 Change in total cholesterol
(mmol/l)
7 499 Mean Difference (IV, Random, 95% CI) -0.09 [-0.23, 0.05]
4.1 Acarbose 100 mg TID
vs Tolbutamide 2000 mg in 3
dose
1 67 Mean Difference (IV, Random, 95% CI) 0.10 [-0.19, 0.39]
4.2 Acarbose 200 mg TID vs
Tolbutamide 1000 mg TID
1 125 Mean Difference (IV, Random, 95% CI) -0.26 [-0.53, 0.01]
4.3 Acarbose 100 mg TID vs
Glibenclamide 1 mg TID
1 34 Mean Difference (IV, Random, 95% CI) 0.15 [-0.40, 0.70]
4.4 Acarbose 100 mg TID vs
Glibenclamide 3,5 mg TID
3 216 Mean Difference (IV, Random, 95% CI) -0.14 [-0.39, 0.10]
4.5 Acarbose 100 mg TID vs
Gliclazide 80 mg BID
1 57 Mean Difference (IV, Random, 95% CI) -0.09 [-0.59, 0.41]
5 Change in HDL-cholesterol
(mmol/l)
7 485 Mean Difference (IV, Random, 95% CI) 0.02 [-0.02, 0.06]
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5.1 Acarbose 100 mg TID
vs Tolbutamide 2000 mg in 3
dose
1 66 Mean Difference (IV, Random, 95% CI) Not estimable
5.2 Acarbose 200 mg TID vs
Tolbutamide 1000 mg TID
1 112 Mean Difference (IV, Random, 95% CI) -0.01 [-0.10, 0.08]
5.3 Acarbose 100 mg TID vs
Glibenclamide 1 mg TID
1 34 Mean Difference (IV, Random, 95% CI) 0.01 [-0.21, 0.23]
5.4 Acarbose 100 mg TID vs
Glibenclamide 3,5 mg TID
3 216 Mean Difference (IV, Random, 95% CI) 0.04 [-0.02, 0.10]
5.5 Acarbose 100 mg TID vs
Gliclazide 80 mg BID
1 57 Mean Difference (IV, Random, 95% CI) 0.02 [-0.13, 0.17]
6 Change in LDL-cholesterol
(mmol/l)
4 312 Mean Difference (IV, Random, 95% CI) 0.10 [-0.07, 0.27]
6.1 Acarbose 100 mg TID
vs Tolbutamide 2000 mg in 3
dose
1 65 Mean Difference (IV, Random, 95% CI) 0.2 [-0.07, 0.47]
6.2 Acarbose 200 mg TID vs
Tolbutamide 1000 mg TID
1 95 Mean Difference (IV, Random, 95% CI) 0.01 [-0.26, 0.28]
6.3 Acarbose 100 mg TID vs
Glibenclamide 3,5 mg TID
1 95 Mean Difference (IV, Random, 95% CI) 0.02 [-0.63, 0.67]
6.4 Acarbose 100 mg TID vs
Gliclazide 80 mg BID
1 57 Mean Difference (IV, Random, 95% CI) 0.09 [-0.36, 0.54]
7 Change in triglycerides (mmol/l) 8 591 Mean Difference (IV, Random, 95% CI) 0.01 [-0.18, 0.20]
7.1 Acarbose 100 mg TID
vs Tolbutamide 2000 mg in 3
dose
1 67 Mean Difference (IV, Random, 95% CI) 0.10 [-0.79, 0.99]
7.2 Acarbose 200 mg TID vs
Tolbutamide 1000 mg TID
1 125 Mean Difference (IV, Random, 95% CI) -0.46 [-1.11, 0.19]
7.3 Acarbose 100 mg TID vs
Glibenclamide 1 mg TID
1 52 Mean Difference (IV, Random, 95% CI) 0.4 [-0.20, 1.00]
7.4 Acarbose 100 mg TID vs
Glibenclamide 3,5 mg TID
4 290 Mean Difference (IV, Random, 95% CI) 0.06 [-0.17, 0.29]
7.5 Acarbose 100 mg TID vs
Gliclazide 80 mg BID
1 57 Mean Difference (IV, Random, 95% CI) -0.31 [-0.86, 0.24]
8 Change in fasting insulin levels
(pmol/l)
7 486 Mean Difference (IV, Random, 95% CI) -24.78 [-43.30, -6.
26]
8.1 Acarbose 100 mg TID
vs Tolbutamide 2000 mg in 3
dose
1 63 Mean Difference (IV, Random, 95% CI) -1.50 [-39.50, 36.
50]
8.2 Acarbose 200 mg TID vs
Tolbutamide 1000 mg TID
1 130 Mean Difference (IV, Random, 95% CI) -25.40 [-63.97, 13.
17]
8.3 Acarbose 100 mg TID vs
Glibenclamide 1 mg TID
1 52 Mean Difference (IV, Random, 95% CI) Not estimable
8.4 Acarbose 100 mg TID vs
Glibenclamide 3,5 mg TID
3 184 Mean Difference (IV, Random, 95% CI) -35.03 [-88.53, 18.
47]
8.5 Acarbose 100 mg TID vs
Gliclazide 80 mg BID
1 57 Mean Difference (IV, Random, 95% CI) -34.81 [-65.98, -3.
64]
9 Change in post-load insulin
levels (pmol/l)
7 483 Mean Difference (IV, Random, 95% CI) -133.17 [-184.53, -
81.82]
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9.1 Acarbose 100 mg TID
vs Tolbutamide 2000 mg in 3
dose (1 hour pp)
1 60 Mean Difference (IV, Random, 95% CI) -18.9 [-126.62, 88.
82]
9.2 Acarbose 200 mg TID vs
Tolbutamide 1000 mg TID
1 130 Mean Difference (IV, Random, 95% CI) -214.1 [-291.77, -
136.43]
9.3 Acarbose 100 mg TID vs
Glibenclamide 1 mg TID
1 52 Mean Difference (IV, Random, 95% CI) -180.0 [-312.44, -
47.56]
9.4 Acarbose 100 mg TID vs
Glibenclamide 3,5 mg TID
3 184 Mean Difference (IV, Random, 95% CI) -100.66 [-124.60, -
76.72]
9.5 Acarbose 100 mg TID vs
Gliclazide 80 mg BID
1 57 Mean Difference (IV, Random, 95% CI) -172.38 [-280.31, -
64.45]
10 Change in fasting C-peptide
levels (nmol/l)
1 57 Mean Difference (IV, Random, 95% CI) -0.18 [-0.51, 0.15]
10.1 Acarbose 100 mg TID vs
Gliclazide 80 mg BID
1 57 Mean Difference (IV, Random, 95% CI) -0.18 [-0.51, 0.15]
11 Change in post-load C-peptide
levels (nmol/l)
1 57 Mean Difference (IV, Random, 95% CI) -0.36 [-0.94, 0.22]
11.1 Acarbose 100 mg TID vs
Gliclazide 80 mg BID
1 57 Mean Difference (IV, Random, 95% CI) -0.36 [-0.94, 0.22]
12 Change in body weight (Kg) 5 397 Mean Difference (IV, Random, 95% CI) -1.90 [-4.01, 0.21]
12.1 Acarbose 200 mg TID vs
Tolbutamide 1000 mg TID
1 132 Mean Difference (IV, Random, 95% CI) -3.26 [-4.22, -2.30]
12.2 Acarbose 100 mg TID vs
Glibenclamide 1 mg TID
1 52 Mean Difference (IV, Random, 95% CI) -3.1 [-10.33, 4.13]
12.3 Acarbose 100 mg TID vs
Glibenclamide 3,5 mg TID
3 213 Mean Difference (IV, Random, 95% CI) -0.57 [-1.19, 0.06]
13 Change in body mass index
(Kg/m2)
4 230 Mean Difference (IV, Random, 95% CI) -0.39 [-0.83, 0.05]
13.1 Acarbose 100 mg TID vs
Glibenclamide 1 mg TID
1 52 Mean Difference (IV, Random, 95% CI) -1.1 [-3.23, 1.03]
13.2 Acarbose 100 mg TID vs
Glibenclamide 3,5 mg TID
2 121 Mean Difference (IV, Random, 95% CI) -0.38 [-1.31, 0.56]
13.3 Acarbose 100 mg TID vs
Gliclazide 80 mg BID
1 57 Mean Difference (IV, Random, 95% CI) -0.6 [-1.15, -0.05]
14 Total deaths 1 133 Odds Ratio (M-H, Random, 95% CI) 0.32 [0.01, 8.08]
14.1 Acarbose 200 mg TID vs
Tolbutamide 1000 mg TID
1 133 Odds Ratio (M-H, Random, 95% CI) 0.32 [0.01, 8.08]
15 Disease related deaths 1 133 Odds Ratio (M-H, Random, 95% CI) 0.32 [0.01, 8.08]
15.1 Acarbose 200 mg TID vs
Tolbutamide 1000 mg TID
1 133 Odds Ratio (M-H, Random, 95% CI) 0.32 [0.01, 8.08]
16 Occurence of adverse effects 7 607 Odds Ratio (M-H, Random, 95% CI) 3.95 [2.00, 7.80]
16.1 Acarbose 100 mg TID
vs Tolbutamide 2000 mg in 3
dose
1 96 Odds Ratio (M-H, Random, 95% CI) 2.54 [1.07, 6.03]
16.2 Acarbose 200 mg TID vs
Tolbutamide 1000 mg TID
1 145 Odds Ratio (M-H, Random, 95% CI) 6.61 [2.66, 16.44]
16.3 Acarbose 100 mg TID vs
Glibenclamide 3,5 mg TID
4 309 Odds Ratio (M-H, Random, 95% CI) 4.88 [1.37, 17.37]
16.4 Acarbose 100 mg TID vs
Gliclazide 80 mg BID
1 57 Odds Ratio (M-H, Random, 95% CI) 2.0 [0.60, 6.64]
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17 Occurence of gastro-intestinal
adverse effects
1 145 Odds Ratio (M-H, Random, 95% CI) 7.70 [3.64, 16.31]
17.1 Acarbose 200 mg TID vs
Tolbutamide 1000 mg TID
1 145 Odds Ratio (M-H, Random, 95% CI) 7.70 [3.64, 16.31]
18 Change in post-load blood
glucose (mmol/l) (2 hours)
8 591 Mean Difference (IV, Random, 95% CI) 0.06 [-0.42, 0.53]
18.1 Acarbose 100 mg TID
vs Tolbutamide 2000 mg in 3
dose
1 70 Mean Difference (IV, Random, 95% CI) 1.00 [-0.66, 2.66]
18.2 Acarbose 200 mg TID vs
Tolbutamide 1000 mg TID
1 133 Mean Difference (IV, Random, 95% CI) 1.39 [-0.10, 2.88]
18.3 Acarbose 100 mg TID vs
Glibenclamide 1 mg TID
1 52 Mean Difference (IV, Random, 95% CI) 0.80 [-2.87, 4.47]
18.4 Acarbose 100 mg TID vs
Glibenclamide 3,5 mg TID
4 279 Mean Difference (IV, Random, 95% CI) -0.15 [-0.46, 0.16]
18.5 Acarbose 100 mg TID vs
Gliclazide 80 mg BID
1 57 Mean Difference (IV, Random, 95% CI) -1.57 [-3.36, 0.22]
19 Change in post-load insulin
levels (pmol/l) (2 hours)
7 484 Mean Difference (IV, Random, 95% CI) -115.84 [-152.52, -
79.15]
19.1 Acarbose 100 mg TID
vs Tolbutamide 2000 mg in 3
dose (1 hour pp)
1 60 Mean Difference (IV, Random, 95% CI) -18.9 [-126.62, 88.
82]
19.2 Acarbose 200 mg TID vs
Tolbutamide 1000 mg TID
1 131 Mean Difference (IV, Random, 95% CI) -148.0 [-235.51, -
60.49]
19.3 Acarbose 100 mg TID vs
Glibenclamide 1 mg TID
1 52 Mean Difference (IV, Random, 95% CI) -180.0 [-312.44, -
47.56]
19.4 Acarbose 100 mg TID vs
Glibenclamide 3,5 mg TID
3 184 Mean Difference (IV, Random, 95% CI) -100.66 [-124.60, -
76.72]
19.5 Acarbose 100 mg TID vs
Gliclazide 80 mg BID
1 57 Mean Difference (IV, Random, 95% CI) -172.38 [-280.31, -
64.45]
Comparison 3. Acarbose versus Metformin




participants Statistical method Effect size
1 Change in glycated haemoglobin
(%)
1 62 Mean Difference (IV, Random, 95% CI) -0.25 [-0.61, 0.11]
1.1 Acarbose 100 mg TID
versus Metformin 850 mg BID
1 62 Mean Difference (IV, Random, 95% CI) -0.25 [-0.61, 0.11]
2 Change in fasting blood glucose
(mmol/l)
1 62 Mean Difference (IV, Random, 95% CI) -0.39 [-0.74, -0.04]
2.1 Acarbose 100 mg TID
versus Metformin 850 mg BID
1 62 Mean Difference (IV, Random, 95% CI) -0.39 [-0.74, -0.04]
3 Change in post-load blood
glucose (mmol/l)
1 62 Mean Difference (IV, Random, 95% CI) -0.42 [-0.79, -0.05]
3.1 Acarbose 100 mg TID
versus Metformin 850 mg BID
1 62 Mean Difference (IV, Random, 95% CI) -0.42 [-0.79, -0.05]
69Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
4 Change in total cholesterol
(mmol/l)
1 62 Mean Difference (IV, Random, 95% CI) -0.94 [-1.66, -0.22]
4.1 Acarbose 100 mg TID
versus Metformin 850 mg BID
1 62 Mean Difference (IV, Random, 95% CI) -0.94 [-1.66, -0.22]
5 Change in HDL-cholesterol
(mmol/l)
1 62 Mean Difference (IV, Random, 95% CI) 0.24 [-0.02, 0.50]
5.1 Acarbose 100 mg TID
versus Metformin 850 mg BID
1 62 Mean Difference (IV, Random, 95% CI) 0.24 [-0.02, 0.50]
6 Change in LDL-cholesterol
(mmol/l)
1 62 Mean Difference (IV, Random, 95% CI) -0.94 [-1.52, -0.36]
6.1 Acarbose 100 mg TID
versus Metformin 850 mg BID
1 62 Mean Difference (IV, Random, 95% CI) -0.94 [-1.52, -0.36]
7 Change in triglycerides (mmol/l) 1 62 Mean Difference (IV, Random, 95% CI) -0.28 [-0.80, 0.24]
7.1 Acarbose 100 mg TID
versus Metformin 850 mg BID
1 62 Mean Difference (IV, Random, 95% CI) -0.28 [-0.80, 0.24]
8 Change in fasting insulin levels
(pmol/l)
1 61 Mean Difference (IV, Random, 95% CI) 33.8 [-28.24, 95.84]
8.1 Acarbose 100 mg TID
versus Metformin 850 mg BID
1 61 Mean Difference (IV, Random, 95% CI) 33.8 [-28.24, 95.84]
9 Change in post-load insulin
levels (pmol/l)
1 61 Mean Difference (IV, Random, 95% CI) 115.30 [-13.22, 243.
82]
9.1 Acarbose 100 mg TID
versus Metformin 850 mg BID
1 61 Mean Difference (IV, Random, 95% CI) 115.30 [-13.22, 243.
82]
10 Change in body weight (Kg) 1 62 Mean Difference (IV, Random, 95% CI) -0.30 [-5.45, 4.85]
10.1 Acarbose 100 mg TID
versus Metformin 850 mg BID
1 62 Mean Difference (IV, Random, 95% CI) -0.30 [-5.45, 4.85]
11 Occurence of adverse effects 1 64 Odds Ratio (M-H, Random, 95% CI) 15.0 [3.06, 73.58]
Comparison 4. Acarbose versus nateglinide / repaglinide




participants Statistical method Effect size
1 Change in glycated haemoglobin
(%)
1 179 Mean Difference (IV, Random, 95% CI) 0.03 [-0.19, 0.25]
1.1 Acarbose 100 mg TID
versus Nateglinide 120 mg
TID
1 179 Mean Difference (IV, Random, 95% CI) 0.03 [-0.19, 0.25]
2 Change in fasting blood glucose
(mmol/l)
1 175 Mean Difference (IV, Random, 95% CI) -0.02 [-1.10, 1.06]
2.1 Acarbose 100 mg TID
versus Nateglinide 120 mg
TID
1 175 Mean Difference (IV, Random, 95% CI) -0.02 [-1.10, 1.06]
3 Change in body weight (Kg) 1 169 Mean Difference (IV, Random, 95% CI) -0.68 [-1.30, -0.06]
3.1 Acarbose 100 mg TID
versus Nateglinide 120 mg
TID
1 169 Mean Difference (IV, Random, 95% CI) -0.68 [-1.30, -0.06]
4 Occurence of adverse effects 1 179 Odds Ratio (M-H, Random, 95% CI) 1.92 [1.05, 3.50]
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4.1 Acarbose 100 mg TID
versus Nateglinide 120 mg
TID
1 179 Odds Ratio (M-H, Random, 95% CI) 1.92 [1.05, 3.50]
5 Occurence of gastro-intestinal
adverse effects
1 179 Odds Ratio (M-H, Random, 95% CI) 3.22 [1.66, 6.24]
5.1 Acarbose 100 mg TID
versus Nateglinide 120 mg
TID
1 179 Odds Ratio (M-H, Random, 95% CI) 3.22 [1.66, 6.24]
Comparison 5. Miglitol versus placebo




participants Statistical method Effect size
1 Change in glycated haemoglobin
(%)
4 1088 Mean Difference (IV, Random, 95% CI) -0.68 [-0.93, -0.44]
1.1 Miglitol 25 mg TID 1 171 Mean Difference (IV, Random, 95% CI) -0.46 [-0.84, -0.08]
1.2 Miglitol 50 mg TID 2 413 Mean Difference (IV, Random, 95% CI) -0.58 [-0.72, -0.43]
1.3 Miglitol 100 mg TID 3 359 Mean Difference (IV, Random, 95% CI) -0.79 [-1.35, -0.22]
1.4 Miglitol 200 mg TID 1 145 Mean Difference (IV, Random, 95% CI) -1.26 [-1.67, -0.85]
2 Change in fasting blood glucose
(mmol/l)
2 398 Mean Difference (IV, Random, 95% CI) -0.52 [-0.88, -0.16]
2.1 Miglitol 50 mg TID 1 236 Mean Difference (IV, Random, 95% CI) -0.6 [-0.95, -0.25]
2.2 Miglitol 100 mg TID
(max)
1 162 Mean Difference (IV, Random, 95% CI) -0.1 [-0.98, 0.78]
3 Change in post-load blood
glucose (mmol/l)
2 398 Mean Difference (IV, Random, 95% CI) -2.70 [-5.54, 0.14]
3.1 Miglitol 50 mg TID 1 236 Mean Difference (IV, Random, 95% CI) -4.1 [-4.68, -3.52]
3.2 Miglitol 100 mg TID
(max)
1 162 Mean Difference (IV, Random, 95% CI) -1.2 [-2.39, -0.01]
4 Change in fasting insulin levels
(pmol/l)
1 162 Mean Difference (IV, Random, 95% CI) -18.2 [-57.01, 20.
61]
4.1 Miglitol 50 mg TID 0 0 Mean Difference (IV, Random, 95% CI) Not estimable
4.2 Miglitol 100 mg TID 1 162 Mean Difference (IV, Random, 95% CI) -18.2 [-57.01, 20.
61]
5 Change in post-load insulin
levels (pmol/l)
2 398 Mean Difference (IV, Random, 95% CI) -16.62 [-39.23, 6.
00]
5.1 Miglitol 50 mg TID 1 236 Mean Difference (IV, Random, 95% CI) -15.80 [-41.15, 9.
55]
5.2 Miglitol 100 mg TID 1 162 Mean Difference (IV, Random, 95% CI) -19.80 [-69.83, 30.
23]
6 Change in body weight (Kg) 1 162 Mean Difference (IV, Random, 95% CI) 0.27 [-0.50, 1.04]
6.1 Miglitol 100 mg TID 1 162 Mean Difference (IV, Random, 95% CI) 0.27 [-0.50, 1.04]
7 Total deaths 1 408 Odds Ratio (M-H, Random, 95% CI) 2.97 [0.31, 28.80]
7.1 Miglitol 25 mg TID 1 205 Odds Ratio (M-H, Random, 95% CI) 2.94 [0.12, 73.07]
7.2 Miglitol 50 mg TID 1 203 Odds Ratio (M-H, Random, 95% CI) 3.00 [0.12, 74.52]
8 Disease related deaths 1 408 Odds Ratio (M-H, Random, 95% CI) 2.94 [0.12, 73.07]
8.1 Miglitol 25 mg TID 1 205 Odds Ratio (M-H, Random, 95% CI) 2.94 [0.12, 73.07]
8.2 Miglitol 50 mg TID 1 203 Odds Ratio (M-H, Random, 95% CI) Not estimable
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9 Occurence of adverse effects 4 1304 Odds Ratio (M-H, Random, 95% CI) 4.01 [1.69, 9.52]
9.1 Miglitol 25 mg TID 1 185 Odds Ratio (M-H, Random, 95% CI) 3.17 [0.62, 16.16]
9.2 Miglitol 50 mg TID 2 449 Odds Ratio (M-H, Random, 95% CI) 1.79 [1.05, 3.03]
9.3 Miglitol 100 mg TID 3 484 Odds Ratio (M-H, Random, 95% CI) 3.93 [0.96, 16.12]
9.4 Miglitol 200 mg TID 1 186 Odds Ratio (M-H, Random, 95% CI) 34.34 [7.98, 147.86]
10 Occurence of gastro-intestinal
adverse effects
2 428 Odds Ratio (M-H, Random, 95% CI) 3.12 [1.62, 6.02]
10.1 Miglitol 50 mg TID 1 263 Odds Ratio (M-H, Random, 95% CI) 2.30 [1.36, 3.89]
10.2 Miglitol 100 mg TID 1 165 Odds Ratio (M-H, Random, 95% CI) 4.5 [2.34, 8.67]
11 Change in post-load blood
glucose (mmol/l) (2-hours)
2 398 Mean Difference (IV, Random, 95% CI) -1.66 [-2.25, -1.07]
11.1 Miglitol 50 mg TID 1 236 Mean Difference (IV, Random, 95% CI) -1.7 [-2.36, -1.04]
11.2 Miglitol 100 mg TID
(max)
1 162 Mean Difference (IV, Random, 95% CI) -1.5 [-2.81, -0.19]
12 Change in post-load insulin
levels (pmol/l) (2-hours)
2 398 Mean Difference (IV, Random, 95% CI) -15.69 [-38.62, 7.
24]
12.1 Miglitol 50 mg TID 1 236 Mean Difference (IV, Random, 95% CI) -15.80 [-41.15, 9.
55]
12.2 Miglitol 100 mg TID 1 162 Mean Difference (IV, Random, 95% CI) -15.20 [-68.99, 38.
59]
Comparison 6. Miglitol versus sulphonylurea (SU)




participants Statistical method Effect size
1 Change in glycated haemoglobin
(%)
1 90 Mean Difference (IV, Random, 95% CI) 0.40 [-0.16, 0.96]
1.1 Miglitol 100 mg TID
versus Glibenclamide 5 mg
BID
1 90 Mean Difference (IV, Random, 95% CI) 0.40 [-0.16, 0.96]
2 Change in fasting blood glucose
(mmol/l)
1 90 Mean Difference (IV, Random, 95% CI) 0.27 [-0.74, 1.28]
2.1 Miglitol 100 mg TID
versus Glibenclamide 5 mg
BID
1 90 Mean Difference (IV, Random, 95% CI) 0.27 [-0.74, 1.28]
3 Change in post-load blood
glucose (mmol/l)
1 88 Mean Difference (IV, Random, 95% CI) -0.60 [-3.43, 2.23]
3.1 Miglitol 100 mg TID
versus Glibenclamide 5 mg
BID
1 88 Mean Difference (IV, Random, 95% CI) -0.60 [-3.43, 2.23]
4 Change in total cholesterol
(mmol/l)
1 88 Mean Difference (IV, Random, 95% CI) 0.08 [-0.29, 0.45]
4.1 Miglitol 100 mg TID
versus Glibenclamide 5 mg
BID
1 88 Mean Difference (IV, Random, 95% CI) 0.08 [-0.29, 0.45]
5 Change in HDL-cholesterol
(mmol/l)
1 86 Mean Difference (IV, Random, 95% CI) -0.01 [-0.26, 0.24]
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5.1 Miglitol 100 mg TID
versus Glibenclamide 5 mg
BID
1 86 Mean Difference (IV, Random, 95% CI) -0.01 [-0.26, 0.24]
6 Change in triglycerides (mmol/l) 1 89 Mean Difference (IV, Random, 95% CI) -0.04 [-0.40, 0.32]
6.1 Miglitol 100 mg TID
versus Glibenclamide 5 mg
BID
1 89 Mean Difference (IV, Random, 95% CI) -0.04 [-0.40, 0.32]
7 Change in fasting insulin levels
(pmol/l)
1 90 Mean Difference (IV, Random, 95% CI) -44.75 [-53.72, -35.
78]
7.1 Miglitol 100 mg TID
versus Glibenclamide 5 mg
BID
1 90 Mean Difference (IV, Random, 95% CI) -44.75 [-53.72, -35.
78]
8 Change in body weight (Kg) 1 90 Mean Difference (IV, Random, 95% CI) 0.46 [-0.48, 1.40]
8.1 Miglitol 100 mg TID
versus Glibenclamide 5 mg
BID
1 90 Mean Difference (IV, Random, 95% CI) 0.46 [-0.48, 1.40]
9 Total deaths 1 414 Odds Ratio (M-H, Random, 95% CI) 0.50 [0.09, 2.76]
9.1 Miglitol 25 mg versus
Glyburide 20 mg 1dd
1 208 Odds Ratio (M-H, Random, 95% CI) 0.50 [0.04, 5.55]
9.2 Miglitol 50 mg versus
Glyburide 20 mg 1dd
1 206 Odds Ratio (M-H, Random, 95% CI) 0.50 [0.05, 5.66]
10 Disease related deaths 1 414 Odds Ratio (M-H, Random, 95% CI) 0.63 [0.08, 5.14]
10.1 Miglitol 25 mg versus
Glyburide 20 mg 1dd
1 208 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.06, 16.20]
10.2 Miglitol 50 mg versus
Glyburide 20 mg 1dd
1 206 Odds Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.36]
11 Occurence of adverse effects 2 232 Odds Ratio (M-H, Random, 95% CI) 1.29 [0.69, 2.41]
11.1 Miglitol 100 mg TID
versus Glibenclamide 5 mg
BID
1 96 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.35, 2.54]
11.2 Miglitol 100 mg TID
versus Glibenclamide 3,5 mg
BID
1 136 Odds Ratio (M-H, Random, 95% CI) 1.58 [0.70, 3.56]
Comparison 7. Miglitol versus metformin




participants Statistical method Effect size
1 Change in glycated haemoglobin
(%)
1 161 Mean Difference (IV, Random, 95% CI) 0.87 [0.56, 1.18]
1.1 miglitol 100 mg TID
vs metformin 500 TID
(maximum)
1 161 Mean Difference (IV, Random, 95% CI) 0.87 [0.56, 1.18]
2 Change in fasting blood glucose
(mmol/l)
1 161 Mean Difference (IV, Random, 95% CI) 1.0 [0.18, 1.82]
2.1 Miglitol 100 mg TID vs
Metformin 500 mg TID
1 161 Mean Difference (IV, Random, 95% CI) 1.0 [0.18, 1.82]
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3 Change in post-load blood
glucose (mmol/l)
1 161 Mean Difference (IV, Random, 95% CI) 0.70 [-0.43, 1.83]
3.1 Miglitol 100 mg TID vs
Metformin 500 mg TID
1 161 Mean Difference (IV, Random, 95% CI) 0.70 [-0.43, 1.83]
4 Change in fasting insulin levels
(pmol/l)
1 161 Mean Difference (IV, Random, 95% CI) -1.10 [-30.04, 27.
84]
4.1 Migitol 100 mg TID vs
Metformin 500 mg TID
1 161 Mean Difference (IV, Random, 95% CI) -1.10 [-30.04, 27.
84]
5 Change in post-load insulin
levels (pmol/l)
1 161 Mean Difference (IV, Random, 95% CI) -48.30 [-94.38, -2.
22]
5.1 Miglitol 100 mg (max)
TID vs Metformin 500 mg
TID
1 161 Mean Difference (IV, Random, 95% CI) -48.30 [-94.38, -2.
22]
6 Change in body weight (Kg) 1 161 Mean Difference (IV, Random, 95% CI) 0.37 [-0.50, 1.24]
6.1 Miglitol 100 mg TID vs
Metformin 500 mg TID
1 161 Mean Difference (IV, Random, 95% CI) 0.37 [-0.50, 1.24]
7 Occurence of gastro-intestinal
side-effects
1 165 Odds Ratio (M-H, Random, 95% CI) 1.60 [0.83, 3.05]
7.1 Miglitol 100 mg TID vs
Metformin 500 mg TID
1 165 Odds Ratio (M-H, Random, 95% CI) 1.60 [0.83, 3.05]
8 Occurence of adverse effects 1 165 Odds Ratio (M-H, Random, 95% CI) 1.69 [0.39, 7.31]
8.1 Miglitol 100 mg TID vs
Metformin 500 mg TID, Total
side effects
1 165 Odds Ratio (M-H, Random, 95% CI) 1.69 [0.39, 7.31]
9 Change in post-load blood
glucose (mmol/l) (2 hours)
1 161 Mean Difference (IV, Random, 95% CI) 0.8 [-0.45, 2.05]
9.1 Miglitol 100 mg TID vs
Metformin 500 mg TID
1 161 Mean Difference (IV, Random, 95% CI) 0.8 [-0.45, 2.05]
10 Change in post-load insulin
levels (pmol/l) (2-hours)
1 161 Mean Difference (IV, Random, 95% CI) -67.2 [-115.65, -18.
75]
10.1 Miglitol 100 mg (max)
TID vs Metformin 500 mg
TID
1 161 Mean Difference (IV, Random, 95% CI) -67.2 [-115.65, -18.
75]
Comparison 8. Voglibose versus placebo




participants Statistical method Effect size
1 Change in glycated haemoglobin
(%)
1 238 Mean Difference (IV, Random, 95% CI) -0.47 [-0.63, -0.31]
1.1 Voglibose 0.2 mg TID 1 238 Mean Difference (IV, Random, 95% CI) -0.47 [-0.63, -0.31]
1.2 Voglibose 0,3 mg TID 0 0 Mean Difference (IV, Random, 95% CI) Not estimable
2 Change in fasting blood glucose
(mmol/l)
1 234 Mean Difference (IV, Random, 95% CI) -0.6 [-0.97, -0.23]
2.1 Voglibose 0.2 mg TID 1 234 Mean Difference (IV, Random, 95% CI) -0.6 [-0.97, -0.23]
2.2 Voglibose 0,3 mg TID 0 0 Mean Difference (IV, Random, 95% CI) Not estimable
3 Change in post-load blood
glucose (mmol/l)
1 234 Mean Difference (IV, Random, 95% CI) -2.4 [-2.97, -1.83]
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3.1 Voglibose 0.2 mg TID 1 234 Mean Difference (IV, Random, 95% CI) -2.4 [-2.97, -1.83]
4 Change in post-load insulin
levels (pmol/l)
1 234 Mean Difference (IV, Random, 95% CI) -12.90 [-37.06, 11.
26]
4.1 Voglibose 0.2 mg TID 1 234 Mean Difference (IV, Random, 95% CI) -12.90 [-37.06, 11.
26]
5 Occurence of adverse effects 1 263 Odds Ratio (M-H, Random, 95% CI) 1.15 [0.67, 1.97]
5.1 Voglibose 0,2 mg TID 1 263 Odds Ratio (M-H, Random, 95% CI) 1.15 [0.67, 1.97]
6 Occurence of gastro-intestinal
adverse effects
1 263 Odds Ratio (M-H, Random, 95% CI) 1.62 [0.96, 2.75]
6.1 Voglibose 0,2 mg TID 1 263 Odds Ratio (M-H, Random, 95% CI) 1.62 [0.96, 2.75]
7 Change in post-load blood
glucose (mmol/l) (2 hours)
1 234 Mean Difference (IV, Random, 95% CI) -1.7 [-2.37, -1.03]
7.1 Voglibose 0.2 mg TID 1 234 Mean Difference (IV, Random, 95% CI) -1.7 [-2.37, -1.03]
Comparison 9. Voglibose versus diet therapy




participants Statistical method Effect size
1 Change in glycated haemoglobin
(%)
1 23 Mean Difference (IV, Random, 95% CI) Not estimable
1.1 Voglibose 0,3 mg TID 1 23 Mean Difference (IV, Random, 95% CI) Not estimable
2 Change in fasting blood glucose
(mmol/l)
1 23 Mean Difference (IV, Random, 95% CI) -2.4 [-4.58, -0.22]
2.1 Voglibose 0,3 mg TID 1 23 Mean Difference (IV, Random, 95% CI) -2.4 [-4.58, -0.22]
3 Change in total cholesterol
(mmol/l)
1 23 Mean Difference (IV, Random, 95% CI) -0.7 [-1.64, 0.24]
3.1 Voglibose 0,3 mg TID 1 23 Mean Difference (IV, Random, 95% CI) -0.7 [-1.64, 0.24]
4 Change in HDL-cholesterol
(mmol/l)
1 23 Mean Difference (IV, Random, 95% CI) -0.4 [-0.81, 0.01]
4.1 Voglibose 0,3 mg TID 1 23 Mean Difference (IV, Random, 95% CI) -0.4 [-0.81, 0.01]
5 Change in fasting insulin levels
(pmol/l)
1 23 Mean Difference (IV, Random, 95% CI) 6.00 [-19.22, 31.22]
5.1 Voglibose 0,3 mg TID 1 23 Mean Difference (IV, Random, 95% CI) 6.00 [-19.22, 31.22]
6 Change in body weight (Kg) 1 23 Mean Difference (IV, Random, 95% CI) 0.20 [-4.99, 5.39]
6.1 Voglibose 0,3 mg TID 1 23 Mean Difference (IV, Random, 95% CI) 0.20 [-4.99, 5.39]
7 Change in body mass index
(Kg/m2)
1 23 Mean Difference (IV, Random, 95% CI) Not estimable
7.1 Voglibose 0,3 mg TID 1 23 Mean Difference (IV, Random, 95% CI) Not estimable
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Comparison 10. .Voglibose versus sulphonylurea (SU)




participants Statistical method Effect size
1 Change in glycated haemoglobin
(%)
1 21 Mean Difference (IV, Random, 95% CI) 1.3 [-0.45, 3.05]
1.1 Voglibose 0,3 mg TID vs
Glyburide 1,25 mg once daily
1 21 Mean Difference (IV, Random, 95% CI) 1.3 [-0.45, 3.05]
2 Change in fasting blood glucose
(mmol/l)
1 21 Mean Difference (IV, Random, 95% CI) -0.5 [-3.15, 2.15]
2.1 Voglibose 0,3 mg TID vs
Glyburide 1,25 mg once daily
1 21 Mean Difference (IV, Random, 95% CI) -0.5 [-3.15, 2.15]
3 Change in total cholesterol
(mmol/l)
1 21 Mean Difference (IV, Random, 95% CI) 0.10 [-1.13, 1.33]
3.1 Voglibose 0,3 mg TID vs
Glyburide 1,25 mg once daily
1 21 Mean Difference (IV, Random, 95% CI) 0.10 [-1.13, 1.33]
4 Change in HDL-cholesterol
(mmol/l)
1 21 Mean Difference (IV, Random, 95% CI) -0.2 [-0.59, 0.19]
4.1 Voglibose 0,3 mg TID vs
Glyburide 1,25 mg once daily
1 21 Mean Difference (IV, Random, 95% CI) -0.2 [-0.59, 0.19]
5 Change in fasting insulin levels
(pmol/l)
1 21 Mean Difference (IV, Random, 95% CI) -11.8 [-25.49, 1.89]
5.1 Voglibose 0,3 mg TID vs
Glyburide 1,25 mg once daily
1 21 Mean Difference (IV, Random, 95% CI) -11.8 [-25.49, 1.89]
6 Change in body weight (Kg) 1 21 Mean Difference (IV, Random, 95% CI) 0.60 [-9.73, 10.93]
6.1 Voglibose 0,3 mg TID vs
Glyburide 1,25 mg once daily
1 21 Mean Difference (IV, Random, 95% CI) 0.60 [-9.73, 10.93]
7 Change in body mass index
(Kg/m2)
1 21 Mean Difference (IV, Random, 95% CI) Not estimable
7.1 Voglibose 0,3 mg TID vs
Glyburide 1,25 mg once daily
1 21 Mean Difference (IV, Random, 95% CI) Not estimable
Comparison 11. Miglitol versus voglibose




participants Statistical method Effect size
1 Change in glycated haemoglobin
(%)
1 312 Mean Difference (IV, Random, 95% CI) -0.13 [-0.24, -0.02]
1.1 Miglitol 50 mg TID
versus Voglibose 0.2 mg TID
1 312 Mean Difference (IV, Random, 95% CI) -0.13 [-0.24, -0.02]
2 Change in fasting blood glucose
(mmol/l)
1 306 Mean Difference (IV, Random, 95% CI) Not estimable
2.1 Miglitol 50 mg TID
versus Voglibose 0.2 mg TID
1 306 Mean Difference (IV, Random, 95% CI) Not estimable
3 Change in post-load blood
glucose (mmol/l)
1 306 Mean Difference (IV, Random, 95% CI) -1.70 [-2.27, -1.13]
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3.1 Miglitol 50 mg TID
versus Voglibose 0.2 mg TID
1 306 Mean Difference (IV, Random, 95% CI) -1.70 [-2.27, -1.13]
4 Change in post-load insulin
levels (pmol/l)
1 306 Mean Difference (IV, Random, 95% CI) -2.90 [-30.04, 24.
24]
4.1 Miglitol 50 mg TID
versus Voglibose 0.2 mg TID
1 306 Mean Difference (IV, Random, 95% CI) -2.90 [-30.04, 24.
24]
5 Occurence of adverse effects 1 348 Odds Ratio (M-H, Random, 95% CI) 1.53 [0.96, 2.45]
5.1 Miglitol 50 mg TID
versus Voglibose 0.2 mg TID
1 348 Odds Ratio (M-H, Random, 95% CI) 1.53 [0.96, 2.45]
6 Occurence of gastro-intestinal
adverse effects
1 348 Odds Ratio (M-H, Random, 95% CI) 1.41 [0.93, 2.16]
6.1 Miglitol 50 mg TID
versus Voglibose 0.2 mg TID
1 348 Odds Ratio (M-H, Random, 95% CI) 1.41 [0.93, 2.16]
7 Change in post-load blood
glucose (mmol/l) (2 hours)
1 312 Mean Difference (IV, Random, 95% CI) Not estimable
Analysis 1.1. Comparison 1 Acarbose versus placebo, Outcome 1 Change in glycated haemoglobin (%).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 1 Acarbose versus placebo
Outcome: 1 Change in glycated haemoglobin (%)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 25 mg TID
Fischer 1998 92 0 (1.07) 86 0.48 (1.49) 4.7 % -0.48 [ -0.86, -0.10 ]
Subtotal (95% CI) 92 86 4.7 % -0.48 [ -0.86, -0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
2 Acarbose 50 mg BID
Delgado 2002 9 -0.1 (1.4) 8 0 (2.9) 0.3 % -0.10 [ -2.31, 2.11 ]
Subtotal (95% CI) 9 8 0.3 % -0.10 [ -2.31, 2.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
3 Acarbose 50 mg TID
Fischer 1998 91 -0.4 (1.18) 86 0.48 (1.49) 4.6 % -0.88 [ -1.28, -0.48 ]
Santeusanio 1993 18 -0.59 (0.68) 22 0.33 (0.88) 3.8 % -0.92 [ -1.40, -0.44 ]
Subtotal (95% CI) 109 108 8.4 % -0.90 [ -1.20, -0.59 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 5.72 (P < 0.00001)
-4 -2 0 2 4
Favours acarbose Favours placebo
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
4 Acarbose 100 mg TID
Braun 1996 42 -2.5 (1.8) 44 -1.1 (2.1) 1.9 % -1.40 [ -2.23, -0.57 ]
Calle-Pascual 1996 17 -0.3 (0.9) 16 -0.03 (1.5) 1.8 % -0.27 [ -1.12, 0.58 ]
Chan 1998 59 -0.7 (1.2) 62 -0.27 (1.1) 4.4 % -0.43 [ -0.84, -0.02 ]
Coniff 1995b 57 -0.46 (0.98) 62 0.35 (1.02) 5.0 % -0.81 [ -1.17, -0.45 ]
Dedov 1995 82 -2.17 (1.8) 73 -1.61 (2.1) 2.8 % -0.56 [ -1.18, 0.06 ]
Fischer 1998 89 -0.26 (1.43) 86 0.48 (1.49) 4.2 % -0.74 [ -1.17, -0.31 ]
Haffner 1997 25 0 (1.6) 25 0.7 (1.4) 1.9 % -0.70 [ -1.53, 0.13 ]
Hanefeld 1991 47 -0.65 (1.3) 47 -0.08 (1.4) 3.3 % -0.57 [ -1.12, -0.02 ]
Hoffmann 1994 28 -0.98 (0.45) 30 0.16 (0.39) 6.6 % -1.14 [ -1.36, -0.92 ]
Hoffmann 1997 31 -1.1 (0.79) 32 0.3 (0.27) 5.7 % -1.40 [ -1.69, -1.11 ]
Holman 1999 83 0.16 (1.78) 107 0.35 (1.56) 3.8 % -0.19 [ -0.67, 0.29 ]
Hotta 1993 16 -1.38 (1.75) 13 -0.42 (1.3) 1.2 % -0.96 [ -2.07, 0.15 ]
Kovacevic 1997 33 -0.7 (0.9) 31 0.2 (1.6) 2.7 % -0.90 [ -1.54, -0.26 ]
Meneilly 2000 80 -0.3 (1) 94 0.3 (1) 5.6 % -0.60 [ -0.90, -0.30 ]
Santeusanio 1993 22 -0.73 (0.96) 22 0.33 (0.88) 3.3 % -1.06 [ -1.60, -0.52 ]
Scott 1999 41 -0.14 (0.9) 42 0.25 (1.2) 4.0 % -0.39 [ -0.85, 0.07 ]
Zheng 1995 39 -0.94 (2.2) 38 -0.46 (2.4) 1.3 % -0.48 [ -1.51, 0.55 ]
Subtotal (95% CI) 791 824 59.5 % -0.76 [ -0.95, -0.56 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 45.01, df = 16 (P = 0.00014); I2 =64%
Test for overall effect: Z = 7.55 (P < 0.00001)
5 Acarbose 200-100-200
Buchanan 1988 9 1.1 (3.5) 11 1.6 (3.9) 0.2 % -0.50 [ -3.75, 2.75 ]
Subtotal (95% CI) 9 11 0.2 % -0.50 [ -3.75, 2.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
6 Acarbose 200 mg TID
Chiasson 1994 30 -0.4 (1.5) 37 0.5 (1.3) 2.5 % -0.90 [ -1.58, -0.22 ]
Coniff 1995 65 -0.54 (1.05) 62 0.04 (1.02) 5.0 % -0.58 [ -0.94, -0.22 ]
Coniff 1995b 54 -0.3 (1.03) 62 0.35 (1.02) 4.8 % -0.65 [ -1.02, -0.28 ]
Fischer 1998 90 -0.59 (1.24) 86 0.48 (1.49) 4.5 % -1.07 [ -1.48, -0.66 ]
Subtotal (95% CI) 239 247 16.7 % -0.77 [ -1.00, -0.53 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.69, df = 3 (P = 0.30); I2 =19%
Test for overall effect: Z = 6.40 (P < 0.00001)
-4 -2 0 2 4
Favours acarbose Favours placebo
(Continued . . . )
78Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
7 Acarbose 300 mg TID
Coniff 1994 87 -0.06 (1.12) 96 0.53 (1.08) 5.4 % -0.59 [ -0.91, -0.27 ]
Coniff 1995b 53 -0.65 (1.02) 62 0.35 (1.02) 4.8 % -1.00 [ -1.37, -0.63 ]
Subtotal (95% CI) 140 158 10.2 % -0.78 [ -1.18, -0.38 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 2.67, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 3.83 (P = 0.00013)
Total (95% CI) 1389 1442 100.0 % -0.77 [ -0.90, -0.64 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 55.87, df = 27 (P = 0.00089); I2 =52%
Test for overall effect: Z = 11.61 (P < 0.00001)
-4 -2 0 2 4
Favours acarbose Favours placebo
Analysis 1.2. Comparison 1 Acarbose versus placebo, Outcome 2 Change in fasting blood glucose (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 1 Acarbose versus placebo
Outcome: 2 Change in fasting blood glucose (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 25 mg TID
Fischer 1998 90 -0.33 (1.82) 87 -0.04 (1.96) 5.0 % -0.29 [ -0.85, 0.27 ]
Subtotal (95% CI) 90 87 5.0 % -0.29 [ -0.85, 0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
2 Acarbose 50 mg BID
Delgado 2002 9 -0.6 (1.5) 8 -0.9 (1.4) 2.3 % 0.30 [ -1.08, 1.68 ]
Santeusanio 1993 18 -1.24 (1.29) 22 0.41 (2.04) 3.2 % -1.65 [ -2.69, -0.61 ]
Subtotal (95% CI) 27 30 5.6 % -0.73 [ -2.64, 1.18 ]
Heterogeneity: Tau2 = 1.51; Chi2 = 4.90, df = 1 (P = 0.03); I2 =80%
Test for overall effect: Z = 0.75 (P = 0.45)
3 Acarbose 50 mg TID
-4 -2 0 2 4
Favours acarbose Favours placebo
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Fischer 1998 92 -1 (1.82) 87 -0.04 (1.96) 5.0 % -0.96 [ -1.51, -0.41 ]
Subtotal (95% CI) 92 87 5.0 % -0.96 [ -1.51, -0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.39 (P = 0.00070)
4 Acarbose 100 mg TID
Braun 1996 42 -2.4 (2.4) 44 -1.1 (2.7) 3.1 % -1.30 [ -2.38, -0.22 ]
Calle-Pascual 1996 17 -0.7 (1.9) 16 0.1 (2.9) 1.8 % -0.80 [ -2.48, 0.88 ]
Chan 1998 59 -0.37 (1.5) 62 0.41 (2) 4.7 % -0.78 [ -1.41, -0.15 ]
Coniff 1995b 51 -0.33 (2.66) 57 1.04 (2.73) 3.3 % -1.37 [ -2.39, -0.35 ]
Dedov 1995 83 -1.9 (1.7) 73 -1.7 (1.5) 5.2 % -0.20 [ -0.70, 0.30 ]
Fischer 1998 86 -0.63 (1.87) 87 -0.04 (1.96) 5.0 % -0.59 [ -1.16, -0.02 ]
Haffner 1997 25 -0.9 (3.6) 25 0.6 (2.7) 1.7 % -1.50 [ -3.26, 0.26 ]
Hanefeld 1991 47 -1.4 (1.9) 47 -0.6 (2.2) 3.9 % -0.80 [ -1.63, 0.03 ]
Hoffmann 1994 28 -1.2 (0.89) 30 0.16 (0.67) 5.6 % -1.36 [ -1.77, -0.95 ]
Hoffmann 1997 31 -1.39 (0.81) 32 0.46 (0.53) 5.8 % -1.85 [ -2.19, -1.51 ]
Holman 1999 102 0.03 (3.08) 115 0.06 (3.65) 3.7 % -0.03 [ -0.93, 0.87 ]
Hotta 1993 16 -0.71 (1.85) 15 -0.04 (1.29) 3.0 % -0.67 [ -1.79, 0.45 ]
Kovacevic 1997 33 -1.9 (3) 31 -0.7 (3.8) 1.8 % -1.20 [ -2.88, 0.48 ]
Meneilly 2000 80 -0.3 (1.9) 94 0.4 (2) 4.9 % -0.70 [ -1.28, -0.12 ]
Santeusanio 1993 22 -1.35 (2.54) 22 0.41 (2.04) 2.4 % -1.76 [ -3.12, -0.40 ]
Scott 1999 41 -0.46 (2) 42 0.9 (2.2) 3.7 % -1.36 [ -2.26, -0.46 ]
Zheng 1995 39 -3.17 (2.3) 38 -0.49 (2.7) 3.0 % -2.68 [ -3.80, -1.56 ]
Subtotal (95% CI) 802 830 62.6 % -1.07 [ -1.41, -0.72 ]
Heterogeneity: Tau2 = 0.32; Chi2 = 54.54, df = 16 (P<0.00001); I2 =71%
Test for overall effect: Z = 6.02 (P < 0.00001)
5 Acarbose 200-100-200
Buchanan 1988 9 0.9 (3.8) 11 -0.7 (5) 0.4 % 1.60 [ -2.26, 5.46 ]
Subtotal (95% CI) 9 11 0.4 % 1.60 [ -2.26, 5.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
6 Acarbose 200 mg TID
Chiasson 1994 30 -0.7 (2.2) 37 1.4 (2.4) 3.0 % -2.10 [ -3.20, -1.00 ]
Coniff 1995 67 -1.11 (3.17) 62 0.12 (3.24) 3.0 % -1.23 [ -2.34, -0.12 ]
Coniff 1995b 49 -0.92 (2.73) 57 1.04 (2.73) 3.2 % -1.96 [ -3.00, -0.92 ]
-4 -2 0 2 4
Favours acarbose Favours placebo
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Fischer 1998 89 -1.27 (2.1) 87 -0.04 (1.96) 4.8 % -1.23 [ -1.83, -0.63 ]
Subtotal (95% CI) 235 243 14.1 % -1.49 [ -1.92, -1.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.89, df = 3 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 6.74 (P < 0.00001)
7 Acarbose 300 mg TID
Coniff 1994 91 -0.28 (2.92) 97 0.58 (2.92) 3.9 % -0.86 [ -1.70, -0.02 ]
Coniff 1995b 50 -0.98 (2.66) 57 1.04 (2.73) 3.3 % -2.02 [ -3.04, -1.00 ]
Subtotal (95% CI) 141 154 7.2 % -1.40 [ -2.54, -0.27 ]
Heterogeneity: Tau2 = 0.45; Chi2 = 2.96, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 2.42 (P = 0.015)
Total (95% CI) 1396 1442 100.0 % -1.09 [ -1.36, -0.83 ]
Heterogeneity: Tau2 = 0.28; Chi2 = 79.39, df = 27 (P<0.00001); I2 =66%
Test for overall effect: Z = 8.08 (P < 0.00001)
-4 -2 0 2 4
Favours acarbose Favours placebo
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Analysis 1.3. Comparison 1 Acarbose versus placebo, Outcome 3 Change in post-load blood glucose
(mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 1 Acarbose versus placebo
Outcome: 3 Change in post-load blood glucose (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 25 mg TID
Fischer 1998 89 -1.34 (2.55) 87 0.02 (2.74) 5.9 % -1.36 [ -2.14, -0.58 ]
Subtotal (95% CI) 89 87 5.9 % -1.36 [ -2.14, -0.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.41 (P = 0.00066)
2 Acarbose 50 mg BID
Delgado 2002 9 -1.5 (1.6) 8 0.3 (1.4) 3.9 % -1.80 [ -3.23, -0.37 ]
Subtotal (95% CI) 9 8 3.9 % -1.80 [ -3.23, -0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.47 (P = 0.013)
3 Acarbose 50 mg TID
Fischer 1998 92 -1.71 (2.86) 87 0.02 (2.74) 5.8 % -1.73 [ -2.55, -0.91 ]
Santeusanio 1993 18 -0.8 (3.5) 22 0.2 (3.2) 2.5 % -1.00 [ -3.10, 1.10 ]
Subtotal (95% CI) 110 109 8.3 % -1.63 [ -2.40, -0.87 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 4.19 (P = 0.000028)
4 Acarbose 100 mg TID
Braun 1996 42 -3.2 (2.5) 44 -1.4 (2.5) 5.0 % -1.80 [ -2.86, -0.74 ]
Chan 1998 59 -0.77 (2.6) 62 0.65 (2.9) 5.2 % -1.42 [ -2.40, -0.44 ]
Coniff 1995b 51 -2.31 (3.31) 56 1.36 (3.39) 4.3 % -3.67 [ -4.94, -2.40 ]
Dedov 1995 82 -3.2 (2.2) 73 -2.5 (2) 6.3 % -0.70 [ -1.36, -0.04 ]
Fischer 1998 87 -1.48 (2.69) 87 0.02 (2.74) 5.8 % -1.50 [ -2.31, -0.69 ]
Haffner 1997 25 -2.4 (6.4) 25 -0.1 (7.4) 1.0 % -2.30 [ -6.14, 1.54 ]
Hanefeld 1991 47 -3.7 (2.3) 47 -0.8 (2.6) 5.2 % -2.90 [ -3.89, -1.91 ]
Hoffmann 1994 28 -1.8 (0.74) 30 0.03 (1.01) 6.9 % -1.83 [ -2.28, -1.38 ]
Hoffmann 1997 31 -2.36 (0.74) 32 0.01 (0.36) 7.3 % -2.37 [ -2.66, -2.08 ]
Hotta 1993 16 -2.69 (3.22) 15 -0.21 (2.93) 2.4 % -2.48 [ -4.65, -0.31 ]
Kovacevic 1997 33 -4.7 (3.7) 31 -1.7 (4.2) 2.7 % -3.00 [ -4.94, -1.06 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Santeusanio 1993 22 -2 (3) 22 0.2 (3.2) 3.0 % -2.20 [ -4.03, -0.37 ]
Zheng 1995 39 -5.82 (3.6) 38 -0.4 (3.5) 3.5 % -5.42 [ -7.01, -3.83 ]
Subtotal (95% CI) 562 562 58.6 % -2.26 [ -2.79, -1.73 ]
Heterogeneity: Tau2 = 0.57; Chi2 = 52.37, df = 12 (P<0.00001); I2 =77%
Test for overall effect: Z = 8.35 (P < 0.00001)
5 Acarbose 200 mg TID
Coniff 1995 67 -2.82 (3.71) 62 -0.61 (3.93) 4.2 % -2.21 [ -3.53, -0.89 ]
Coniff 1995b 51 -2.5 (3.39) 56 1.36 (3.39) 4.3 % -3.86 [ -5.15, -2.57 ]
Fischer 1998 88 -2.4 (2.96) 87 0.02 (2.74) 5.7 % -2.42 [ -3.26, -1.58 ]
Subtotal (95% CI) 206 205 14.2 % -2.78 [ -3.72, -1.85 ]
Heterogeneity: Tau2 = 0.35; Chi2 = 4.07, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 5.83 (P < 0.00001)
6 Acarbose 300 mg TID
Coniff 1994 90 -1.7 (3.7) 95 1.07 (3.91) 4.9 % -2.77 [ -3.87, -1.67 ]
Coniff 1995b 50 -3.17 (3.31) 56 1.36 (3.39) 4.3 % -4.53 [ -5.81, -3.25 ]
Subtotal (95% CI) 140 151 9.2 % -3.62 [ -5.34, -1.89 ]
Heterogeneity: Tau2 = 1.18; Chi2 = 4.20, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 4.11 (P = 0.000039)
Total (95% CI) 1116 1122 100.0 % -2.32 [ -2.73, -1.92 ]
Heterogeneity: Tau2 = 0.56; Chi2 = 80.59, df = 21 (P<0.00001); I2 =74%
Test for overall effect: Z = 11.28 (P < 0.00001)
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Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 1 Acarbose versus placebo
Outcome: 4 Change in total cholesterol (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 25 mg TID
Fischer 1998 92 0.03 (0.98) 87 -0.09 (0.96) 7.1 % 0.12 [ -0.16, 0.40 ]
Subtotal (95% CI) 92 87 7.1 % 0.12 [ -0.16, 0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
2 Acarbose 50 mg BID
Delgado 2002 9 0.2 (1.2) 8 0.5 (1.1) 0.7 % -0.30 [ -1.39, 0.79 ]
Subtotal (95% CI) 9 8 0.7 % -0.30 [ -1.39, 0.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
3 Acarbose 50 mg TID
Fischer 1998 91 -0.06 (0.94) 87 -0.09 (0.96) 7.3 % 0.03 [ -0.25, 0.31 ]
Santeusanio 1993 18 -0.03 (0.81) 22 0.06 (0.91) 2.7 % -0.09 [ -0.62, 0.44 ]
Subtotal (95% CI) 109 109 10.0 % 0.00 [ -0.24, 0.25 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.97)
4 Acarbose 100 mg TID
Braun 1996 41 -0.9 (1.1) 42 -0.3 (1) 3.6 % -0.60 [ -1.05, -0.15 ]
Calle-Pascual 1996 17 -0.05 (1.1) 16 0.13 (1) 1.6 % -0.18 [ -0.90, 0.54 ]
Chan 1998 59 0.13 (0.5) 62 -0.04 (5.4) 0.5 % 0.17 [ -1.18, 1.52 ]
Coniff 1995b 56 0.15 (0.7) 62 -0.06 (0.7) 8.2 % 0.21 [ -0.04, 0.46 ]
Fischer 1998 89 0.32 (1) 87 -0.09 (0.96) 6.9 % 0.41 [ 0.12, 0.70 ]
Haffner 1997 17 0.05 (0.93) 16 -0.04 (0.86) 2.1 % 0.09 [ -0.52, 0.70 ]
Hanefeld 1991 47 0.1 (0.9) 47 0.1 (0.9) 5.0 % 0.0 [ -0.36, 0.36 ]
Hoffmann 1994 28 -0.59 (1.34) 30 0.01 (1.67) 1.4 % -0.60 [ -1.38, 0.18 ]
Hoffmann 1997 31 -0.85 (1.67) 32 -0.05 (1.37) 1.5 % -0.80 [ -1.56, -0.04 ]
Hotta 1993 16 0.04 (0.68) 13 0.12 (0.57) 3.6 % -0.08 [ -0.54, 0.38 ]
Kovacevic 1997 33 -0.3 (1.1) 31 0 (1.8) 1.5 % -0.30 [ -1.04, 0.44 ]
Santeusanio 1993 22 0.05 (1.01) 22 0.06 (0.91) 2.4 % -0.01 [ -0.58, 0.56 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Scott 1999 41 -0.04 (1.4) 42 0.28 (1.3) 2.3 % -0.32 [ -0.90, 0.26 ]
Subtotal (95% CI) 497 502 40.7 % -0.10 [ -0.30, 0.11 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 25.95, df = 12 (P = 0.01); I2 =54%
Test for overall effect: Z = 0.90 (P = 0.37)
5 Acarbose 200-100-200
Buchanan 1988 9 -0.1 (1.2) 11 0.2 (1.8) 0.5 % -0.30 [ -1.62, 1.02 ]
Subtotal (95% CI) 9 11 0.5 % -0.30 [ -1.62, 1.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
6 Acarbose 200 mg TID
Coniff 1995 64 -0.21 (0.79) 58 -0.13 (0.8) 7.2 % -0.08 [ -0.36, 0.20 ]
Coniff 1995b 51 -0.09 (0.71) 62 -0.06 (0.7) 7.9 % -0.03 [ -0.29, 0.23 ]
Fischer 1998 88 -0.04 (1) 87 -0.09 (0.96) 6.9 % 0.05 [ -0.24, 0.34 ]
Subtotal (95% CI) 203 207 21.9 % -0.02 [ -0.18, 0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
7 Acarbose 300 mg TID
Coniff 1994 80 0.09 (0.63) 95 0.14 (0.64) 11.0 % -0.05 [ -0.24, 0.14 ]
Coniff 1995b 53 0.09 (0.7) 62 -0.06 (0.7) 8.1 % 0.15 [ -0.11, 0.41 ]
Subtotal (95% CI) 133 157 19.1 % 0.03 [ -0.16, 0.22 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.51, df = 1 (P = 0.22); I2 =34%
Test for overall effect: Z = 0.31 (P = 0.76)
Total (95% CI) 1052 1081 100.0 % 0.00 [ -0.10, 0.09 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 29.29, df = 22 (P = 0.14); I2 =25%
Test for overall effect: Z = 0.10 (P = 0.92)
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Analysis 1.5. Comparison 1 Acarbose versus placebo, Outcome 5 Change in HDL-cholesterol (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 1 Acarbose versus placebo
Outcome: 5 Change in HDL-cholesterol (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 50 mg BID
Delgado 2002 9 0 (0.3) 8 0.1 (0.3) 1.8 % -0.10 [ -0.39, 0.19 ]
Subtotal (95% CI) 9 8 1.8 % -0.10 [ -0.39, 0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 Acarbose 50 mg TID
Santeusanio 1993 17 -0.05 (0.31) 21 0.04 (0.29) 3.9 % -0.09 [ -0.28, 0.10 ]
Subtotal (95% CI) 17 21 3.9 % -0.09 [ -0.28, 0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
3 Acarbose 100 mg TID
Braun 1996 41 0.1 (0.3) 42 0.1 (0.5) 4.6 % 0.0 [ -0.18, 0.18 ]
Calle-Pascual 1996 17 0.11 (0.3) 16 -0.03 (0.9) 0.7 % 0.14 [ -0.32, 0.60 ]
Chan 1998 59 -0.02 (0.3) 62 -0.03 (0.3) 11.8 % 0.01 [ -0.10, 0.12 ]
Haffner 1997 17 0.01 (0.3) 16 0 (0.26) 4.0 % 0.01 [ -0.18, 0.20 ]
Hoffmann 1994 28 0.09 (0.44) 30 0.15 (0.64) 1.9 % -0.06 [ -0.34, 0.22 ]
Hoffmann 1997 31 0.23 (0.63) 31 -0.15 (0.4) 2.2 % 0.38 [ 0.12, 0.64 ]
Hotta 1993 16 0.06 (0.18) 12 0.15 (0.17) 8.2 % -0.09 [ -0.22, 0.04 ]
Kovacevic 1997 33 0.1 (0.3) 31 0 (0.4) 4.8 % 0.10 [ -0.07, 0.27 ]
Santeusanio 1993 22 0.02 (0.3) 21 0.04 (0.29) 4.7 % -0.02 [ -0.20, 0.16 ]
Scott 1999 41 0 (0.3) 42 0.06 (0.3) 8.4 % -0.06 [ -0.19, 0.07 ]
Subtotal (95% CI) 305 303 51.2 % 0.01 [ -0.06, 0.07 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 12.58, df = 9 (P = 0.18); I2 =28%
Test for overall effect: Z = 0.25 (P = 0.80)
4 Acarbose 200 mg TID
Coniff 1995 58 0.07 (0.23) 51 0.06 (0.24) 16.4 % 0.01 [ -0.08, 0.10 ]
Subtotal (95% CI) 58 51 16.4 % 0.01 [ -0.08, 0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
5 Acarbose 300 mg TID
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Coniff 1994 71 0.03 (0.2) 81 0.03 (0.21) 26.7 % 0.0 [ -0.07, 0.07 ]
Subtotal (95% CI) 71 81 26.7 % 0.0 [ -0.07, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 460 464 100.0 % 0.00 [ -0.04, 0.04 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 13.92, df = 13 (P = 0.38); I2 =7%
Test for overall effect: Z = 0.14 (P = 0.89)
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Analysis 1.6. Comparison 1 Acarbose versus placebo, Outcome 6 Change in LDL-cholesterol (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 1 Acarbose versus placebo
Outcome: 6 Change in LDL-cholesterol (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Chan 1998 59 0.15 (0.8) 62 -0.02 (0.7) 27.7 % 0.17 [ -0.10, 0.44 ]
Hoffmann 1997 31 -0.89 (1.22) 32 0.18 (1.32) 15.2 % -1.07 [ -1.70, -0.44 ]
Subtotal (95% CI) 90 94 42.9 % -0.42 [ -1.63, 0.80 ]
Heterogeneity: Tau2 = 0.71; Chi2 = 12.69, df = 1 (P = 0.00037); I2 =92%
Test for overall effect: Z = 0.67 (P = 0.50)
2 Acarbose 200 mg TID
Coniff 1995 48 -0.09 (0.67) 45 -0.25 (0.69) 27.4 % 0.16 [ -0.12, 0.44 ]
Subtotal (95% CI) 48 45 27.4 % 0.16 [ -0.12, 0.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
3 Acarbose 300 mg TID
Coniff 1994 55 0.07 (0.6) 70 0.11 (0.62) 29.7 % -0.04 [ -0.26, 0.18 ]
Subtotal (95% CI) 55 70 29.7 % -0.04 [ -0.26, 0.18 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI) 193 209 100.0 % -0.08 [ -0.41, 0.25 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 14.08, df = 3 (P = 0.003); I2 =79%
Test for overall effect: Z = 0.50 (P = 0.62)
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Analysis 1.7. Comparison 1 Acarbose versus placebo, Outcome 7 Change in triglycerides (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 1 Acarbose versus placebo
Outcome: 7 Change in triglycerides (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 25 mg TID
Fischer 1998 92 0.34 (1.87) 87 0.12 (1) 4.5 % 0.22 [ -0.22, 0.66 ]
Subtotal (95% CI) 92 87 4.5 % 0.22 [ -0.22, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
2 Acarbose 50 mg BID
Delgado 2002 9 -0.2 (0.9) 8 0 (2.4) 0.3 % -0.20 [ -1.96, 1.56 ]
Subtotal (95% CI) 9 8 0.3 % -0.20 [ -1.96, 1.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
3 Acarbose 50 mg TID
Fischer 1998 93 0.16 (1.01) 87 0.12 (1) 9.9 % 0.04 [ -0.25, 0.33 ]
Santeusanio 1993 17 0.09 (1) 20 -0.04 (1.4) 1.4 % 0.13 [ -0.65, 0.91 ]
Subtotal (95% CI) 110 107 11.3 % 0.05 [ -0.22, 0.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
4 Acarbose 100 mg TID
Braun 1996 41 -0.2 (0.5) 42 -0.1 (0.6) 15.2 % -0.10 [ -0.34, 0.14 ]
Calle-Pascual 1996 17 -0.05 (0.5) 16 0.01 (1) 2.9 % -0.06 [ -0.60, 0.48 ]
Chan 1998 59 -0.05 (0.8) 62 -0.06 (1.2) 6.5 % 0.01 [ -0.35, 0.37 ]
Coniff 1995b 56 0.17 (1.32) 62 0.23 (1.34) 3.7 % -0.06 [ -0.54, 0.42 ]
Fischer 1998 89 -0.07 (1.36) 87 0.12 (1) 6.9 % -0.19 [ -0.54, 0.16 ]
Haffner 1997 25 0 (1.1) 25 0.2 (1.1) 2.3 % -0.20 [ -0.81, 0.41 ]
Hoffmann 1994 28 -0.58 (1.21) 30 -0.27 (0.95) 2.7 % -0.31 [ -0.87, 0.25 ]
Hoffmann 1997 31 -0.4 (1.06) 30 -0.17 (1.08) 3.0 % -0.23 [ -0.77, 0.31 ]
Hotta 1993 16 -0.18 (0.55) 13 0.15 (0.58) 5.0 % -0.33 [ -0.74, 0.08 ]
Kovacevic 1997 33 -0.4 (1.4) 31 -0.1 (3.1) 0.6 % -0.30 [ -1.49, 0.89 ]
Santeusanio 1993 21 0.22 (1.03) 20 -0.04 (1.4) 1.5 % 0.26 [ -0.50, 1.02 ]
Subtotal (95% CI) 416 418 50.2 % -0.13 [ -0.26, 0.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.47, df = 10 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.96 (P = 0.049)
5 Acarbose 200-100-200
Buchanan 1988 9 0.2 (0.6) 11 -0.2 (2) 0.6 % 0.40 [ -0.85, 1.65 ]
Subtotal (95% CI) 9 11 0.6 % 0.40 [ -0.85, 1.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
6 Acarbose 200 mg TID
Coniff 1995 64 -0.49 (1.87) 58 -0.31 (1.9) 1.9 % -0.18 [ -0.85, 0.49 ]
Coniff 1995b 51 0.02 (1.34) 62 0.23 (1.34) 3.5 % -0.21 [ -0.71, 0.29 ]
Fischer 1998 90 -0.24 (1.8) 87 0.12 (1) 4.7 % -0.36 [ -0.79, 0.07 ]
Subtotal (95% CI) 205 207 10.1 % -0.27 [ -0.57, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.30, df = 2 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.065)
7 Acarbose 300 mg TID
Coniff 1994 80 0.12 (0.7) 95 0.18 (0.71) 19.5 % -0.06 [ -0.27, 0.15 ]
Coniff 1995b 53 0.2 (1.33) 62 0.23 (1.34) 3.6 % -0.03 [ -0.52, 0.46 ]
Subtotal (95% CI) 133 157 23.0 % -0.06 [ -0.25, 0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.57)
Total (95% CI) 974 995 100.0 % -0.09 [ -0.18, 0.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 9.42, df = 20 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.88 (P = 0.060)
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Analysis 1.8. Comparison 1 Acarbose versus placebo, Outcome 8 Change in fasting insulin levels (pmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 1 Acarbose versus placebo
Outcome: 8 Change in fasting insulin levels (pmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 50 mg TID
Santeusanio 1993 10 13.4 (19.4) 14 16.9 (35.1) 7.7 % -3.50 [ -25.47, 18.47 ]
Subtotal (95% CI) 10 14 7.7 % -3.50 [ -25.47, 18.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.75)
2 Acarbose 100 mg TID
Calle-Pascual 1996 17 -14.2 (39) 16 -10.1 (45) 5.2 % -4.10 [ -32.91, 24.71 ]
Chan 1998 59 -10.7 (103) 62 -11.6 (50) 5.1 % 0.90 [ -28.18, 29.98 ]
Coniff 1995b 57 14.64 (72.6) 63 6.74 (73.5) 6.0 % 7.90 [ -18.27, 34.07 ]
Haffner 1997 25 10 (92) 25 10 (110) 1.6 % 0.0 [ -56.21, 56.21 ]
Hanefeld 1991 47 0 (50) 47 10 (66) 7.0 % -10.00 [ -33.67, 13.67 ]
Hoffmann 1994 28 -33.56 (139.81) 30 -4.31 (118.67) 1.2 % -29.25 [ -96.22, 37.72 ]
Hoffmann 1997 31 -7.6 (123.8) 32 21.7 (157.9) 1.1 % -29.30 [ -99.24, 40.64 ]
Kovacevic 1997 33 -14.4 (11.9) 31 -28.9 (14) 20.8 % 14.50 [ 8.11, 20.89 ]
Meneilly 2000 80 -9 (39) 94 -9 (30) 16.5 % 0.0 [ -10.48, 10.48 ]
Santeusanio 1993 14 4.1 (38.7) 14 16.9 (35.1) 5.6 % -12.80 [ -40.17, 14.57 ]
Zheng 1995 39 -7.5 (50.8) 38 4.9 (47.6) 7.7 % -12.40 [ -34.38, 9.58 ]
Subtotal (95% CI) 430 452 77.7 % 0.07 [ -8.60, 8.73 ]
Heterogeneity: Tau2 = 66.18; Chi2 = 16.94, df = 10 (P = 0.08); I2 =41%
Test for overall effect: Z = 0.02 (P = 0.99)
3 Acarbose 200 mg TID
Coniff 1995 65 -3.2 (112.8) 62 -25.3 (114.7) 3.0 % 22.10 [ -17.49, 61.69 ]
Coniff 1995b 52 1.87 (74) 63 6.74 (73.5) 5.7 % -4.87 [ -31.96, 22.22 ]
Subtotal (95% CI) 117 125 8.7 % 4.59 [ -20.63, 29.82 ]
Heterogeneity: Tau2 = 64.19; Chi2 = 1.21, df = 1 (P = 0.27); I2 =18%
Test for overall effect: Z = 0.36 (P = 0.72)
4 Acarbose 300 mg TID
Coniff 1995b 53 -9.61 (73.7) 63 6.74 (73.5) 5.8 % -16.35 [ -43.24, 10.54 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 53 63 5.8 % -16.35 [ -43.24, 10.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
Total (95% CI) 610 654 100.0 % -0.52 [ -7.90, 6.86 ]
Heterogeneity: Tau2 = 57.50; Chi2 = 21.60, df = 14 (P = 0.09); I2 =35%
Test for overall effect: Z = 0.14 (P = 0.89)
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Analysis 1.9. Comparison 1 Acarbose versus placebo, Outcome 9 Change in post-load insulin levels (pmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 1 Acarbose versus placebo
Outcome: 9 Change in post-load insulin levels (pmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 50 mg TID
Santeusanio 1993 10 -12.8 (149) 14 -53.6 (178) 2.1 % 40.80 [ -90.43, 172.03 ]
Subtotal (95% CI) 10 14 2.1 % 40.80 [ -90.43, 172.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
2 Acarbose 100 mg TID
Chan 1998 59 6.7 (172) 62 24.3 (165) 7.9 % -17.60 [ -77.71, 42.51 ]
Coniff 1995b 57 2.4 (136.5) 61 17.7 (138.4) 10.3 % -15.30 [ -64.92, 34.32 ]
Haffner 1997 25 -40 (196) 25 -20 (196) 3.0 % -20.00 [ -128.65, 88.65 ]
Hanefeld 1991 47 -10 (133) 47 60 (175) 7.4 % -70.00 [ -132.84, -7.16 ]
Hoffmann 1994 28 -105.54 (134.07) 30 -28.7 (195.22) 4.5 % -76.84 [ -162.55, 8.87 ]
Hoffmann 1997 31 -117.6 (194.4) 32 14.1 (159.7) 4.3 % -131.70 [ -219.70, -43.70 ]
Kovacevic 1997 33 -32.2 (14.9) 31 14.3 (12.6) 28.3 % -46.50 [ -53.25, -39.75 ]
Santeusanio 1993 14 89.6 (234) 14 -53.6 (178) 1.6 % 143.20 [ -10.81, 297.21 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Zheng 1995 39 -33.8 (135.9) 38 47.3 (196.6) 5.6 % -81.10 [ -156.77, -5.43 ]
Subtotal (95% CI) 333 340 72.9 % -45.83 [ -71.68, -19.98 ]
Heterogeneity: Tau2 = 529.35; Chi2 = 13.88, df = 8 (P = 0.08); I2 =42%
Test for overall effect: Z = 3.47 (P = 0.00051)
3 Acarbose 200 mg TID
Coniff 1995 65 -45.1 (226.8) 61 -51.4 (230.9) 5.1 % 6.30 [ -73.68, 86.28 ]
Coniff 1995b 52 -6.7 (138.7) 61 17.7 (138.4) 9.9 % -24.40 [ -75.66, 26.86 ]
Subtotal (95% CI) 117 122 15.0 % -15.46 [ -58.62, 27.69 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
4 Acarbose 300 mg TID
Coniff 1995b 53 -44.7 (137.9) 61 17.7 (138.4) 10.0 % -62.40 [ -113.24, -11.56 ]
Subtotal (95% CI) 53 61 10.0 % -62.40 [ -113.24, -11.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.41 (P = 0.016)
Total (95% CI) 513 537 100.0 % -40.82 [ -60.64, -21.01 ]
Heterogeneity: Tau2 = 349.29; Chi2 = 18.29, df = 12 (P = 0.11); I2 =34%
Test for overall effect: Z = 4.04 (P = 0.000054)
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Analysis 1.10. Comparison 1 Acarbose versus placebo, Outcome 10 Change in fasting C-peptide levels
(nmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 1 Acarbose versus placebo
Outcome: 10 Change in fasting C-peptide levels (nmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Hanefeld 1991 47 -0.28 (0.27) 47 -0.23 (0.35) 100.0 % -0.05 [ -0.18, 0.08 ]
Total (95% CI) 47 47 100.0 % -0.05 [ -0.18, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
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Analysis 1.11. Comparison 1 Acarbose versus placebo, Outcome 11 Change in post-load C-peptide levels
(nmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 1 Acarbose versus placebo
Outcome: 11 Change in post-load C-peptide levels (nmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID
Hanefeld 1991 47 -0.47 (0.62) 47 -0.37 (0.56) 100.0 % -0.10 [ -0.34, 0.14 ]
Total (95% CI) 47 47 100.0 % -0.10 [ -0.34, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
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Analysis 1.12. Comparison 1 Acarbose versus placebo, Outcome 12 Change in body weight (Kg).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 1 Acarbose versus placebo
Outcome: 12 Change in body weight (Kg)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 50 mg BID
Delgado 2002 9 0.8 (9.5) 8 0.5 (27.1) 0.0 % 0.30 [ -19.48, 20.08 ]
Subtotal (95% CI) 9 8 0.0 % 0.30 [ -19.48, 20.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
2 Acarbose 100 mg TID
Braun 1996 42 -1 (10.6) 44 0 (9.1) 0.6 % -1.00 [ -5.18, 3.18 ]
Calle-Pascual 1996 17 -5.3 (19.1) 16 -1.3 (17.7) 0.1 % -4.00 [ -16.56, 8.56 ]
Chan 1998 59 -1.31 (4.5) 62 0.16 (1.9) 7.1 % -1.47 [ -2.71, -0.23 ]
Coniff 1995b 58 -0.09 (2.21) 63 -0.58 (2.22) 17.4 % 0.49 [ -0.30, 1.28 ]
Haffner 1997 25 -1.5 (12.9) 25 -1.3 (9.6) 0.3 % -0.20 [ -6.50, 6.10 ]
Hanefeld 1991 47 -1.43 (12.4) 46 -1.51 (13.4) 0.4 % 0.08 [ -5.17, 5.33 ]
Hoffmann 1997 31 -0.8 (11.2) 32 0.2 (10.5) 0.4 % -1.00 [ -6.36, 4.36 ]
Holman 1999 104 0.38 (4.06) 117 0.48 (4.85) 7.9 % -0.10 [ -1.28, 1.08 ]
Hotta 1993 16 -0.81 (3.22) 15 -0.82 (1.09) 3.9 % 0.01 [ -1.66, 1.68 ]
Meneilly 2000 22 -1.9 (2.8) 23 -1.9 (3.8) 2.9 % 0.0 [ -1.94, 1.94 ]
Subtotal (95% CI) 421 443 40.9 % -0.09 [ -0.61, 0.42 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 7.51, df = 9 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
3 Acarbose 200-100-200
Buchanan 1988 9 -3.2 (9.8) 11 -2.3 (10.8) 0.1 % -0.90 [ -9.94, 8.14 ]
Subtotal (95% CI) 9 11 0.1 % -0.90 [ -9.94, 8.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.85)
4 Acarbose 200 mg TID
Coniff 1995 66 -1.42 (2.84) 62 -1.4 (2.91) 10.9 % -0.02 [ -1.02, 0.98 ]
Coniff 1995b 54 -0.95 (2.2) 63 -0.58 (2.22) 16.9 % -0.37 [ -1.17, 0.43 ]
Subtotal (95% CI) 120 125 27.8 % -0.23 [ -0.86, 0.39 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 0.73 (P = 0.47)
5 Acarbose 300 mg TID
Coniff 1994 91 -0.93 (3.05) 98 -0.77 (3.07) 14.3 % -0.16 [ -1.03, 0.71 ]
Coniff 1995b 53 -0.59 (2.18) 63 -0.58 (2.22) 16.9 % -0.01 [ -0.81, 0.79 ]
Subtotal (95% CI) 144 161 31.1 % -0.08 [ -0.67, 0.51 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.79)
Total (95% CI) 703 748 100.0 % -0.13 [ -0.46, 0.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 8.03, df = 15 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
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Analysis 1.13. Comparison 1 Acarbose versus placebo, Outcome 13 Change in body mass index (Kg/m2).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 1 Acarbose versus placebo
Outcome: 13 Change in body mass index (Kg/m2)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 25 mg TID
Fischer 1998 90 -0.15 (0.6) 87 -0.12 (0.87) 15.7 % -0.03 [ -0.25, 0.19 ]
Subtotal (95% CI) 90 87 15.7 % -0.03 [ -0.25, 0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
2 Acarbose 50 mg BID
Delgado 2002 9 0.2 (5.1) 8 0.1 (8.4) 0.0 % 0.10 [ -6.61, 6.81 ]
Subtotal (95% CI) 9 8 0.0 % 0.10 [ -6.61, 6.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
3 Acarbose 50 mg TID
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Fischer 1998 92 -0.15 (0.75) 87 -0.13 (0.87) 13.5 % -0.02 [ -0.26, 0.22 ]
Santeusanio 1993 18 -0.25 (0.57) 22 -0.11 (0.89) 3.7 % -0.14 [ -0.60, 0.32 ]
Subtotal (95% CI) 110 109 17.2 % -0.05 [ -0.26, 0.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
4 Acarbose 100 mg TID
Calle-Pascual 1996 17 -2.2 (9.3) 16 -0.5 (8.3) 0.0 % -1.70 [ -7.71, 4.31 ]
Chan 1998 59 -0.52 (1.6) 62 0.04 (0.7) 3.9 % -0.56 [ -1.00, -0.12 ]
Fischer 1998 87 -0.22 (0.98) 87 -0.12 (0.87) 10.1 % -0.10 [ -0.38, 0.18 ]
Haffner 1997 25 -0.5 (4.1) 25 -0.5 (3.8) 0.2 % 0.0 [ -2.19, 2.19 ]
Hoffmann 1994 28 -0.42 (0.27) 30 -0.12 (0.35) 29.8 % -0.30 [ -0.46, -0.14 ]
Holman 1999 104 0.12 (1.45) 117 0.16 (1.67) 4.5 % -0.04 [ -0.45, 0.37 ]
Kovacevic 1997 33 -0.8 (3) 31 -0.6 (3) 0.4 % -0.20 [ -1.67, 1.27 ]
Santeusanio 1993 22 -0.35 (0.67) 22 -0.11 (0.89) 3.5 % -0.24 [ -0.71, 0.23 ]
Zheng 1995 39 -0.31 (2.7) 38 -0.18 (3.5) 0.4 % -0.13 [ -1.53, 1.27 ]
Subtotal (95% CI) 414 428 52.8 % -0.25 [ -0.37, -0.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.70, df = 8 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 4.11 (P = 0.000040)
5 Acarbose 200 mg TID
Fischer 1998 88 -0.28 (0.68) 87 -0.13 (0.87) 14.3 % -0.15 [ -0.38, 0.08 ]
Subtotal (95% CI) 88 87 14.3 % -0.15 [ -0.38, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
Total (95% CI) 711 719 100.0 % -0.17 [ -0.25, -0.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 9.60, df = 13 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 3.74 (P = 0.00018)
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Analysis 1.14. Comparison 1 Acarbose versus placebo, Outcome 14 Total deaths.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 1 Acarbose versus placebo
Outcome: 14 Total deaths








1 Acarbose 100 mg TID
Holman 1999 5/136 4/120 1.11 [ 0.29, 4.22 ]
Subtotal (95% CI) 136 120 1.11 [ 0.29, 4.22 ]
Total events: 5 (Acarbose), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
2 Acarbose 200 mg TID
Coniff 1995 0/67 0/62 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 67 62 0.0 [ 0.0, 0.0 ]
Total events: 0 (Acarbose), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 203 182 1.11 [ 0.29, 4.22 ]
Total events: 5 (Acarbose), 4 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
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Analysis 1.15. Comparison 1 Acarbose versus placebo, Outcome 15 Disease related deaths.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 1 Acarbose versus placebo
Outcome: 15 Disease related deaths








1 Acarbose 200 mg TID
Coniff 1995 0/67 0/62 0.0 [ 0.0, 0.0 ]
Total (95% CI) 67 62 0.0 [ 0.0, 0.0 ]
Total events: 0 (Acarbose), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 1.18. Comparison 1 Acarbose versus placebo, Outcome 18 Occurence of adverse effects.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 1 Acarbose versus placebo
Outcome: 18 Occurence of adverse effects








1 Acarbose 25 mg TID
Fischer 1998 46/102 33/97 7.1 % 1.59 [ 0.90, 2.83 ]
Subtotal (95% CI) 102 97 7.1 % 1.59 [ 0.90, 2.83 ]
Total events: 46 (Acarbose), 33 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
2 Acarbose 50 mg TID
Campbell 1998 248/259 242/263 5.7 % 1.96 [ 0.92, 4.14 ]
Fischer 1998 59/99 33/97 7.0 % 2.86 [ 1.60, 5.11 ]
Santeusanio 1993 9/28 9/29 3.6 % 1.05 [ 0.34, 3.22 ]
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Subtotal (95% CI) 386 389 16.2 % 2.11 [ 1.29, 3.47 ]
Total events: 316 (Acarbose), 284 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 2.55, df = 2 (P = 0.28); I2 =22%
Test for overall effect: Z = 2.95 (P = 0.0032)
3 Acarbose 100 mg TID
Braun 1996 21/55 4/57 3.4 % 8.18 [ 2.58, 25.92 ]
Calle-Pascual 1996 5/17 2/16 1.7 % 2.92 [ 0.48, 17.86 ]
Campbell 1998 247/255 242/263 5.1 % 2.68 [ 1.16, 6.17 ]
Chan 1998 39/62 27/62 5.9 % 2.20 [ 1.07, 4.51 ]
Coniff 1995b 70/73 59/73 2.9 % 5.54 [ 1.52, 20.20 ]
Fischer 1998 57/99 33/97 7.0 % 2.63 [ 1.48, 4.70 ]
Hanefeld 1991 42/50 21/50 4.4 % 7.25 [ 2.83, 18.59 ]
Hoffmann 1997 16/32 1/32 1.3 % 31.00 [ 3.76, 255.30 ]
Holman 1999 91/136 50/120 7.6 % 2.83 [ 1.70, 4.71 ]
Hotta 1993 15/19 11/18 2.5 % 2.39 [ 0.56, 10.22 ]
Kovacevic 1997 18/33 5/31 3.3 % 6.24 [ 1.92, 20.25 ]
Meneilly 2000 90/93 94/99 2.4 % 1.60 [ 0.37, 6.87 ]
Santeusanio 1993 17/27 9/29 3.6 % 3.78 [ 1.25, 11.45 ]
Scott 1999 51/53 49/52 1.7 % 1.56 [ 0.25, 9.75 ]
Subtotal (95% CI) 1004 999 53.0 % 3.38 [ 2.53, 4.52 ]
Total events: 779 (Acarbose), 607 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 15.52, df = 13 (P = 0.28); I2 =16%
Test for overall effect: Z = 8.25 (P < 0.00001)
4 Acarbose 200 mg TID
Coniff 1995 67/74 31/72 4.6 % 12.66 [ 5.11, 31.37 ]
Coniff 1995b 69/72 59/73 2.9 % 5.46 [ 1.50, 19.92 ]
Fischer 1998 72/98 33/97 6.7 % 5.37 [ 2.91, 9.93 ]
Subtotal (95% CI) 244 242 14.3 % 6.97 [ 4.01, 12.12 ]
Total events: 208 (Acarbose), 123 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 2.48, df = 2 (P = 0.29); I2 =19%
Test for overall effect: Z = 6.87 (P < 0.00001)
5 Acarbose 300 mg TID
Coniff 1994 69/104 45/107 7.2 % 2.72 [ 1.55, 4.75 ]
Coniff 1995b 70/72 59/73 2.3 % 8.31 [ 1.81, 38.03 ]
Subtotal (95% CI) 176 180 9.5 % 3.78 [ 1.38, 10.37 ]
Total events: 139 (Acarbose), 104 (Placebo)
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Heterogeneity: Tau2 = 0.30; Chi2 = 1.86, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 2.58 (P = 0.0098)
Total (95% CI) 1912 1907 100.0 % 3.37 [ 2.60, 4.36 ]
Total events: 1488 (Acarbose), 1151 (Placebo)
Heterogeneity: Tau2 = 0.16; Chi2 = 40.89, df = 22 (P = 0.01); I2 =46%
Test for overall effect: Z = 9.18 (P < 0.00001)
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Analysis 1.19. Comparison 1 Acarbose versus placebo, Outcome 19 Occurence of gastro-intestinal adverse
effects.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 1 Acarbose versus placebo
Outcome: 19 Occurence of gastro-intestinal adverse effects








1 Acarbose 50 mg TID
Campbell 1998 160/259 98/263 32.1 % 2.72 [ 1.91, 3.88 ]
Subtotal (95% CI) 259 263 32.1 % 2.72 [ 1.91, 3.88 ]
Total events: 160 (Acarbose), 98 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 5.54 (P < 0.00001)
2 Acarbose 100 mg TID
Campbell 1998 155/255 98/263 32.0 % 2.61 [ 1.83, 3.72 ]
Holman 1999 56/136 20/120 20.6 % 3.50 [ 1.94, 6.31 ]
Subtotal (95% CI) 391 383 52.6 % 2.82 [ 2.08, 3.82 ]
Total events: 211 (Acarbose), 118 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 6.69 (P < 0.00001)
3 Acarbose 200 mg TID
Coniff 1995 59/74 25/72 15.3 % 7.39 [ 3.51, 15.59 ]
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Subtotal (95% CI) 74 72 15.3 % 7.39 [ 3.51, 15.59 ]
Total events: 59 (Acarbose), 25 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 5.26 (P < 0.00001)
Total (95% CI) 724 718 100.0 % 3.30 [ 2.31, 4.71 ]
Total events: 430 (Acarbose), 241 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 6.76, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 6.56 (P < 0.00001)
0.01 0.1 1 10 100
Favours acarbose Favours placebo
Analysis 1.21. Comparison 1 Acarbose versus placebo, Outcome 21 Change in post-load blood glucose
(mmol/l) (2-hours).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 1 Acarbose versus placebo
Outcome: 21 Change in post-load blood glucose (mmol/l) (2-hours)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 25 mg TID
Fischer 1998 89 -1.34 (2.55) 87 0.02 (2.74) 6.2 % -1.36 [ -2.14, -0.58 ]
Subtotal (95% CI) 89 87 6.2 % -1.36 [ -2.14, -0.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.41 (P = 0.00066)
2 Acarbose 50 mg BID
Delgado 2002 9 -1.5 (1.6) 8 0.3 (1.4) 4.0 % -1.80 [ -3.23, -0.37 ]
Subtotal (95% CI) 9 8 4.0 % -1.80 [ -3.23, -0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.47 (P = 0.013)
3 Acarbose 50 mg TID
Fischer 1998 92 -1.71 (2.86) 87 0.02 (2.74) 6.0 % -1.73 [ -2.55, -0.91 ]
Santeusanio 1993 18 -1.41 (2.87) 22 -0.54 (3.28) 2.8 % -0.87 [ -2.78, 1.04 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 110 109 8.8 % -1.60 [ -2.35, -0.84 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 4.15 (P = 0.000033)
4 Acarbose 100 mg TID
Braun 1996 42 -3.2 (2.5) 44 -1.4 (2.5) 5.1 % -1.80 [ -2.86, -0.74 ]
Chan 1998 59 -0.77 (2.6) 62 0.65 (2.9) 5.4 % -1.42 [ -2.40, -0.44 ]
Coniff 1995b 52 -2.15 (3.95) 57 1.23 (4.05) 3.7 % -3.38 [ -4.88, -1.88 ]
Dedov 1995 82 -3.2 (2.2) 73 -2.5 (2) 6.6 % -0.70 [ -1.36, -0.04 ]
Fischer 1998 87 -1.48 (2.69) 87 0.02 (2.74) 6.1 % -1.50 [ -2.31, -0.69 ]
Haffner 1997 25 -2.4 (6.4) 25 -0.1 (7.4) 0.9 % -2.30 [ -6.14, 1.54 ]
Hanefeld 1991 47 -3.7 (2.3) 47 -0.8 (2.6) 5.4 % -2.90 [ -3.89, -1.91 ]
Hoffmann 1994 28 -1.8 (0.74) 30 0.03 (1.01) 7.4 % -1.83 [ -2.28, -1.38 ]
Hoffmann 1997 31 -2.36 (0.74) 32 0.01 (0.36) 7.8 % -2.37 [ -2.66, -2.08 ]
Hotta 1993 16 -2.69 (3.22) 15 -0.21 (2.93) 2.4 % -2.48 [ -4.65, -0.31 ]
Kovacevic 1997 33 -4.7 (3.7) 31 -1.7 (4.2) 2.7 % -3.00 [ -4.94, -1.06 ]
Santeusanio 1993 22 -2.92 (4.11) 22 -0.54 (3.28) 2.3 % -2.38 [ -4.58, -0.18 ]
Zheng 1995 39 -5.82 (3.6) 38 -0.4 (3.5) 3.5 % -5.42 [ -7.01, -3.83 ]
Subtotal (95% CI) 563 563 59.4 % -2.22 [ -2.75, -1.70 ]
Heterogeneity: Tau2 = 0.54; Chi2 = 49.35, df = 12 (P<0.00001); I2 =76%
Test for overall effect: Z = 8.31 (P < 0.00001)
5 Acarbose 200 mg TID
Coniff 1995 67 -3.16 (4.38) 61 -0.76 (4.47) 3.7 % -2.40 [ -3.94, -0.86 ]
Coniff 1995b 51 -2.79 (4.05) 57 1.23 (4.05) 3.7 % -4.02 [ -5.55, -2.49 ]
Fischer 1998 88 -2.4 (2.96) 87 0.02 (2.74) 5.9 % -2.42 [ -3.26, -1.58 ]
Subtotal (95% CI) 206 205 13.3 % -2.83 [ -3.78, -1.88 ]
Heterogeneity: Tau2 = 0.30; Chi2 = 3.42, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 5.82 (P < 0.00001)
6 Acarbose 300 mg TID
Coniff 1994 91 -2.11 (4.18) 96 0.69 (4.18) 4.7 % -2.80 [ -4.00, -1.60 ]
Coniff 1995b 50 -3.19 (3.94) 57 1.23 (4.05) 3.7 % -4.42 [ -5.94, -2.90 ]
Subtotal (95% CI) 141 153 8.4 % -3.54 [ -5.12, -1.96 ]
Heterogeneity: Tau2 = 0.83; Chi2 = 2.70, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 4.39 (P = 0.000011)
Total (95% CI) 1118 1125 100.0 % -2.27 [ -2.67, -1.88 ]
Heterogeneity: Tau2 = 0.50; Chi2 = 72.36, df = 21 (P<0.00001); I2 =71%
Test for overall effect: Z = 11.27 (P < 0.00001)
-10 -5 0 5 10
Favours treatment Favours control
102Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.22. Comparison 1 Acarbose versus placebo, Outcome 22 Change in post-load insulin levels
(pmol/l) (2-hours).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 1 Acarbose versus placebo
Outcome: 22 Change in post-load insulin levels (pmol/l) (2-hours)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 50 mg TID
Santeusanio 1993 10 63.6 (141.5) 14 7.7 (190.1) 2.1 % 55.90 [ -76.79, 188.59 ]
Subtotal (95% CI) 10 14 2.1 % 55.90 [ -76.79, 188.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
2 Acarbose 100 mg TID
Chan 1998 59 6.7 (172) 62 24.3 (165) 8.5 % -17.60 [ -77.71, 42.51 ]
Coniff 1995b 57 25.04 (190.1) 63 5.96 (192.5) 6.9 % 19.08 [ -49.44, 87.60 ]
Haffner 1997 25 -40 (196) 25 -20 (196) 3.1 % -20.00 [ -128.65, 88.65 ]
Hanefeld 1991 47 -10 (133) 47 60 (175) 7.9 % -70.00 [ -132.84, -7.16 ]
Hoffmann 1994 28 -105.54 (134.07) 30 -28.7 (195.22) 4.7 % -76.84 [ -162.55, 8.87 ]
Hoffmann 1997 31 -117.6 (194.4) 32 14.1 (159.7) 4.5 % -131.70 [ -219.70, -43.70 ]
Kovacevic 1997 33 -32.2 (14.9) 31 14.3 (12.6) 36.1 % -46.50 [ -53.25, -39.75 ]
Santeusanio 1993 14 35.5 (119.1) 14 7.7 (190.1) 2.7 % 27.80 [ -89.71, 145.31 ]
Zheng 1995 39 -33.8 (135.9) 38 47.3 (196.6) 5.9 % -81.10 [ -156.77, -5.43 ]
Subtotal (95% CI) 333 342 80.3 % -45.71 [ -69.57, -21.85 ]
Heterogeneity: Tau2 = 360.84; Chi2 = 11.59, df = 8 (P = 0.17); I2 =31%
Test for overall effect: Z = 3.75 (P = 0.00017)
3 Acarbose 200 mg TID
Coniff 1995 66 -47.8 (256.5) 61 -48.4 (260.6) 4.3 % 0.60 [ -89.43, 90.63 ]
Coniff 1995b 52 -4.59 (193) 63 5.96 (192.5) 6.6 % -10.55 [ -81.34, 60.24 ]
Subtotal (95% CI) 118 124 10.9 % -6.29 [ -61.94, 49.36 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.82)
4 Acarbose 300 mg TID
Coniff 1995b 53 -33.51 (192.2) 63 5.96 (192.5) 6.6 % -39.47 [ -109.73, 30.79 ]
Subtotal (95% CI) 53 63 6.6 % -39.47 [ -109.73, 30.79 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI) 514 543 100.0 % -38.83 [ -58.77, -18.89 ]
Heterogeneity: Tau2 = 274.78; Chi2 = 15.88, df = 12 (P = 0.20); I2 =24%
Test for overall effect: Z = 3.82 (P = 0.00013)
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Analysis 2.1. Comparison 2 Acarbose versus sulphonylurea (SU), Outcome 1 Change in glycated
haemoglobin (%).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 2 Acarbose versus sulphonylurea (SU)
Outcome: 1 Change in glycated haemoglobin (%)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID vs Tolbutamide 2000 mg in 3 dose
Van de Laar 2004a 32 -1.1 (1) 43 -1.8 (1.3) 13.3 % 0.70 [ 0.18, 1.22 ]
Subtotal (95% CI) 32 43 13.3 % 0.70 [ 0.18, 1.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.64 (P = 0.0084)
2 Acarbose 200 mg TID vs Tolbutamide 1000 mg TID
Coniff 1995 67 -0.54 (1.05) 66 -0.93 (1.04) 15.1 % 0.39 [ 0.03, 0.75 ]
Subtotal (95% CI) 67 66 15.1 % 0.39 [ 0.03, 0.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.031)
3 Acarbose 100 mg TID vs Glibenclamide 1 mg TID
Haffner 1997 25 0 (1.6) 27 -1.3 (1) 10.9 % 1.30 [ 0.57, 2.03 ]
Subtotal (95% CI) 25 27 10.9 % 1.30 [ 0.57, 2.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.48 (P = 0.00050)
4 Acarbose 100 mg TID vs Glibenclamide 3,5 mg TID
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hoffmann 1990 48 -1.78 (3.62) 47 -1.87 (3.95) 4.9 % 0.09 [ -1.43, 1.61 ]
Hoffmann 1994 28 -0.98 (0.45) 27 -0.76 (0.39) 16.3 % -0.22 [ -0.44, 0.00 ]
Kovacevic 1997 33 -0.7 (0.9) 33 -1.6 (1.2) 13.4 % 0.90 [ 0.39, 1.41 ]
Rosenthal 2002 32 -0.5 (0.36) 31 -0.2 (0.78) 15.6 % -0.30 [ -0.60, 0.00 ]
Subtotal (95% CI) 141 138 50.1 % 0.07 [ -0.43, 0.58 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 17.48, df = 3 (P = 0.00056); I2 =83%
Test for overall effect: Z = 0.29 (P = 0.77)
5 Acarbose 100 mg TID vs Gliclazide 80 mg BID
Salman 2001 27 -1.78 (1.64) 30 -2.16 (1.17) 10.7 % 0.38 [ -0.37, 1.13 ]
Subtotal (95% CI) 27 30 10.7 % 0.38 [ -0.37, 1.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Total (95% CI) 292 304 100.0 % 0.38 [ -0.02, 0.77 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 42.61, df = 7 (P<0.00001); I2 =84%
Test for overall effect: Z = 1.85 (P = 0.065)
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Analysis 2.2. Comparison 2 Acarbose versus sulphonylurea (SU), Outcome 2 Change in fasting blood
glucose (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 2 Acarbose versus sulphonylurea (SU)
Outcome: 2 Change in fasting blood glucose (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID vs Tolbutamide 2000 mg in 3 dose
Van de Laar 2004a 32 -1.5 (2.1) 43 -2.9 (2.6) 12.3 % 1.40 [ 0.34, 2.46 ]
Subtotal (95% CI) 32 43 12.3 % 1.40 [ 0.34, 2.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.58 (P = 0.010)
2 Acarbose 200 mg TID vs Tolbutamide 1000 mg TID
Coniff 1995 67 -1.11 (3.17) 66 -2.02 (3.13) 12.2 % 0.91 [ -0.16, 1.98 ]
Subtotal (95% CI) 67 66 12.2 % 0.91 [ -0.16, 1.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.096)
3 Acarbose 100 mg TID vs Glibenclamide 1 mg TID
Haffner 1997 25 -0.9 (3.6) 27 -3.4 (3) 6.4 % 2.50 [ 0.69, 4.31 ]
Subtotal (95% CI) 25 27 6.4 % 2.50 [ 0.69, 4.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.71 (P = 0.0068)
4 Acarbose 100 mg TID vs Glibenclamide 3,5 mg TID
Hoffmann 1990 48 -1.7 (1.2) 47 -1.7 (0.9) 20.9 % 0.0 [ -0.43, 0.43 ]
Hoffmann 1994 28 -1.2 (0.89) 27 -1.25 (0.89) 20.3 % 0.05 [ -0.42, 0.52 ]
Kovacevic 1997 33 -1.9 (3) 33 -4 (4) 7.0 % 2.10 [ 0.39, 3.81 ]
Rosenthal 2002 32 -0.7 (2.4) 31 -0.9 (2.5) 10.8 % 0.20 [ -1.01, 1.41 ]
Subtotal (95% CI) 141 138 58.8 % 0.20 [ -0.29, 0.69 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 5.56, df = 3 (P = 0.14); I2 =46%
Test for overall effect: Z = 0.79 (P = 0.43)
5 Acarbose 100 mg TID vs Gliclazide 80 mg BID
Salman 2001 27 -1.93 (2.8) 30 -2.62 (1.93) 10.3 % 0.69 [ -0.57, 1.95 ]
Subtotal (95% CI) 27 30 10.3 % 0.69 [ -0.57, 1.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
Total (95% CI) 292 304 100.0 % 0.69 [ 0.16, 1.23 ]
Heterogeneity: Tau2 = 0.31; Chi2 = 18.68, df = 7 (P = 0.01); I2 =63%
Test for overall effect: Z = 2.54 (P = 0.011)
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Analysis 2.3. Comparison 2 Acarbose versus sulphonylurea (SU), Outcome 3 Change in post-load blood
glucose (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 2 Acarbose versus sulphonylurea (SU)
Outcome: 3 Change in post-load blood glucose (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID vs Tolbutamide 2000 mg in 3 dose
Van de Laar 2004a 29 -1.2 (3.9) 41 -2.2 (2.8) 3.8 % 1.00 [ -0.66, 2.66 ]
Subtotal (95% CI) 29 41 3.8 % 1.00 [ -0.66, 2.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
2 Acarbose 200 mg TID vs Tolbutamide 1000 mg TID
Coniff 1995 67 -2.82 (3.71) 66 -3.15 (3.83) 6.2 % 0.33 [ -0.95, 1.61 ]
Subtotal (95% CI) 67 66 6.2 % 0.33 [ -0.95, 1.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.61)
3 Acarbose 100 mg TID vs Glibenclamide 1 mg TID
Haffner 1997 25 -2.4 (6.4) 27 -3.2 (7.1) 0.8 % 0.80 [ -2.87, 4.47 ]
Subtotal (95% CI) 25 27 0.8 % 0.80 [ -2.87, 4.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
4 Acarbose 100 mg TID vs Glibenclamide 3,5 mg TID
Hoffmann 1990 48 -2.2 (1.3) 47 -1.9 (1.2) 34.0 % -0.30 [ -0.80, 0.20 ]
Hoffmann 1994 28 -1.8 (0.74) 27 -1.63 (0.9) 42.5 % -0.17 [ -0.61, 0.27 ]
Kovacevic 1997 33 -4.7 (3.7) 33 -5.1 (3.9) 3.1 % 0.40 [ -1.43, 2.23 ]
Rosenthal 2002 32 -1.4 (2.4) 31 -2.1 (2.7) 6.4 % 0.70 [ -0.56, 1.96 ]
Subtotal (95% CI) 141 138 86.0 % -0.15 [ -0.46, 0.16 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.44, df = 3 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
5 Acarbose 100 mg TID vs Gliclazide 80 mg BID
Salman 2001 27 -3.73 (3.45) 30 -2.16 (3.45) 3.2 % -1.57 [ -3.36, 0.22 ]
Subtotal (95% CI) 27 30 3.2 % -1.57 [ -3.36, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.086)
Total (95% CI) 289 302 100.0 % -0.10 [ -0.43, 0.22 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 7.45, df = 7 (P = 0.38); I2 =6%
Test for overall effect: Z = 0.62 (P = 0.53)
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Analysis 2.4. Comparison 2 Acarbose versus sulphonylurea (SU), Outcome 4 Change in total cholesterol
(mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 2 Acarbose versus sulphonylurea (SU)
Outcome: 4 Change in total cholesterol (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID vs Tolbutamide 2000 mg in 3 dose
Van de Laar 2004a 28 0.1 (0.5) 39 0 (0.7) 24.4 % 0.10 [ -0.19, 0.39 ]
Subtotal (95% CI) 28 39 24.4 % 0.10 [ -0.19, 0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 Acarbose 200 mg TID vs Tolbutamide 1000 mg TID
Coniff 1995 64 -0.21 (0.79) 61 0.05 (0.77) 27.0 % -0.26 [ -0.53, 0.01 ]
Subtotal (95% CI) 64 61 27.0 % -0.26 [ -0.53, 0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.062)
3 Acarbose 100 mg TID vs Glibenclamide 1 mg TID
Haffner 1997 17 0.05 (0.93) 17 -0.1 (0.7) 6.6 % 0.15 [ -0.40, 0.70 ]
Subtotal (95% CI) 17 17 6.6 % 0.15 [ -0.40, 0.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
4 Acarbose 100 mg TID vs Glibenclamide 3,5 mg TID
Hoffmann 1990 48 -0.45 (0.67) 47 -0.33 (0.73) 25.4 % -0.12 [ -0.40, 0.16 ]
Hoffmann 1994 28 -0.59 (1.34) 27 -0.18 (1.61) 3.3 % -0.41 [ -1.19, 0.37 ]
Kovacevic 1997 33 -0.3 (1.1) 33 -0.2 (1.4) 5.5 % -0.10 [ -0.71, 0.51 ]
Subtotal (95% CI) 109 107 34.1 % -0.14 [ -0.39, 0.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.49, df = 2 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
5 Acarbose 100 mg TID vs Gliclazide 80 mg BID
Salman 2001 27 -0.4 (0.8) 30 -0.31 (1.13) 7.9 % -0.09 [ -0.59, 0.41 ]
Subtotal (95% CI) 27 30 7.9 % -0.09 [ -0.59, 0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Total (95% CI) 245 254 100.0 % -0.09 [ -0.23, 0.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.57, df = 6 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
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Analysis 2.5. Comparison 2 Acarbose versus sulphonylurea (SU), Outcome 5 Change in HDL-cholesterol
(mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 2 Acarbose versus sulphonylurea (SU)
Outcome: 5 Change in HDL-cholesterol (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID vs Tolbutamide 2000 mg in 3 dose
Van de Laar 2004a 28 0.1 (0.2) 38 0.1 (0.4) 9.0 % 0.0 [ -0.15, 0.15 ]
Subtotal (95% CI) 28 38 9.0 % 0.0 [ -0.15, 0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Acarbose 200 mg TID vs Tolbutamide 1000 mg TID
Coniff 1995 58 0.07 (0.23) 54 0.08 (0.23) 26.9 % -0.01 [ -0.10, 0.08 ]
Subtotal (95% CI) 58 54 26.9 % -0.01 [ -0.10, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
3 Acarbose 100 mg TID vs Glibenclamide 1 mg TID
Haffner 1997 17 0.01 (0.3) 17 0 (0.34) 4.2 % 0.01 [ -0.21, 0.23 ]
Subtotal (95% CI) 17 17 4.2 % 0.01 [ -0.21, 0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
4 Acarbose 100 mg TID vs Glibenclamide 3,5 mg TID
Hoffmann 1990 48 0.06 (0.13) 47 0.02 (0.2) 42.4 % 0.04 [ -0.03, 0.11 ]
Hoffmann 1994 28 0.09 (0.44) 27 -0.07 (0.68) 2.1 % 0.16 [ -0.14, 0.46 ]
Kovacevic 1997 33 0.1 (0.3) 33 0.1 (0.4) 6.7 % 0.0 [ -0.17, 0.17 ]
Subtotal (95% CI) 109 107 51.2 % 0.04 [ -0.02, 0.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.81, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
5 Acarbose 100 mg TID vs Gliclazide 80 mg BID
Salman 2001 27 0.06 (0.3) 30 0.04 (0.28) 8.6 % 0.02 [ -0.13, 0.17 ]
Subtotal (95% CI) 27 30 8.6 % 0.02 [ -0.13, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
Total (95% CI) 239 246 100.0 % 0.02 [ -0.02, 0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.76, df = 6 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
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Analysis 2.6. Comparison 2 Acarbose versus sulphonylurea (SU), Outcome 6 Change in LDL-cholesterol
(mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 2 Acarbose versus sulphonylurea (SU)
Outcome: 6 Change in LDL-cholesterol (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID vs Tolbutamide 2000 mg in 3 dose
Van de Laar 2004a 27 0.1 (0.4) 38 -0.1 (0.7) 39.8 % 0.20 [ -0.07, 0.47 ]
Subtotal (95% CI) 27 38 39.8 % 0.20 [ -0.07, 0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
2 Acarbose 200 mg TID vs Tolbutamide 1000 mg TID
Coniff 1995 48 -0.09 (0.67) 47 -0.1 (0.68) 39.0 % 0.01 [ -0.26, 0.28 ]
Subtotal (95% CI) 48 47 39.0 % 0.01 [ -0.26, 0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
3 Acarbose 100 mg TID vs Glibenclamide 3,5 mg TID
Hoffmann 1990 48 -0.05 (1.49) 47 -0.07 (1.74) 6.8 % 0.02 [ -0.63, 0.67 ]
Subtotal (95% CI) 48 47 6.8 % 0.02 [ -0.63, 0.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
4 Acarbose 100 mg TID vs Gliclazide 80 mg BID
Salman 2001 27 -0.33 (0.78) 30 -0.42 (0.94) 14.4 % 0.09 [ -0.36, 0.54 ]
Subtotal (95% CI) 27 30 14.4 % 0.09 [ -0.36, 0.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.69)
Total (95% CI) 150 162 100.0 % 0.10 [ -0.07, 0.27 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.01, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
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Analysis 2.7. Comparison 2 Acarbose versus sulphonylurea (SU), Outcome 7 Change in triglycerides
(mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 2 Acarbose versus sulphonylurea (SU)
Outcome: 7 Change in triglycerides (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID vs Tolbutamide 2000 mg in 3 dose
Van de Laar 2004a 28 -0.3 (1.6) 39 -0.4 (2.1) 4.5 % 0.10 [ -0.79, 0.99 ]
Subtotal (95% CI) 28 39 4.5 % 0.10 [ -0.79, 0.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
2 Acarbose 200 mg TID vs Tolbutamide 1000 mg TID
Coniff 1995 64 -0.49 (1.87) 61 -0.03 (1.84) 8.4 % -0.46 [ -1.11, 0.19 ]
Subtotal (95% CI) 64 61 8.4 % -0.46 [ -1.11, 0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
3 Acarbose 100 mg TID vs Glibenclamide 1 mg TID
Haffner 1997 25 0 (1.1) 27 -0.4 (1.1) 9.9 % 0.40 [ -0.20, 1.00 ]
Subtotal (95% CI) 25 27 9.9 % 0.40 [ -0.20, 1.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
4 Acarbose 100 mg TID vs Glibenclamide 3,5 mg TID
Hoffmann 1990 48 -0.1 (0.4) 47 -0.2 (0.9) 44.8 % 0.10 [ -0.18, 0.38 ]
Hoffmann 1994 28 -0.58 (1.21) 27 -0.44 (1.36) 7.6 % -0.14 [ -0.82, 0.54 ]
Kovacevic 1997 33 -0.4 (1.4) 33 -0.7 (1.5) 7.2 % 0.30 [ -0.40, 1.00 ]
Rosenthal 2002 38 -0.13 (1.28) 36 0.17 (2.04) 5.8 % -0.30 [ -1.08, 0.48 ]
Subtotal (95% CI) 147 143 65.4 % 0.06 [ -0.17, 0.29 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.68, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
5 Acarbose 100 mg TID vs Gliclazide 80 mg BID
Salman 2001 27 -0.43 (1.22) 30 -0.12 (0.83) 11.8 % -0.31 [ -0.86, 0.24 ]
Subtotal (95% CI) 27 30 11.8 % -0.31 [ -0.86, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Total (95% CI) 291 300 100.0 % 0.01 [ -0.18, 0.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 6.83, df = 7 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
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Analysis 2.8. Comparison 2 Acarbose versus sulphonylurea (SU), Outcome 8 Change in fasting insulin levels
(pmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 2 Acarbose versus sulphonylurea (SU)
Outcome: 8 Change in fasting insulin levels (pmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID vs Tolbutamide 2000 mg in 3 dose
Van de Laar 2004a 28 -4.7 (56) 35 -3.2 (96.1) 13.8 % -1.50 [ -39.50, 36.50 ]
Subtotal (95% CI) 28 35 13.8 % -1.50 [ -39.50, 36.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
2 Acarbose 200 mg TID vs Tolbutamide 1000 mg TID
Coniff 1995 65 -3.2 (112.8) 65 22.2 (111.6) 13.5 % -25.40 [ -63.97, 13.17 ]
Subtotal (95% CI) 65 65 13.5 % -25.40 [ -63.97, 13.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
3 Acarbose 100 mg TID vs Glibenclamide 1 mg TID
Haffner 1997 25 10 (92) 27 10 (110) 8.4 % 0.0 [ -54.97, 54.97 ]
Subtotal (95% CI) 25 27 8.4 % 0.0 [ -54.97, 54.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Acarbose 100 mg TID vs Glibenclamide 3,5 mg TID
Hoffmann 1994 28 -33.56 (139.81) 27 -52.62 (121.54) 5.9 % 19.06 [ -50.10, 88.22 ]
Kovacevic 1997 33 -14.4 (11.9) 33 7.2 (13.8) 31.5 % -21.60 [ -27.82, -15.38 ]
Rosenthal 2002 32 -53 (60) 31 43 (126) 9.9 % -96.00 [ -144.98, -47.02 ]
Subtotal (95% CI) 93 91 47.3 % -35.03 [ -88.53, 18.47 ]
Heterogeneity: Tau2 = 1719.60; Chi2 = 10.12, df = 2 (P = 0.01); I2 =80%
Test for overall effect: Z = 1.28 (P = 0.20)
5 Acarbose 100 mg TID vs Gliclazide 80 mg BID
Salman 2001 27 -19.69 (67.08) 30 15.12 (50.89) 17.0 % -34.81 [ -65.98, -3.64 ]
Subtotal (95% CI) 27 30 17.0 % -34.81 [ -65.98, -3.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.029)
Total (95% CI) 238 248 100.0 % -24.78 [ -43.30, -6.26 ]
Heterogeneity: Tau2 = 273.12; Chi2 = 12.54, df = 6 (P = 0.05); I2 =52%
Test for overall effect: Z = 2.62 (P = 0.0087)
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Analysis 2.9. Comparison 2 Acarbose versus sulphonylurea (SU), Outcome 9 Change in post-load insulin
levels (pmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 2 Acarbose versus sulphonylurea (SU)
Outcome: 9 Change in post-load insulin levels (pmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID vs Tolbutamide 2000 mg in 3 dose (1 hour pp)
Van de Laar 2004a 25 7.5 (136.5) 35 26.4 (282.2) 12.5 % -18.90 [ -126.62, 88.82 ]
Subtotal (95% CI) 25 35 12.5 % -18.90 [ -126.62, 88.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
2 Acarbose 200 mg TID vs Tolbutamide 1000 mg TID
Coniff 1995 65 -45.1 (226.8) 65 169 (225) 16.9 % -214.10 [ -291.77, -136.43 ]
Subtotal (95% CI) 65 65 16.9 % -214.10 [ -291.77, -136.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.40 (P < 0.00001)
3 Acarbose 100 mg TID vs Glibenclamide 1 mg TID
Haffner 1997 25 -40 (196) 27 140 (286) 9.7 % -180.00 [ -312.44, -47.56 ]
Subtotal (95% CI) 25 27 9.7 % -180.00 [ -312.44, -47.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0077)
4 Acarbose 100 mg TID vs Glibenclamide 3,5 mg TID
Hoffmann 1994 28 -105.54 (134.07) 27 61.92 (214.46) 14.2 % -167.46 [ -262.38, -72.54 ]
Kovacevic 1997 33 -32.2 (14.9) 33 64.6 (13.9) 27.4 % -96.80 [ -103.75, -89.85 ]
Rosenthal 2002 32 18 (304) 31 96 (381) 6.8 % -78.00 [ -248.54, 92.54 ]
Subtotal (95% CI) 93 91 48.5 % -100.66 [ -124.60, -76.72 ]
Heterogeneity: Tau2 = 149.40; Chi2 = 2.17, df = 2 (P = 0.34); I2 =8%
Test for overall effect: Z = 8.24 (P < 0.00001)
5 Acarbose 100 mg TID vs Gliclazide 80 mg BID
Salman 2001 27 -69.36 (182.74) 30 103.02 (232.11) 12.4 % -172.38 [ -280.31, -64.45 ]
Subtotal (95% CI) 27 30 12.4 % -172.38 [ -280.31, -64.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.13 (P = 0.0017)
Total (95% CI) 235 248 100.0 % -133.17 [ -184.53, -81.82 ]
Heterogeneity: Tau2 = 2488.80; Chi2 = 16.17, df = 6 (P = 0.01); I2 =63%
Test for overall effect: Z = 5.08 (P < 0.00001)
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Analysis 2.10. Comparison 2 Acarbose versus sulphonylurea (SU), Outcome 10 Change in fasting C-peptide
levels (nmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 2 Acarbose versus sulphonylurea (SU)
Outcome: 10 Change in fasting C-peptide levels (nmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID vs Gliclazide 80 mg BID
Salman 2001 27 -0.17 (0.56) 30 0.01 (0.71) 100.0 % -0.18 [ -0.51, 0.15 ]
Total (95% CI) 27 30 100.0 % -0.18 [ -0.51, 0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
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Analysis 2.11. Comparison 2 Acarbose versus sulphonylurea (SU), Outcome 11 Change in post-load C-
peptide levels (nmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 2 Acarbose versus sulphonylurea (SU)
Outcome: 11 Change in post-load C-peptide levels (nmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID vs Gliclazide 80 mg BID
Salman 2001 27 -0.43 (1.23) 30 -0.07 (0.99) 100.0 % -0.36 [ -0.94, 0.22 ]
Total (95% CI) 27 30 100.0 % -0.36 [ -0.94, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
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Analysis 2.12. Comparison 2 Acarbose versus sulphonylurea (SU), Outcome 12 Change in body weight (Kg).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 2 Acarbose versus sulphonylurea (SU)
Outcome: 12 Change in body weight (Kg)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 200 mg TID vs Tolbutamide 1000 mg TID
Coniff 1995 66 -1.42 (2.84) 66 1.84 (2.76) 37.4 % -3.26 [ -4.22, -2.30 ]
Subtotal (95% CI) 66 66 37.4 % -3.26 [ -4.22, -2.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.69 (P < 0.00001)
2 Acarbose 100 mg TID vs Glibenclamide 1 mg TID
Haffner 1997 25 -1.5 (12.9) 27 1.6 (13.7) 7.0 % -3.10 [ -10.33, 4.13 ]
Subtotal (95% CI) 25 27 7.0 % -3.10 [ -10.33, 4.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
3 Acarbose 100 mg TID vs Glibenclamide 3,5 mg TID
Hoffmann 1990 48 -1.14 (1.59) 47 -0.59 (1.55) 39.0 % -0.55 [ -1.18, 0.08 ]
Rosenthal 2002 32 -2.5 (15.7) 31 0.2 (14.6) 6.6 % -2.70 [ -10.18, 4.78 ]
Spengler 1992 26 -0.7 (11.8) 29 0 (10) 9.9 % -0.70 [ -6.52, 5.12 ]
Subtotal (95% CI) 106 107 55.6 % -0.57 [ -1.19, 0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.32, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.076)
Total (95% CI) 197 200 100.0 % -1.90 [ -4.01, 0.21 ]
Heterogeneity: Tau2 = 2.86; Chi2 = 21.90, df = 4 (P = 0.00021); I2 =82%
Test for overall effect: Z = 1.77 (P = 0.078)
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Analysis 2.13. Comparison 2 Acarbose versus sulphonylurea (SU), Outcome 13 Change in body mass index
(Kg/m2).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 2 Acarbose versus sulphonylurea (SU)
Outcome: 13 Change in body mass index (Kg/m2)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID vs Glibenclamide 1 mg TID
Haffner 1997 25 -0.5 (4.1) 27 0.6 (3.7) 4.0 % -1.10 [ -3.23, 1.03 ]
Subtotal (95% CI) 25 27 4.0 % -1.10 [ -3.23, 1.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
2 Acarbose 100 mg TID vs Glibenclamide 3,5 mg TID
Hoffmann 1994 28 -0.42 (0.27) 27 -0.32 (0.66) 55.2 % -0.10 [ -0.37, 0.17 ]
Kovacevic 1997 33 -0.8 (3) 33 0.4 (3.4) 7.3 % -1.20 [ -2.75, 0.35 ]
Subtotal (95% CI) 61 60 62.5 % -0.38 [ -1.31, 0.56 ]
Heterogeneity: Tau2 = 0.28; Chi2 = 1.89, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 0.79 (P = 0.43)
3 Acarbose 100 mg TID vs Gliclazide 80 mg BID
Salman 2001 27 -0.41 (1.03) 30 0.19 (1.08) 33.5 % -0.60 [ -1.15, -0.05 ]
Subtotal (95% CI) 27 30 33.5 % -0.60 [ -1.15, -0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.032)
Total (95% CI) 113 117 100.0 % -0.39 [ -0.83, 0.05 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 4.81, df = 3 (P = 0.19); I2 =38%
Test for overall effect: Z = 1.72 (P = 0.085)
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Analysis 2.14. Comparison 2 Acarbose versus sulphonylurea (SU), Outcome 14 Total deaths.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 2 Acarbose versus sulphonylurea (SU)
Outcome: 14 Total deaths








1 Acarbose 200 mg TID vs Tolbutamide 1000 mg TID
Coniff 1995 0/67 1/66 100.0 % 0.32 [ 0.01, 8.08 ]
Total (95% CI) 67 66 100.0 % 0.32 [ 0.01, 8.08 ]
Total events: 0 (Acarbose), 1 (Sulphonylurea)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
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Analysis 2.15. Comparison 2 Acarbose versus sulphonylurea (SU), Outcome 15 Disease related deaths.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 2 Acarbose versus sulphonylurea (SU)
Outcome: 15 Disease related deaths








1 Acarbose 200 mg TID vs Tolbutamide 1000 mg TID
Coniff 1995 0/67 1/66 100.0 % 0.32 [ 0.01, 8.08 ]
Total (95% CI) 67 66 100.0 % 0.32 [ 0.01, 8.08 ]
Total events: 0 (Acarbose), 1 (Sulphonylurea)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
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Analysis 2.16. Comparison 2 Acarbose versus sulphonylurea (SU), Outcome 16 Occurence of adverse
effects.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 2 Acarbose versus sulphonylurea (SU)
Outcome: 16 Occurence of adverse effects








1 Acarbose 100 mg TID vs Tolbutamide 2000 mg in 3 dose
Van de Laar 2004a 22/48 12/48 17.1 % 2.54 [ 1.07, 6.03 ]
Subtotal (95% CI) 48 48 17.1 % 2.54 [ 1.07, 6.03 ]
Total events: 22 (Acarbose), 12 (Sulphonylurea)
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
2 Acarbose 200 mg TID vs Tolbutamide 1000 mg TID
Coniff 1995 67/74 42/71 16.6 % 6.61 [ 2.66, 16.44 ]
Subtotal (95% CI) 74 71 16.6 % 6.61 [ 2.66, 16.44 ]
Total events: 67 (Acarbose), 42 (Sulphonylurea)
Heterogeneity: not applicable
Test for overall effect: Z = 4.06 (P = 0.000049)
3 Acarbose 100 mg TID vs Glibenclamide 3,5 mg TID
Hoffmann 1990 14/48 12/47 16.7 % 1.20 [ 0.49, 2.97 ]
Kovacevic 1997 18/33 5/33 13.9 % 6.72 [ 2.08, 21.71 ]
Rosenthal 2002 8/39 2/37 10.1 % 4.52 [ 0.89, 22.89 ]
Spengler 1992 23/36 3/36 12.1 % 19.46 [ 4.98, 76.10 ]
Subtotal (95% CI) 156 153 52.7 % 4.88 [ 1.37, 17.37 ]
Total events: 63 (Acarbose), 22 (Sulphonylurea)
Heterogeneity: Tau2 = 1.26; Chi2 = 12.74, df = 3 (P = 0.01); I2 =76%
Test for overall effect: Z = 2.45 (P = 0.014)
4 Acarbose 100 mg TID vs Gliclazide 80 mg BID
Salman 2001 9/27 6/30 13.6 % 2.00 [ 0.60, 6.64 ]
Subtotal (95% CI) 27 30 13.6 % 2.00 [ 0.60, 6.64 ]
Total events: 9 (Acarbose), 6 (Sulphonylurea)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
Total (95% CI) 305 302 100.0 % 3.95 [ 2.00, 7.80 ]
Total events: 161 (Acarbose), 82 (Sulphonylurea)
Heterogeneity: Tau2 = 0.51; Chi2 = 16.02, df = 6 (P = 0.01); I2 =63%
Test for overall effect: Z = 3.95 (P = 0.000078)
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Analysis 2.17. Comparison 2 Acarbose versus sulphonylurea (SU), Outcome 17 Occurence of gastro-
intestinal adverse effects.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 2 Acarbose versus sulphonylurea (SU)
Outcome: 17 Occurence of gastro-intestinal adverse effects








1 Acarbose 200 mg TID vs Tolbutamide 1000 mg TID
Coniff 1995 59/74 24/71 100.0 % 7.70 [ 3.64, 16.31 ]
Total (95% CI) 74 71 100.0 % 7.70 [ 3.64, 16.31 ]
Total events: 59 (Acarbose), 24 (Sulphonylurea)
Heterogeneity: not applicable
Test for overall effect: Z = 5.33 (P < 0.00001)
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Analysis 2.18. Comparison 2 Acarbose versus sulphonylurea (SU), Outcome 18 Change in post-load blood
glucose (mmol/l) (2 hours).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 2 Acarbose versus sulphonylurea (SU)
Outcome: 18 Change in post-load blood glucose (mmol/l) (2 hours)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID vs Tolbutamide 2000 mg in 3 dose
Van de Laar 2004a 29 -1.2 (3.9) 41 -2.2 (2.8) 6.9 % 1.00 [ -0.66, 2.66 ]
Subtotal (95% CI) 29 41 6.9 % 1.00 [ -0.66, 2.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
2 Acarbose 200 mg TID vs Tolbutamide 1000 mg TID
Coniff 1995 67 -3.16 (4.38) 66 -4.55 (4.37) 8.2 % 1.39 [ -0.10, 2.88 ]
Subtotal (95% CI) 67 66 8.2 % 1.39 [ -0.10, 2.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.067)
3 Acarbose 100 mg TID vs Glibenclamide 1 mg TID
Haffner 1997 25 -2.4 (6.4) 27 -3.2 (7.1) 1.6 % 0.80 [ -2.87, 4.47 ]
Subtotal (95% CI) 25 27 1.6 % 0.80 [ -2.87, 4.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
4 Acarbose 100 mg TID vs Glibenclamide 3,5 mg TID
Hoffmann 1990 48 -2.2 (1.3) 47 -1.9 (1.2) 29.1 % -0.30 [ -0.80, 0.20 ]
Hoffmann 1994 28 -1.8 (0.74) 27 -1.63 (0.9) 31.7 % -0.17 [ -0.61, 0.27 ]
Kovacevic 1997 33 -4.7 (3.7) 33 -5.1 (3.9) 5.8 % 0.40 [ -1.43, 2.23 ]
Rosenthal 2002 32 -1.4 (2.4) 31 -2.1 (2.7) 10.7 % 0.70 [ -0.56, 1.96 ]
Subtotal (95% CI) 141 138 77.2 % -0.15 [ -0.46, 0.16 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.44, df = 3 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
5 Acarbose 100 mg TID vs Gliclazide 80 mg BID
Salman 2001 27 -3.73 (3.45) 30 -2.16 (3.45) 6.0 % -1.57 [ -3.36, 0.22 ]
Subtotal (95% CI) 27 30 6.0 % -1.57 [ -3.36, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.086)
Total (95% CI) 289 302 100.0 % 0.06 [ -0.42, 0.53 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 10.88, df = 7 (P = 0.14); I2 =36%
Test for overall effect: Z = 0.24 (P = 0.81)
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Analysis 2.19. Comparison 2 Acarbose versus sulphonylurea (SU), Outcome 19 Change in post-load insulin
levels (pmol/l) (2 hours).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 2 Acarbose versus sulphonylurea (SU)
Outcome: 19 Change in post-load insulin levels (pmol/l) (2 hours)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID vs Tolbutamide 2000 mg in 3 dose (1 hour pp)
Van de Laar 2004a 25 7.5 (136.5) 35 26.4 (282.2) 9.3 % -18.90 [ -126.62, 88.82 ]
Subtotal (95% CI) 25 35 9.3 % -18.90 [ -126.62, 88.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
2 Acarbose 200 mg TID vs Tolbutamide 1000 mg TID
Coniff 1995 66 -47.8 (256.5) 65 100.2 (254.5) 12.8 % -148.00 [ -235.51, -60.49 ]
Subtotal (95% CI) 66 65 12.8 % -148.00 [ -235.51, -60.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.31 (P = 0.00092)
3 Acarbose 100 mg TID vs Glibenclamide 1 mg TID
Haffner 1997 25 -40 (196) 27 140 (286) 6.6 % -180.00 [ -312.44, -47.56 ]
Subtotal (95% CI) 25 27 6.6 % -180.00 [ -312.44, -47.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0077)
4 Acarbose 100 mg TID vs Glibenclamide 3,5 mg TID
Hoffmann 1994 28 -105.54 (134.07) 27 61.92 (214.46) 11.3 % -167.46 [ -262.38, -72.54 ]
Kovacevic 1997 33 -32.2 (14.9) 33 64.6 (13.9) 46.4 % -96.80 [ -103.75, -89.85 ]
Rosenthal 2002 32 18 (304) 31 96 (381) 4.2 % -78.00 [ -248.54, 92.54 ]
Subtotal (95% CI) 93 91 62.0 % -100.66 [ -124.60, -76.72 ]
Heterogeneity: Tau2 = 149.40; Chi2 = 2.17, df = 2 (P = 0.34); I2 =8%
Test for overall effect: Z = 8.24 (P < 0.00001)
5 Acarbose 100 mg TID vs Gliclazide 80 mg BID
Salman 2001 27 -69.36 (182.74) 30 103.02 (232.11) 9.3 % -172.38 [ -280.31, -64.45 ]
Subtotal (95% CI) 27 30 9.3 % -172.38 [ -280.31, -64.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.13 (P = 0.0017)
Total (95% CI) 236 248 100.0 % -115.84 [ -152.52, -79.15 ]
Heterogeneity: Tau2 = 741.94; Chi2 = 8.84, df = 6 (P = 0.18); I2 =32%
Test for overall effect: Z = 6.19 (P < 0.00001)
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Analysis 3.1. Comparison 3 Acarbose versus Metformin, Outcome 1 Change in glycated haemoglobin (%).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 3 Acarbose versus Metformin
Outcome: 1 Change in glycated haemoglobin (%)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID versus Metformin 850 mg BID
Hoffmann 1997 31 -1.11 (0.79) 31 -0.86 (0.65) 100.0 % -0.25 [ -0.61, 0.11 ]
Total (95% CI) 31 31 100.0 % -0.25 [ -0.61, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.17)
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Analysis 3.2. Comparison 3 Acarbose versus Metformin, Outcome 2 Change in fasting blood glucose
(mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 3 Acarbose versus Metformin
Outcome: 2 Change in fasting blood glucose (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID versus Metformin 850 mg BID
Hoffmann 1997 31 -1.39 (0.81) 31 -1 (0.59) 100.0 % -0.39 [ -0.74, -0.04 ]
Total (95% CI) 31 31 100.0 % -0.39 [ -0.74, -0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.17 (P = 0.030)
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Analysis 3.3. Comparison 3 Acarbose versus Metformin, Outcome 3 Change in post-load blood glucose
(mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 3 Acarbose versus Metformin
Outcome: 3 Change in post-load blood glucose (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID versus Metformin 850 mg BID
Hoffmann 1997 31 -2.36 (0.74) 31 -1.94 (0.74) 100.0 % -0.42 [ -0.79, -0.05 ]
Total (95% CI) 31 31 100.0 % -0.42 [ -0.79, -0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.23 (P = 0.025)
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Analysis 3.4. Comparison 3 Acarbose versus Metformin, Outcome 4 Change in total cholesterol (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 3 Acarbose versus Metformin
Outcome: 4 Change in total cholesterol (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID versus Metformin 850 mg BID
Hoffmann 1997 31 -0.85 (1.67) 31 0.09 (1.16) 100.0 % -0.94 [ -1.66, -0.22 ]
Total (95% CI) 31 31 100.0 % -0.94 [ -1.66, -0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.57 (P = 0.010)
-4 -2 0 2 4
Favours acarbose Favours metformin
123Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.5. Comparison 3 Acarbose versus Metformin, Outcome 5 Change in HDL-cholesterol (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 3 Acarbose versus Metformin
Outcome: 5 Change in HDL-cholesterol (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID versus Metformin 850 mg BID
Hoffmann 1997 31 0.23 (0.63) 31 -0.01 (0.4) 100.0 % 0.24 [ -0.02, 0.50 ]
Total (95% CI) 31 31 100.0 % 0.24 [ -0.02, 0.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.073)
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Analysis 3.6. Comparison 3 Acarbose versus Metformin, Outcome 6 Change in LDL-cholesterol (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 3 Acarbose versus Metformin
Outcome: 6 Change in LDL-cholesterol (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID versus Metformin 850 mg BID
Hoffmann 1997 31 -0.89 (1.22) 31 0.05 (1.12) 100.0 % -0.94 [ -1.52, -0.36 ]
Total (95% CI) 31 31 100.0 % -0.94 [ -1.52, -0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.16 (P = 0.0016)
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Analysis 3.7. Comparison 3 Acarbose versus Metformin, Outcome 7 Change in triglycerides (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 3 Acarbose versus Metformin
Outcome: 7 Change in triglycerides (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID versus Metformin 850 mg BID
Hoffmann 1997 31 -0.4 (1.06) 31 -0.12 (1.02) 100.0 % -0.28 [ -0.80, 0.24 ]
Total (95% CI) 31 31 100.0 % -0.28 [ -0.80, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
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Analysis 3.8. Comparison 3 Acarbose versus Metformin, Outcome 8 Change in fasting insulin levels (pmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 3 Acarbose versus Metformin
Outcome: 8 Change in fasting insulin levels (pmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID versus Metformin 850 mg BID
Hoffmann 1997 31 -7.6 (123.8) 30 -41.4 (123.4) 100.0 % 33.80 [ -28.24, 95.84 ]
Total (95% CI) 31 30 100.0 % 33.80 [ -28.24, 95.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
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Analysis 3.9. Comparison 3 Acarbose versus Metformin, Outcome 9 Change in post-load insulin levels
(pmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 3 Acarbose versus Metformin
Outcome: 9 Change in post-load insulin levels (pmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID versus Metformin 850 mg BID
Hoffmann 1997 31 -117.6 (194.4) 30 -232.9 (304) 100.0 % 115.30 [ -13.22, 243.82 ]
Total (95% CI) 31 30 100.0 % 115.30 [ -13.22, 243.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.079)
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Analysis 3.10. Comparison 3 Acarbose versus Metformin, Outcome 10 Change in body weight (Kg).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 3 Acarbose versus Metformin
Outcome: 10 Change in body weight (Kg)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID versus Metformin 850 mg BID
Hoffmann 1997 31 -0.8 (11.2) 31 -0.5 (9.4) 100.0 % -0.30 [ -5.45, 4.85 ]
Total (95% CI) 31 31 100.0 % -0.30 [ -5.45, 4.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
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Analysis 3.11. Comparison 3 Acarbose versus Metformin, Outcome 11 Occurence of adverse effects.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 3 Acarbose versus Metformin
Outcome: 11 Occurence of adverse effects








Hoffmann 1997 16/32 2/32 100.0 % 15.00 [ 3.06, 73.58 ]
Total (95% CI) 32 32 100.0 % 15.00 [ 3.06, 73.58 ]
Total events: 16 (Acarbose), 2 (Metformin)
Heterogeneity: not applicable
Test for overall effect: Z = 3.34 (P = 0.00085)
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Analysis 4.1. Comparison 4 Acarbose versus nateglinide / repaglinide, Outcome 1 Change in glycated
haemoglobin (%).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 4 Acarbose versus nateglinide / repaglinide
Outcome: 1 Change in glycated haemoglobin (%)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID versus Nateglinide 120 mg TID
Holmes 2001 92 -0.39 (0.73) 87 -0.42 (0.74) 100.0 % 0.03 [ -0.19, 0.25 ]
Total (95% CI) 92 87 100.0 % 0.03 [ -0.19, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.78)
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Analysis 4.2. Comparison 4 Acarbose versus nateglinide / repaglinide, Outcome 2 Change in fasting blood
glucose (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 4 Acarbose versus nateglinide / repaglinide
Outcome: 2 Change in fasting blood glucose (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID versus Nateglinide 120 mg TID
Holmes 2001 89 -0.4 (3.8) 86 -0.38 (3.5) 100.0 % -0.02 [ -1.10, 1.06 ]
Total (95% CI) 89 86 100.0 % -0.02 [ -1.10, 1.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
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Analysis 4.3. Comparison 4 Acarbose versus nateglinide / repaglinide, Outcome 3 Change in body weight
(Kg).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 4 Acarbose versus nateglinide / repaglinide
Outcome: 3 Change in body weight (Kg)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Acarbose 100 mg TID versus Nateglinide 120 mg TID
Holmes 2001 88 -0.53 (2.06) 81 0.15 (2.07) 100.0 % -0.68 [ -1.30, -0.06 ]
Total (95% CI) 88 81 100.0 % -0.68 [ -1.30, -0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.032)
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Analysis 4.4. Comparison 4 Acarbose versus nateglinide / repaglinide, Outcome 4 Occurence of adverse
effects.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 4 Acarbose versus nateglinide / repaglinide
Outcome: 4 Occurence of adverse effects








1 Acarbose 100 mg TID versus Nateglinide 120 mg TID
Holmes 2001 60/92 43/87 100.0 % 1.92 [ 1.05, 3.50 ]
Total (95% CI) 92 87 100.0 % 1.92 [ 1.05, 3.50 ]
Total events: 60 (Acarbose), 43 (Nateglinide/Repagl.)
Heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.033)
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Analysis 4.5. Comparison 4 Acarbose versus nateglinide / repaglinide, Outcome 5 Occurence of gastro-
intestinal adverse effects.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 4 Acarbose versus nateglinide / repaglinide
Outcome: 5 Occurence of gastro-intestinal adverse effects








1 Acarbose 100 mg TID versus Nateglinide 120 mg TID
Holmes 2001 42/92 18/87 100.0 % 3.22 [ 1.66, 6.24 ]
Total (95% CI) 92 87 100.0 % 3.22 [ 1.66, 6.24 ]
Total events: 42 (Acarbose), 18 (Nateglinide/Repagl.)
Heterogeneity: not applicable
Test for overall effect: Z = 3.47 (P = 0.00053)
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Analysis 5.1. Comparison 5 Miglitol versus placebo, Outcome 1 Change in glycated haemoglobin (%).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 5 Miglitol versus placebo
Outcome: 1 Change in glycated haemoglobin (%)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 25 mg TID
Drent 2002 84 -0.06 (1) 87 0.4 (1.5) 15.1 % -0.46 [ -0.84, -0.08 ]
Subtotal (95% CI) 84 87 15.1 % -0.46 [ -0.84, -0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.37 (P = 0.018)
2 Miglitol 50 mg TID
Drent 2002 84 0.02 (1.5) 87 0.4 (1.5) 13.2 % -0.38 [ -0.83, 0.07 ]
Kawamori 2003 158 -0.35 (0.5) 84 0.25 (0.64) 21.5 % -0.60 [ -0.76, -0.44 ]
Subtotal (95% CI) 242 171 34.7 % -0.58 [ -0.72, -0.43 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.82, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 7.59 (P < 0.00001)
3 Miglitol 100 mg TID
Chiasson 2001 80 0.02 (0.9) 82 0.38 (1.1) 17.2 % -0.36 [ -0.67, -0.05 ]
Drent 2002 71 -0.46 (0.9) 87 0.4 (1.5) 15.2 % -0.86 [ -1.24, -0.48 ]
Johnston 1998b 30 -0.84 (1.1) 9 1 (1.8) 3.4 % -1.84 [ -3.08, -0.60 ]
Subtotal (95% CI) 181 178 35.8 % -0.79 [ -1.35, -0.22 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 7.97, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 2.71 (P = 0.0067)
4 Miglitol 200 mg TID
Drent 2002 58 -0.86 (1) 87 0.4 (1.5) 14.4 % -1.26 [ -1.67, -0.85 ]
Subtotal (95% CI) 58 87 14.4 % -1.26 [ -1.67, -0.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.07 (P < 0.00001)
Total (95% CI) 565 523 100.0 % -0.68 [ -0.93, -0.44 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 19.30, df = 6 (P = 0.004); I2 =69%
Test for overall effect: Z = 5.44 (P < 0.00001)
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Analysis 5.2. Comparison 5 Miglitol versus placebo, Outcome 2 Change in fasting blood glucose (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 5 Miglitol versus placebo
Outcome: 2 Change in fasting blood glucose (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 50 mg TID
Kawamori 2003 154 -0.6 (1.3) 82 0 (1.3) 83.8 % -0.60 [ -0.95, -0.25 ]
Subtotal (95% CI) 154 82 83.8 % -0.60 [ -0.95, -0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.38 (P = 0.00074)
2 Miglitol 100 mg TID (max)
Chiasson 2001 80 -0.1 (2.8) 82 0 (2.9) 16.2 % -0.10 [ -0.98, 0.78 ]
Subtotal (95% CI) 80 82 16.2 % -0.10 [ -0.98, 0.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
Total (95% CI) 234 164 100.0 % -0.52 [ -0.88, -0.16 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.08, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 2.82 (P = 0.0049)
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Analysis 5.3. Comparison 5 Miglitol versus placebo, Outcome 3 Change in post-load blood glucose (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 5 Miglitol versus placebo
Outcome: 3 Change in post-load blood glucose (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 50 mg TID
Kawamori 2003 154 -4.1 (2.6) 82 0 (1.9) 51.7 % -4.10 [ -4.68, -3.52 ]
Subtotal (95% CI) 154 82 51.7 % -4.10 [ -4.68, -3.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 13.83 (P < 0.00001)
2 Miglitol 100 mg TID (max)
Chiasson 2001 80 -0.9 (3.8) 82 0.3 (3.9) 48.3 % -1.20 [ -2.39, -0.01 ]
Subtotal (95% CI) 80 82 48.3 % -1.20 [ -2.39, -0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.047)
Total (95% CI) 234 164 100.0 % -2.70 [ -5.54, 0.14 ]
Heterogeneity: Tau2 = 3.98; Chi2 = 18.53, df = 1 (P = 0.00002); I2 =95%
Test for overall effect: Z = 1.86 (P = 0.063)
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Analysis 5.4. Comparison 5 Miglitol versus placebo, Outcome 4 Change in fasting insulin levels (pmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 5 Miglitol versus placebo
Outcome: 4 Change in fasting insulin levels (pmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 50 mg TID
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Miglitol 100 mg TID
Chiasson 2001 80 -18.5 (125.2) 82 -0.3 (126.8) 100.0 % -18.20 [ -57.01, 20.61 ]
Subtotal (95% CI) 80 82 100.0 % -18.20 [ -57.01, 20.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Total (95% CI) 80 82 100.0 % -18.20 [ -57.01, 20.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
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Analysis 5.5. Comparison 5 Miglitol versus placebo, Outcome 5 Change in post-load insulin levels (pmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 5 Miglitol versus placebo
Outcome: 5 Change in post-load insulin levels (pmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 50 mg TID
Kawamori 2003 154 -20.1 (126.3) 82 -4.3 (72.3) 79.6 % -15.80 [ -41.15, 9.55 ]
Subtotal (95% CI) 154 82 79.6 % -15.80 [ -41.15, 9.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
2 Miglitol 100 mg TID
Chiasson 2001 80 -68.2 (161.9) 82 -48.4 (163) 20.4 % -19.80 [ -69.83, 30.23 ]
Subtotal (95% CI) 80 82 20.4 % -19.80 [ -69.83, 30.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Total (95% CI) 234 164 100.0 % -16.62 [ -39.23, 6.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
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Analysis 5.6. Comparison 5 Miglitol versus placebo, Outcome 6 Change in body weight (Kg).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 5 Miglitol versus placebo
Outcome: 6 Change in body weight (Kg)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 100 mg TID
Chiasson 2001 80 -0.42 (2.6) 82 -0.69 (2.4) 100.0 % 0.27 [ -0.50, 1.04 ]
Total (95% CI) 80 82 100.0 % 0.27 [ -0.50, 1.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
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Analysis 5.7. Comparison 5 Miglitol versus placebo, Outcome 7 Total deaths.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 5 Miglitol versus placebo
Outcome: 7 Total deaths








1 Miglitol 25 mg TID
Johnston 1998 1/104 0/101 50.0 % 2.94 [ 0.12, 73.07 ]
Subtotal (95% CI) 104 101 50.0 % 2.94 [ 0.12, 73.07 ]
Total events: 1 (Miglitol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 Miglitol 50 mg TID
Johnston 1998 1/102 0/101 50.0 % 3.00 [ 0.12, 74.52 ]
Subtotal (95% CI) 102 101 50.0 % 3.00 [ 0.12, 74.52 ]
Total events: 1 (Miglitol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Total (95% CI) 206 202 100.0 % 2.97 [ 0.31, 28.80 ]
Total events: 2 (Miglitol), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
0.01 0.1 1 10 100
Favours miglitol Favours placebo
135Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.8. Comparison 5 Miglitol versus placebo, Outcome 8 Disease related deaths.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 5 Miglitol versus placebo
Outcome: 8 Disease related deaths








1 Miglitol 25 mg TID
Johnston 1998 1/104 0/101 2.94 [ 0.12, 73.07 ]
Subtotal (95% CI) 104 101 2.94 [ 0.12, 73.07 ]
Total events: 1 (Miglitol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 Miglitol 50 mg TID
Johnston 1998 0/102 0/101 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 102 101 0.0 [ 0.0, 0.0 ]
Total events: 0 (Miglitol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 206 202 2.94 [ 0.12, 73.07 ]
Total events: 1 (Miglitol), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
0.01 0.1 1 10 100
Favours miglitol Favours placebo
136Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.9. Comparison 5 Miglitol versus placebo, Outcome 9 Occurence of adverse effects.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 5 Miglitol versus placebo
Outcome: 9 Occurence of adverse effects








1 Miglitol 25 mg TID
Drent 2002 6/92 2/93 12.0 % 3.17 [ 0.62, 16.16 ]
Subtotal (95% CI) 92 93 12.0 % 3.17 [ 0.62, 16.16 ]
Total events: 6 (Miglitol), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
2 Miglitol 50 mg TID
Drent 2002 4/93 2/93 11.4 % 2.04 [ 0.37, 11.45 ]
Kawamori 2003 132/174 57/89 19.1 % 1.76 [ 1.01, 3.07 ]
Subtotal (95% CI) 267 182 30.5 % 1.79 [ 1.05, 3.03 ]
Total events: 136 (Miglitol), 59 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 2.16 (P = 0.031)
3 Miglitol 100 mg TID
Chiasson 2001 79/82 71/83 14.1 % 4.45 [ 1.21, 16.41 ]
Drent 2002 22/94 2/93 12.9 % 13.90 [ 3.16, 61.08 ]
Segal 1997 18/67 14/65 17.6 % 1.34 [ 0.60, 2.98 ]
Subtotal (95% CI) 243 241 44.6 % 3.93 [ 0.96, 16.12 ]
Total events: 119 (Miglitol), 87 (Placebo)
Heterogeneity: Tau2 = 1.18; Chi2 = 8.61, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 1.90 (P = 0.058)
4 Miglitol 200 mg TID
Drent 2002 40/93 2/93 13.0 % 34.34 [ 7.98, 147.86 ]
Subtotal (95% CI) 93 93 13.0 % 34.34 [ 7.98, 147.86 ]
Total events: 40 (Miglitol), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.75 (P < 0.00001)
Total (95% CI) 695 609 100.0 % 4.01 [ 1.69, 9.52 ]
Total events: 301 (Miglitol), 150 (Placebo)
Heterogeneity: Tau2 = 0.94; Chi2 = 24.19, df = 6 (P = 0.00048); I2 =75%
Test for overall effect: Z = 3.15 (P = 0.0016)
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Analysis 5.10. Comparison 5 Miglitol versus placebo, Outcome 10 Occurence of gastro-intestinal adverse
effects.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 5 Miglitol versus placebo
Outcome: 10 Occurence of gastro-intestinal adverse effects








1 Miglitol 50 mg TID
Kawamori 2003 98/174 32/89 54.4 % 2.30 [ 1.36, 3.89 ]
Subtotal (95% CI) 174 89 54.4 % 2.30 [ 1.36, 3.89 ]
Total events: 98 (Miglitol), 32 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.10 (P = 0.0020)
2 Miglitol 100 mg TID
Chiasson 2001 58/82 29/83 45.6 % 4.50 [ 2.34, 8.67 ]
Subtotal (95% CI) 82 83 45.6 % 4.50 [ 2.34, 8.67 ]
Total events: 58 (Miglitol), 29 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.50 (P < 0.00001)
Total (95% CI) 256 172 100.0 % 3.12 [ 1.62, 6.02 ]
Total events: 156 (Miglitol), 61 (Placebo)
Heterogeneity: Tau2 = 0.13; Chi2 = 2.46, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 3.40 (P = 0.00068)
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Analysis 5.11. Comparison 5 Miglitol versus placebo, Outcome 11 Change in post-load blood glucose
(mmol/l) (2-hours).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 5 Miglitol versus placebo
Outcome: 11 Change in post-load blood glucose (mmol/l) (2-hours)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 50 mg TID
Kawamori 2003 154 -1.5 (2.7) 82 0.2 (2.3) 79.9 % -1.70 [ -2.36, -1.04 ]
Subtotal (95% CI) 154 82 79.9 % -1.70 [ -2.36, -1.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.08 (P < 0.00001)
2 Miglitol 100 mg TID (max)
Chiasson 2001 80 -1.3 (4.2) 82 0.2 (4.3) 20.1 % -1.50 [ -2.81, -0.19 ]
Subtotal (95% CI) 80 82 20.1 % -1.50 [ -2.81, -0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.025)
Total (95% CI) 234 164 100.0 % -1.66 [ -2.25, -1.07 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 5.55 (P < 0.00001)
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Analysis 5.12. Comparison 5 Miglitol versus placebo, Outcome 12 Change in post-load insulin levels (pmol/l)
(2-hours).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 5 Miglitol versus placebo
Outcome: 12 Change in post-load insulin levels (pmol/l) (2-hours)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 50 mg TID
Kawamori 2003 154 -20.1 (126.3) 82 -4.3 (72.3) 81.8 % -15.80 [ -41.15, 9.55 ]
Subtotal (95% CI) 154 82 81.8 % -15.80 [ -41.15, 9.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
2 Miglitol 100 mg TID
Chiasson 2001 80 -63.6 (177.1) 82 -48.4 (172.1) 18.2 % -15.20 [ -68.99, 38.59 ]
Subtotal (95% CI) 80 82 18.2 % -15.20 [ -68.99, 38.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Total (95% CI) 234 164 100.0 % -15.69 [ -38.62, 7.24 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
-10 -5 0 5 10
Favours treatment Favours control
140Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.1. Comparison 6 Miglitol versus sulphonylurea (SU), Outcome 1 Change in glycated
haemoglobin (%).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 6 Miglitol versus sulphonylurea (SU)
Outcome: 1 Change in glycated haemoglobin (%)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 100 mg TID versus Glibenclamide 5 mg BID
Pagano 1995 45 -0.78 (1.4) 45 -1.18 (1.3) 100.0 % 0.40 [ -0.16, 0.96 ]
Total (95% CI) 45 45 100.0 % 0.40 [ -0.16, 0.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
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Analysis 6.2. Comparison 6 Miglitol versus sulphonylurea (SU), Outcome 2 Change in fasting blood glucose
(mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 6 Miglitol versus sulphonylurea (SU)
Outcome: 2 Change in fasting blood glucose (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 100 mg TID versus Glibenclamide 5 mg BID
Pagano 1995 45 -0.77 (2.19) 45 -1.04 (2.66) 100.0 % 0.27 [ -0.74, 1.28 ]
Total (95% CI) 45 45 100.0 % 0.27 [ -0.74, 1.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
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Analysis 6.3. Comparison 6 Miglitol versus sulphonylurea (SU), Outcome 3 Change in post-load blood
glucose (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 6 Miglitol versus sulphonylurea (SU)
Outcome: 3 Change in post-load blood glucose (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 100 mg TID versus Glibenclamide 5 mg BID
Pagano 1995 44 -2.21 (3.43) 44 -1.61 (8.94) 100.0 % -0.60 [ -3.43, 2.23 ]
Total (95% CI) 44 44 100.0 % -0.60 [ -3.43, 2.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
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Analysis 6.4. Comparison 6 Miglitol versus sulphonylurea (SU), Outcome 4 Change in total cholesterol
(mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 6 Miglitol versus sulphonylurea (SU)
Outcome: 4 Change in total cholesterol (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 100 mg TID versus Glibenclamide 5 mg BID
Pagano 1995 45 0.03 (0.85) 43 -0.05 (0.92) 100.0 % 0.08 [ -0.29, 0.45 ]
Total (95% CI) 45 43 100.0 % 0.08 [ -0.29, 0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
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Analysis 6.5. Comparison 6 Miglitol versus sulphonylurea (SU), Outcome 5 Change in HDL-cholesterol
(mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 6 Miglitol versus sulphonylurea (SU)
Outcome: 5 Change in HDL-cholesterol (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 100 mg TID versus Glibenclamide 5 mg BID
Pagano 1995 43 0 (0.22) 43 0.01 (0.82) 100.0 % -0.01 [ -0.26, 0.24 ]
Total (95% CI) 43 43 100.0 % -0.01 [ -0.26, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
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Analysis 6.6. Comparison 6 Miglitol versus sulphonylurea (SU), Outcome 6 Change in triglycerides (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 6 Miglitol versus sulphonylurea (SU)
Outcome: 6 Change in triglycerides (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 100 mg TID versus Glibenclamide 5 mg BID
Pagano 1995 44 -0.07 (0.82) 45 -0.03 (0.93) 100.0 % -0.04 [ -0.40, 0.32 ]
Total (95% CI) 44 45 100.0 % -0.04 [ -0.40, 0.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
-0.5 -0.25 0 0.25 0.5
Favours miglitol Favours SU
143Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.7. Comparison 6 Miglitol versus sulphonylurea (SU), Outcome 7 Change in fasting insulin levels
(pmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 6 Miglitol versus sulphonylurea (SU)
Outcome: 7 Change in fasting insulin levels (pmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 100 mg TID versus Glibenclamide 5 mg BID
Pagano 1995 45 -8.38 (20.95) 45 36.37 (22.45) 100.0 % -44.75 [ -53.72, -35.78 ]
Total (95% CI) 45 45 100.0 % -44.75 [ -53.72, -35.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.78 (P < 0.00001)
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Analysis 6.8. Comparison 6 Miglitol versus sulphonylurea (SU), Outcome 8 Change in body weight (Kg).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 6 Miglitol versus sulphonylurea (SU)
Outcome: 8 Change in body weight (Kg)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 100 mg TID versus Glibenclamide 5 mg BID
Pagano 1995 45 -0.79 (2.42) 45 -1.25 (2.14) 100.0 % 0.46 [ -0.48, 1.40 ]
Total (95% CI) 45 45 100.0 % 0.46 [ -0.48, 1.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
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Analysis 6.9. Comparison 6 Miglitol versus sulphonylurea (SU), Outcome 9 Total deaths.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 6 Miglitol versus sulphonylurea (SU)
Outcome: 9 Total deaths








1 Miglitol 25 mg versus Glyburide 20 mg 1dd
Johnston 1998 1/104 2/104 50.0 % 0.50 [ 0.04, 5.55 ]
Subtotal (95% CI) 104 104 50.0 % 0.50 [ 0.04, 5.55 ]
Total events: 1 (Miglitol), 2 (Sulphonylurea)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
2 Miglitol 50 mg versus Glyburide 20 mg 1dd
Johnston 1998 1/102 2/104 50.0 % 0.50 [ 0.05, 5.66 ]
Subtotal (95% CI) 102 104 50.0 % 0.50 [ 0.05, 5.66 ]
Total events: 1 (Miglitol), 2 (Sulphonylurea)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Total (95% CI) 206 208 100.0 % 0.50 [ 0.09, 2.76 ]
Total events: 2 (Miglitol), 4 (Sulphonylurea)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.43)
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Analysis 6.10. Comparison 6 Miglitol versus sulphonylurea (SU), Outcome 10 Disease related deaths.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 6 Miglitol versus sulphonylurea (SU)
Outcome: 10 Disease related deaths








1 Miglitol 25 mg versus Glyburide 20 mg 1dd
Johnston 1998 1/104 1/104 57.1 % 1.00 [ 0.06, 16.20 ]
Subtotal (95% CI) 104 104 57.1 % 1.00 [ 0.06, 16.20 ]
Total events: 1 (Miglitol), 1 (Sulphonylurea)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Miglitol 50 mg versus Glyburide 20 mg 1dd
Johnston 1998 0/102 1/104 42.9 % 0.34 [ 0.01, 8.36 ]
Subtotal (95% CI) 102 104 42.9 % 0.34 [ 0.01, 8.36 ]
Total events: 0 (Miglitol), 1 (Sulphonylurea)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Total (95% CI) 206 208 100.0 % 0.63 [ 0.08, 5.14 ]
Total events: 1 (Miglitol), 2 (Sulphonylurea)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
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Analysis 6.11. Comparison 6 Miglitol versus sulphonylurea (SU), Outcome 11 Occurence of adverse effects.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 6 Miglitol versus sulphonylurea (SU)
Outcome: 11 Occurence of adverse effects








1 Miglitol 100 mg TID versus Glibenclamide 5 mg BID
Pagano 1995 10/49 10/47 40.3 % 0.95 [ 0.35, 2.54 ]
Subtotal (95% CI) 49 47 40.3 % 0.95 [ 0.35, 2.54 ]
Total events: 10 (Miglitol), 10 (Sulphonylurea)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
2 Miglitol 100 mg TID versus Glibenclamide 3,5 mg BID
Segal 1997 18/67 13/69 59.7 % 1.58 [ 0.70, 3.56 ]
Subtotal (95% CI) 67 69 59.7 % 1.58 [ 0.70, 3.56 ]
Total events: 18 (Miglitol), 13 (Sulphonylurea)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Total (95% CI) 116 116 100.0 % 1.29 [ 0.69, 2.41 ]
Total events: 28 (Miglitol), 23 (Sulphonylurea)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
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Analysis 7.1. Comparison 7 Miglitol versus metformin, Outcome 1 Change in glycated haemoglobin (%).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 7 Miglitol versus metformin
Outcome: 1 Change in glycated haemoglobin (%)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 miglitol 100 mg TID vs metformin 500 TID (maximum)
Chiasson 2001 80 0.02 (0.9) 81 -0.85 (1.1) 100.0 % 0.87 [ 0.56, 1.18 ]
Total (95% CI) 80 81 100.0 % 0.87 [ 0.56, 1.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.50 (P < 0.00001)
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Analysis 7.2. Comparison 7 Miglitol versus metformin, Outcome 2 Change in fasting blood glucose (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 7 Miglitol versus metformin
Outcome: 2 Change in fasting blood glucose (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 100 mg TID vs Metformin 500 mg TID
Chiasson 2001 80 -0.1 (2.8) 81 -1.1 (2.5) 100.0 % 1.00 [ 0.18, 1.82 ]
Total (95% CI) 80 81 100.0 % 1.00 [ 0.18, 1.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.39 (P = 0.017)
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Analysis 7.3. Comparison 7 Miglitol versus metformin, Outcome 3 Change in post-load blood glucose
(mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 7 Miglitol versus metformin
Outcome: 3 Change in post-load blood glucose (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 100 mg TID vs Metformin 500 mg TID
Chiasson 2001 80 -0.9 (3.8) 81 -1.6 (3.5) 100.0 % 0.70 [ -0.43, 1.83 ]
Total (95% CI) 80 81 100.0 % 0.70 [ -0.43, 1.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
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Analysis 7.4. Comparison 7 Miglitol versus metformin, Outcome 4 Change in fasting insulin levels (pmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 7 Miglitol versus metformin
Outcome: 4 Change in fasting insulin levels (pmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Migitol 100 mg TID vs Metformin 500 mg TID
Chiasson 2001 80 -18.5 (125.2) 81 -17.4 (42.3) 100.0 % -1.10 [ -30.04, 27.84 ]
Total (95% CI) 80 81 100.0 % -1.10 [ -30.04, 27.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
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Analysis 7.5. Comparison 7 Miglitol versus metformin, Outcome 5 Change in post-load insulin levels
(pmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 7 Miglitol versus metformin
Outcome: 5 Change in post-load insulin levels (pmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 100 mg (max) TID vs Metformin 500 mg TID
Chiasson 2001 80 -68.2 (161.9) 81 -19.9 (135) 100.0 % -48.30 [ -94.38, -2.22 ]
Total (95% CI) 80 81 100.0 % -48.30 [ -94.38, -2.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.040)
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Analysis 7.6. Comparison 7 Miglitol versus metformin, Outcome 6 Change in body weight (Kg).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 7 Miglitol versus metformin
Outcome: 6 Change in body weight (Kg)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 100 mg TID vs Metformin 500 mg TID
Chiasson 2001 80 -0.42 (2.6) 81 -0.79 (3) 100.0 % 0.37 [ -0.50, 1.24 ]
Total (95% CI) 80 81 100.0 % 0.37 [ -0.50, 1.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
-4 -2 0 2 4
Favours miglitol Favours metformin
150Alpha-glucosidase inhibitors for type 2 diabetes mellitus (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.7. Comparison 7 Miglitol versus metformin, Outcome 7 Occurence of gastro-intestinal side-
effects.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 7 Miglitol versus metformin
Outcome: 7 Occurence of gastro-intestinal side-effects








1 Miglitol 100 mg TID vs Metformin 500 mg TID
Chiasson 2001 58/82 50/83 100.0 % 1.60 [ 0.83, 3.05 ]
Total (95% CI) 82 83 100.0 % 1.60 [ 0.83, 3.05 ]
Total events: 58 (Miglitol), 50 (Metformin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
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Analysis 7.8. Comparison 7 Miglitol versus metformin, Outcome 8 Occurence of adverse effects.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 7 Miglitol versus metformin
Outcome: 8 Occurence of adverse effects








1 Miglitol 100 mg TID vs Metformin 500 mg TID, Total side effects
Chiasson 2001 79/82 78/83 100.0 % 1.69 [ 0.39, 7.31 ]
Total (95% CI) 82 83 100.0 % 1.69 [ 0.39, 7.31 ]
Total events: 79 (Miglitol), 78 (Metformin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
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Analysis 7.9. Comparison 7 Miglitol versus metformin, Outcome 9 Change in post-load blood glucose
(mmol/l) (2 hours).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 7 Miglitol versus metformin
Outcome: 9 Change in post-load blood glucose (mmol/l) (2 hours)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 100 mg TID vs Metformin 500 mg TID
Chiasson 2001 80 -1.3 (4.2) 81 -2.1 (3.9) 100.0 % 0.80 [ -0.45, 2.05 ]
Total (95% CI) 80 81 100.0 % 0.80 [ -0.45, 2.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
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Analysis 7.10. Comparison 7 Miglitol versus metformin, Outcome 10 Change in post-load insulin levels
(pmol/l) (2-hours).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 7 Miglitol versus metformin
Outcome: 10 Change in post-load insulin levels (pmol/l) (2-hours)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 100 mg (max) TID vs Metformin 500 mg TID
Chiasson 2001 80 -63.3 (177.1) 81 3.9 (133.2) 100.0 % -67.20 [ -115.65, -18.75 ]
Total (95% CI) 80 81 100.0 % -67.20 [ -115.65, -18.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.72 (P = 0.0066)
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Analysis 8.1. Comparison 8 Voglibose versus placebo, Outcome 1 Change in glycated haemoglobin (%).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 8 Voglibose versus placebo
Outcome: 1 Change in glycated haemoglobin (%)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Voglibose 0.2 mg TID
Kawamori 2003 154 -0.22 (0.5) 84 0.25 (0.64) 100.0 % -0.47 [ -0.63, -0.31 ]
Subtotal (95% CI) 154 84 100.0 % -0.47 [ -0.63, -0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.83 (P < 0.00001)
2 Voglibose 0,3 mg TID
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 154 84 100.0 % -0.47 [ -0.63, -0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.83 (P < 0.00001)
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Analysis 8.2. Comparison 8 Voglibose versus placebo, Outcome 2 Change in fasting blood glucose (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 8 Voglibose versus placebo
Outcome: 2 Change in fasting blood glucose (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Voglibose 0.2 mg TID
Kawamori 2003 152 -0.6 (1.5) 82 0 (1.3) 100.0 % -0.60 [ -0.97, -0.23 ]
Subtotal (95% CI) 152 82 100.0 % -0.60 [ -0.97, -0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.19 (P = 0.0014)
2 Voglibose 0,3 mg TID
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 152 82 100.0 % -0.60 [ -0.97, -0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.19 (P = 0.0014)
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Analysis 8.3. Comparison 8 Voglibose versus placebo, Outcome 3 Change in post-load blood glucose
(mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 8 Voglibose versus placebo
Outcome: 3 Change in post-load blood glucose (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Voglibose 0.2 mg TID
Kawamori 2003 152 -2.4 (2.5) 82 0 (1.9) 100.0 % -2.40 [ -2.97, -1.83 ]
Total (95% CI) 152 82 100.0 % -2.40 [ -2.97, -1.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.23 (P < 0.00001)
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Analysis 8.4. Comparison 8 Voglibose versus placebo, Outcome 4 Change in post-load insulin levels (pmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 8 Voglibose versus placebo
Outcome: 4 Change in post-load insulin levels (pmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Voglibose 0.2 mg TID
Kawamori 2003 152 -17.2 (115.8) 82 -4.3 (72.3) 100.0 % -12.90 [ -37.06, 11.26 ]
Total (95% CI) 152 82 100.0 % -12.90 [ -37.06, 11.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.30)
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Analysis 8.5. Comparison 8 Voglibose versus placebo, Outcome 5 Occurence of adverse effects.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 8 Voglibose versus placebo
Outcome: 5 Occurence of adverse effects








1 Voglibose 0,2 mg TID
Kawamori 2003 117/174 57/89 100.0 % 1.15 [ 0.67, 1.97 ]
Total (95% CI) 174 89 100.0 % 1.15 [ 0.67, 1.97 ]
Total events: 117 (Voglibose), 57 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
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Analysis 8.6. Comparison 8 Voglibose versus placebo, Outcome 6 Occurence of gastro-intestinal adverse
effects.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 8 Voglibose versus placebo
Outcome: 6 Occurence of gastro-intestinal adverse effects








1 Voglibose 0,2 mg TID
Kawamori 2003 83/174 32/89 100.0 % 1.62 [ 0.96, 2.75 ]
Total (95% CI) 174 89 100.0 % 1.62 [ 0.96, 2.75 ]
Total events: 83 (Voglibose), 32 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
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Analysis 8.7. Comparison 8 Voglibose versus placebo, Outcome 7 Change in post-load blood glucose
(mmol/l) (2 hours).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 8 Voglibose versus placebo
Outcome: 7 Change in post-load blood glucose (mmol/l) (2 hours)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Voglibose 0.2 mg TID
Kawamori 2003 152 -1.5 (2.8) 82 0.2 (2.3) 100.0 % -1.70 [ -2.37, -1.03 ]
Total (95% CI) 152 82 100.0 % -1.70 [ -2.37, -1.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.99 (P < 0.00001)
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Analysis 9.1. Comparison 9 Voglibose versus diet therapy, Outcome 1 Change in glycated haemoglobin (%).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 9 Voglibose versus diet therapy
Outcome: 1 Change in glycated haemoglobin (%)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Voglibose 0,3 mg TID
Takami 2002 12 -1.7 (1.6) 11 -1.7 (1.2) 100.0 % 0.0 [ -1.15, 1.15 ]
Total (95% CI) 12 11 100.0 % 0.0 [ -1.15, 1.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 9.2. Comparison 9 Voglibose versus diet therapy, Outcome 2 Change in fasting blood glucose
(mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 9 Voglibose versus diet therapy
Outcome: 2 Change in fasting blood glucose (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Voglibose 0,3 mg TID
Takami 2002 12 -3.3 (3.6) 11 -0.9 (1.3) 100.0 % -2.40 [ -4.58, -0.22 ]
Total (95% CI) 12 11 100.0 % -2.40 [ -4.58, -0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.031)
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Analysis 9.3. Comparison 9 Voglibose versus diet therapy, Outcome 3 Change in total cholesterol (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 9 Voglibose versus diet therapy
Outcome: 3 Change in total cholesterol (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Voglibose 0,3 mg TID
Takami 2002 12 -1.2 (1.3) 11 -0.5 (1) 100.0 % -0.70 [ -1.64, 0.24 ]
Total (95% CI) 12 11 100.0 % -0.70 [ -1.64, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
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Analysis 9.4. Comparison 9 Voglibose versus diet therapy, Outcome 4 Change in HDL-cholesterol (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 9 Voglibose versus diet therapy
Outcome: 4 Change in HDL-cholesterol (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Voglibose 0,3 mg TID
Takami 2002 12 -0.2 (0.5) 11 0.2 (0.5) 100.0 % -0.40 [ -0.81, 0.01 ]
Total (95% CI) 12 11 100.0 % -0.40 [ -0.81, 0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
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Analysis 9.5. Comparison 9 Voglibose versus diet therapy, Outcome 5 Change in fasting insulin levels
(pmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 9 Voglibose versus diet therapy
Outcome: 5 Change in fasting insulin levels (pmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Voglibose 0,3 mg TID
Takami 2002 12 -15.4 (12.4) 11 -21.4 (41) 100.0 % 6.00 [ -19.22, 31.22 ]
Total (95% CI) 12 11 100.0 % 6.00 [ -19.22, 31.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
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Analysis 9.6. Comparison 9 Voglibose versus diet therapy, Outcome 6 Change in body weight (Kg).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 9 Voglibose versus diet therapy
Outcome: 6 Change in body weight (Kg)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Voglibose 0,3 mg TID
Takami 2002 12 -2.5 (5.4) 11 -2.7 (7.1) 100.0 % 0.20 [ -4.99, 5.39 ]
Total (95% CI) 12 11 100.0 % 0.20 [ -4.99, 5.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
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Analysis 9.7. Comparison 9 Voglibose versus diet therapy, Outcome 7 Change in body mass index (Kg/m2).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 9 Voglibose versus diet therapy
Outcome: 7 Change in body mass index (Kg/m2)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Voglibose 0,3 mg TID
Takami 2002 12 -1.1 (3.2) 11 -1.1 (2.3) 100.0 % 0.0 [ -2.26, 2.26 ]
Total (95% CI) 12 11 100.0 % 0.0 [ -2.26, 2.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 10.1. Comparison 10 .Voglibose versus sulphonylurea (SU), Outcome 1 Change in glycated
haemoglobin (%).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 10 .Voglibose versus sulphonylurea (SU)
Outcome: 1 Change in glycated haemoglobin (%)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Voglibose 0,3 mg TID vs Glyburide 1,25 mg once daily
Takami 2002 12 -1.7 (1.6) 9 -3 (2.3) 100.0 % 1.30 [ -0.45, 3.05 ]
Total (95% CI) 12 9 100.0 % 1.30 [ -0.45, 3.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
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Analysis 10.2. Comparison 10 .Voglibose versus sulphonylurea (SU), Outcome 2 Change in fasting blood
glucose (mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 10 .Voglibose versus sulphonylurea (SU)
Outcome: 2 Change in fasting blood glucose (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Voglibose 0,3 mg TID vs Glyburide 1,25 mg once daily
Takami 2002 12 -3.3 (3.6) 9 -2.8 (2.6) 100.0 % -0.50 [ -3.15, 2.15 ]
Total (95% CI) 12 9 100.0 % -0.50 [ -3.15, 2.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
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Analysis 10.3. Comparison 10 .Voglibose versus sulphonylurea (SU), Outcome 3 Change in total cholesterol
(mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 10 .Voglibose versus sulphonylurea (SU)
Outcome: 3 Change in total cholesterol (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Voglibose 0,3 mg TID vs Glyburide 1,25 mg once daily
Takami 2002 12 -1.2 (1.3) 9 -1.3 (1.5) 100.0 % 0.10 [ -1.13, 1.33 ]
Total (95% CI) 12 9 100.0 % 0.10 [ -1.13, 1.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
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Analysis 10.4. Comparison 10 .Voglibose versus sulphonylurea (SU), Outcome 4 Change in HDL-cholesterol
(mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 10 .Voglibose versus sulphonylurea (SU)
Outcome: 4 Change in HDL-cholesterol (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Voglibose 0,3 mg TID vs Glyburide 1,25 mg once daily
Takami 2002 12 -0.2 (0.5) 9 0 (0.4) 100.0 % -0.20 [ -0.59, 0.19 ]
Total (95% CI) 12 9 100.0 % -0.20 [ -0.59, 0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
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Analysis 10.5. Comparison 10 .Voglibose versus sulphonylurea (SU), Outcome 5 Change in fasting insulin
levels (pmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 10 .Voglibose versus sulphonylurea (SU)
Outcome: 5 Change in fasting insulin levels (pmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Voglibose 0,3 mg TID vs Glyburide 1,25 mg once daily
Takami 2002 12 -15.4 (12.4) 9 -3.6 (18) 100.0 % -11.80 [ -25.49, 1.89 ]
Total (95% CI) 12 9 100.0 % -11.80 [ -25.49, 1.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
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Analysis 10.6. Comparison 10 .Voglibose versus sulphonylurea (SU), Outcome 6 Change in body weight
(Kg).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 10 .Voglibose versus sulphonylurea (SU)
Outcome: 6 Change in body weight (Kg)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Voglibose 0,3 mg TID vs Glyburide 1,25 mg once daily
Takami 2002 12 -2.5 (5.4) 9 -3.1 (15.1) 100.0 % 0.60 [ -9.73, 10.93 ]
Total (95% CI) 12 9 100.0 % 0.60 [ -9.73, 10.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
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Analysis 10.7. Comparison 10 .Voglibose versus sulphonylurea (SU), Outcome 7 Change in body mass index
(Kg/m2).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 10 .Voglibose versus sulphonylurea (SU)
Outcome: 7 Change in body mass index (Kg/m2)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Voglibose 0,3 mg TID vs Glyburide 1,25 mg once daily
Takami 2002 12 -1.1 (3.2) 9 -1.1 (2.4) 100.0 % 0.0 [ -2.40, 2.40 ]
Total (95% CI) 12 9 100.0 % 0.0 [ -2.40, 2.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 11.1. Comparison 11 Miglitol versus voglibose, Outcome 1 Change in glycated haemoglobin (%).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 11 Miglitol versus voglibose
Outcome: 1 Change in glycated haemoglobin (%)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 50 mg TID versus Voglibose 0.2 mg TID
Kawamori 2003 158 -0.35 (0.5) 154 -0.22 (0.5) 100.0 % -0.13 [ -0.24, -0.02 ]
Total (95% CI) 158 154 100.0 % -0.13 [ -0.24, -0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.30 (P = 0.022)
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Analysis 11.2. Comparison 11 Miglitol versus voglibose, Outcome 2 Change in fasting blood glucose
(mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 11 Miglitol versus voglibose
Outcome: 2 Change in fasting blood glucose (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 50 mg TID versus Voglibose 0.2 mg TID
Kawamori 2003 154 -0.6 (1.3) 152 -0.6 (1.5) 100.0 % 0.0 [ -0.31, 0.31 ]
Total (95% CI) 154 152 100.0 % 0.0 [ -0.31, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 11.3. Comparison 11 Miglitol versus voglibose, Outcome 3 Change in post-load blood glucose
(mmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 11 Miglitol versus voglibose
Outcome: 3 Change in post-load blood glucose (mmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 50 mg TID versus Voglibose 0.2 mg TID
Kawamori 2003 154 -4.1 (2.6) 152 -2.4 (2.5) 100.0 % -1.70 [ -2.27, -1.13 ]
Total (95% CI) 154 152 100.0 % -1.70 [ -2.27, -1.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.83 (P < 0.00001)
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Analysis 11.4. Comparison 11 Miglitol versus voglibose, Outcome 4 Change in post-load insulin levels
(pmol/l).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 11 Miglitol versus voglibose
Outcome: 4 Change in post-load insulin levels (pmol/l)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Miglitol 50 mg TID versus Voglibose 0.2 mg TID
Kawamori 2003 154 -20.1 (126.3) 152 -17.2 (115.8) 100.0 % -2.90 [ -30.04, 24.24 ]
Total (95% CI) 154 152 100.0 % -2.90 [ -30.04, 24.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
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Analysis 11.5. Comparison 11 Miglitol versus voglibose, Outcome 5 Occurence of adverse effects.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 11 Miglitol versus voglibose
Outcome: 5 Occurence of adverse effects








1 Miglitol 50 mg TID versus Voglibose 0.2 mg TID
Kawamori 2003 132/174 117/174 100.0 % 1.53 [ 0.96, 2.45 ]
Total (95% CI) 174 174 100.0 % 1.53 [ 0.96, 2.45 ]
Total events: 132 (Miglitol), 117 (Voglibose)
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.076)
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Analysis 11.6. Comparison 11 Miglitol versus voglibose, Outcome 6 Occurence of gastro-intestinal adverse
effects.
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 11 Miglitol versus voglibose
Outcome: 6 Occurence of gastro-intestinal adverse effects








1 Miglitol 50 mg TID versus Voglibose 0.2 mg TID
Kawamori 2003 98/174 83/174 100.0 % 1.41 [ 0.93, 2.16 ]
Total (95% CI) 174 174 100.0 % 1.41 [ 0.93, 2.16 ]
Total events: 98 (Miglitol), 83 (Voglibose)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
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Analysis 11.7. Comparison 11 Miglitol versus voglibose, Outcome 7 Change in post-load blood glucose
(mmol/l) (2 hours).
Review: Alpha-glucosidase inhibitors for type 2 diabetes mellitus
Comparison: 11 Miglitol versus voglibose
Outcome: 7 Change in post-load blood glucose (mmol/l) (2 hours)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kawamori 2003 158 -1.5 (2.7) 154 -1.5 (2.8) 100.0 % 0.0 [ -0.61, 0.61 ]
Total (95% CI) 158 154 100.0 % 0.0 [ -0.61, 0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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A D D I T I O N A L T A B L E S
Table 1. Methods post-load glucose / insulin measurement
Study Type of test Interval Data used Medication given?
Braun 1996 Breakfast (’no special
meals’)
1 hour 1 hour glucose unclear
Buchanan 1988 No post-load test
Calle-Pascual 1996 No post-load test
Campbell 1998 No post-load test
Chan 1998 Individually tailored meal
recommended by dieti-
cian (60% carbohydrate,
<30% fat, 12-20% pro-
tein)
1 hour 1 hour glucose & insulin yes (at least at 24 weeks
measurement)
Chiasson 1994 Standard breakfast: 450
kcal, 55% carbohydrates,
30.5% lipids, 14.5% pro-
tein
1, 1.5 and 2 hours mea-
sured
Data not reported yes
Chiasson 2001 Standardised liquid test
breakfast (55% carbohy-
drate, 30% fat, and 15%
1, 1.5 and 2 hours mea-
sured and reported
1 hour (2 hours value
in sensitivity analysis) glu-
cose & insulin
yes
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Table 1. Methods post-load glucose / insulin measurement (Continued)
protein; providing ~450
kcal)
Coniff 1994 Breakfast, 2520 kJ, with
50% carbohydrates, 30%
fat, 20% protein
1, 1.5 and 2 hours mea-
sured and reported
1 hour (2 hours value
in sensitivity analysis) glu-
cose
yes
Coniff 1995 Full-meal tolerance test:
600 kcal breakfast (50%
carbohydrate, 30% fat,
20% protein
1, 1.5 and 2 hours mea-
sured and reported
1 hour (2 hours value
in sensitivity analysis) glu-
cose & insulin
yes
Coniff 1995b Standardised meal toler-
ance test, 600-kcal break-
fast of 50% carbohydrates
(75g), 30% fat (20g),
20% protein (30g)
1, 1.5 and 2 hours mea-
sured and reported
1 hour (2 hours value
in sensitivity analysis) glu-
cose & insulin
yes
Dedov 1995 Post-load test performed,
type of test unclear
1 hour 1 hour glucose unclear
Delgado 2002 Post-load test performed,
type of test unclear
Not reported post-load glucose unclear
Drent 2002 White bread, margarine,
diet jam and cheese, 1556
kJ, 49% carbohydrate,
40% fat, 11% protein, 2,
5 g fibre
1, 1.5 and 2 hours mea-
sured
Data not reported yes
Fischer 1998 Test meal 1562 kJ, 49%
carbohydrate, 40% fat,
11% protein (80 g white
bread, 10g spread, 25g
diet jam, 20 g 45% fat
cheese)
1 hour measured and re-
ported (2 hours value
measured but not re-
ported adequately)
1 hour glucose yes
Gentile 1999 Home cooked breakfast,
lunch and diner
2 hours (after diner also
after 4 hours) measured,
not reported adequately
Data not reported unclear
Haffner 1997 Standardised
breakfast (370 kcal; 49%
carbohydrates, 40 % fat,
11% protein)
1 hour measured and re-
ported
1 hour glucose & insulin unclear
Hanefeld 1991 Testmeal: 400 kcal (50%
carbohydrates, 35% fat,
15% protein)
1 hour measured and re-
ported (2, 3, 4 and5hours
also measured but not re-
1 hour glucose & insulin yes
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Table 1. Methods post-load glucose / insulin measurement (Continued)
ported)
Hillebrand 1987 Unclear Measurement at 11 AM
and 5 AM, interval not
clear
Data not adequately re-
ported
unclear
Hoffmann 1990 Standard breakfast: 80 g
bread, 20g low fat spread,
25g marmalade, 20 g
cheese (45% fat), 1 egg
1 hour measured and re-
ported
1 hour glucose yes
Hoffmann 1994 Standardised breakfast: 1,
569 kJ (372 Kcal), 49%
energy as (mainly com-
plex) carbohydrates, 40%
fat, 11% protein
1 hour measured and re-
ported
1 hour glucose & insulin yes
Hoffmann 1997 Standardised breakfast: 1,
569 kJ (372 Kcal), 49%
energy as (mainly com-
plex) carbohydrates, 40%
fat, 11% protein
1 hour measured and re-
ported
1 hour glucose & insulin yes
Holman 1999 No post-load test
Holmes 2001 No post-load test
Hotta 1993 75 grams Oral Glucose
Tolerance Test
0.5, 1, 2 and 3 hours mea-
sured
2hours glucose, 0.5, 1 and
3 hours not reported ade-
quately
yes
Johnston 1998 Standardised test meal:
480 calories, 51% carbo-
hydrates
1, 1.5 and 2 hours mea-
sured
Data not reported ade-
quately
unclear
Johnston 1998a Standard 483 kcal, 51%
carbohydrate mixed-meal
breakfast
2 hours measured Data not reported ade-
quately
unclear
Johnston 1998b Standard 438 kcal, 51%
carbohydrate, 14% pro-
tein, 35% fat meal
2 hours measured Data not reported ade-
quately
unclear
Kawamori 2003 ’meal-loading test’ 1 and 2 hours measured
and reported
1 hour (2 hours value
in sensitivity analysis) glu-
cose & insulin
unclear
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Table 1. Methods post-load glucose / insulin measurement (Continued)
Kovacevic 1997 Full meal tolerance test:
80 g white bread; 10 g
butter, 25 g diet mar-
malade (with 23% fruc-
tose); 20 g cheese (45%
fat); 250 ml coffee or tea
1 hour measured and re-
ported
1 hour glucose & insulin unclear
Meneilly 2000 400 ml Ensure™with fi-
bre (450 kcal, 55% carbo-
hydrate, 30% fat and15%
protein)
1, 1.5 and 2 hours mea-
sured
Data not reported ade-
quately
yes
Pagano 1995 Standard breakfast, with
125 g fruit juice, 75 g ham
and 80 g white bread (590
kcal, 44% carbohydrates,
41% lipids, 15% protein)
0.5, 1,2 and 3 hours mea-
sured and reported, 0.5, 1,
and 3 hours measured
2 hour glucose, 0.5, 1 and
3 hours not reported ade-
quately
yes (not with respect to
glibencamide)
Rosenthal 2002 Standard breakfast: 80g
bread, 20 g low fat spread,
25 g marmalade, 20 g
cheese (45%), 1 egg
1 hour measured and re-
ported
1 hour glucose & insulin yes
Rybka 1999 Unclear 1 hour measured Data not reported ade-
quately
unclear
Salman 2001 Breakfast which was pre-
pared by an experienced
dietician according to in-
dividual needs
1.5 hours measured and
reported
1.5 hours glucose, insulin
& c-peptide
no
Santeusanio 1993 Mixed meal test, consist-
ing 440 calories, as 30%
protein, 20% lipid and
50% carbohydrate
1, 2 and 3 hours measured
and reported (0.5 hours
not reported)
1 hour (2 hours value
in sensitivity analysis) glu-
cose & insulin
unclear
Scott 1999 Standardised breakfast
meal (1.6 MJ)
1 and 2 hours measured Data not reported ade-
quately
unclear
Segal 1997 Standardised break-
fast test meal (372 kcal;
49% carbohydrate, 40%
fat, 11% protein)
1 and 2 hour measured Data not reported ade-
quately
unclear
Spengler 1992 Standard breakfast: 80 g,
20 g low fat spread, 25 g
marmelade, 20 g cheese, 1
egg
1 hour measured Data not reported ade-
quately
yes
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Table 1. Methods post-load glucose / insulin measurement (Continued)
Takami 2002 No post-load test
Van de Laar 2004a 75 grams Oral Glucose
Tolerance Test
1 hour mesured and re-
ported
1 hour glucose & insulin no
Zheng 1995 ’meal’ 1 hour measured and re-
ported
1 hour glucose & insulin unclear
A P P E N D I C E S
Appendix 1. Search strategy
Search terms
Unless otherwise stated, search terms are free text terms; MeSH = Medical subject heading (Medline medical index term); exp =
exploded MeSH; the dollar sign ($) stands for any character(s); the question mark (?) = to substitute for one or no characters; tw =
text word; pt = publication type; sh = MeSH; adj = adjacent
1 TYPE 2 DIABETES MELLITUS (see Metabolic and Endocrine Disorders Group search strategy)
ACARBOSE
2 Acarbose [MeSH, all subheadings included]
3 acarbose OR (alph* glucos* inh*) OR (alf* glucos* inh*) OR glucobay OR precos* OR prandas* OR akarbos*
4 #2 or #3
TYPE 2 DIABETES MELLITUS AND ACARBOSE
5 #1 AND #4
CLINICAL TRIALS
6 See Metabolic and Endocrine Disorders Group search strategy
TYPE 2 DIABETES AND ACARBOSE AND CLINICAL TRIALS
7 #5 AND #6
Appendix 2. Methods post-load glucose / insulin measurement
Study Type of test Interval Data used Medication given?
Braun 1996 Breakfast (’no special
meals’)
1 hour 1 hour glucose unclear
Buchanan 1988 No post-load test
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Calle-Pascual 1996 No post-load test
Campbell 1998 No post-load test
Chan 1998 Individually tailored meal
recommended by dieti-
cian (60% carbohydrate,
<30% fat, 12-20% pro-
tein)
1 hour 1 hour glucose & insulin yes (at least at 24 weeks
measurement)
Chiasson 1994 Standard breakfast: 450
kcal, 55% carbohydrates,
30.5% lipids, 14.5% pro-
tein
1, 1.5 and 2 hours mea-
sured
Data not reported yes
Chiasson 2001 Standardised liquid test
breakfast (55% carbohy-
drate, 30% fat, and 15%
protein; providing ~450
kcal)
1, 1.5 and 2 hours mea-
sured and reported
1 hour (2 hours value
in sensitivity analysis) glu-
cose & insulin
yes
Coniff 1994 Breakfast, 2520 kJ, with
50% carbohydrates, 30%
fat, 20% protein
1, 1.5 and 2 hours mea-
sured and reported
1 hour (2 hours value
in sensitivity analysis) glu-
cose
yes
Coniff 1995 Full-meal tolerance test:
600 kcal breakfast (50%
carbohydrate, 30% fat,
20% protein
1, 1.5 and 2 hours mea-
sured and reported
1 hour (2 hours value
in sensitivity analysis) glu-
cose & insulin
yes
Coniff 1995b Standardised meal toler-
ance test, 600-kcal break-
fast of 50% carbohydrates
(75g), 30% fat (20g),
20% protein (30g)
1, 1.5 and 2 hours mea-
sured and reported
1 hour (2 hours value
in sensitivity analysis) glu-
cose & insulin
yes
Dedov 1995 Post-load test performed,
type of test unclear
1 hour 1 hour glucose unclear
Delgado 2002 Post-load test performed,
type of test unclear
Not reported post-load glucose unclear
Drent 2002 White bread, margarine,
diet jam and cheese, 1556
kJ, 49% carbohydrate,
40% fat, 11% protein, 2,
5 g fibre
1, 1.5 and 2 hours mea-
sured
Data not reported yes
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Fischer 1998 Test meal 1562 kJ, 49%
carbohydrate, 40% fat,
11% protein (80 g white
bread, 10g spread, 25g
diet jam, 20 g 45% fat
cheese)
1 hour measured and re-
ported (2 hours value
measured but not re-
ported adequately)
1 hour glucose yes
Gentile 1999 Home cooked breakfast,
lunch and diner
2 hours (after diner also
after 4 hours) measured,
not reported adequately
Data not reported unclear
Haffner 1997 Standardised
breakfast (370 kcal; 49%
carbohydrates, 40 % fat,
11% protein)
1 hour measured and re-
ported
1 hour glucose & insulin unclear
Hanefeld 1991 Testmeal: 400 kcal (50%
carbohydrates, 35% fat,
15% protein)
1 hour measured and re-
ported (2, 3, 4 and5hours
also measured but not re-
ported)
1 hour glucose & insulin yes
Hillebrand 1987 Unclear Measurement at 11 AM
and 5 AM, interval not
clear
Data not adequately re-
ported
unclear
Hoffmann 1990 Standard breakfast: 80 g
bread, 20g low fat spread,
25g marmalade, 20 g
cheese (45% fat), 1 egg
1 hour measured and re-
ported
1 hour glucose yes
Hoffmann 1994 Standardised breakfast: 1,
569 kJ (372 Kcal), 49%
energy as (mainly com-
plex) carbohydrates, 40%
fat, 11% protein
1 hour measured and re-
ported
1 hour glucose & insulin yes
Hoffmann 1997 Standardised breakfast: 1,
569 kJ (372 Kcal), 49%
energy as (mainly com-
plex) carbohydrates, 40%
fat, 11% protein
1 hour measured and re-
ported
1 hour glucose & insulin yes
Holman 1999 No post-load test
Holmes 2001 No post-load test
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Hotta 1993 75 grams Oral Glucose
Tolerance Test
0.5, 1, 2 and 3 hours mea-
sured
2hours glucose, 0.5, 1 and
3 hours not reported ade-
quately
yes
Johnston 1998 Standardised test meal:
480 calories, 51% carbo-
hydrates
1, 1.5 and 2 hours mea-
sured
Data not reported ade-
quately
unclear
Johnston 1998a Standard 483 kcal, 51%
carbohydrate mixed-meal
breakfast
2 hours measured Data not reported ade-
quately
unclear
Johnston 1998b Standard 438 kcal, 51%
carbohydrate, 14% pro-
tein, 35% fat meal
2 hours measured Data not reported ade-
quately
unclear
Kawamori 2003 ’meal-loading test’ 1 and 2 hours measured
and reported
1 hour (2 hours value
in sensitivity analysis) glu-
cose & insulin
unclear
Kovacevic 1997 Full meal tolerance test:
80 g white bread; 10 g
butter, 25 g diet mar-
malade (with 23% fruc-
tose); 20 g cheese (45%
fat); 250 ml coffee or tea
1 hour measured and re-
ported
1 hour glucose & insulin unclear
Meneilly 2000 400 ml Ensure™with fi-
bre (450 kcal, 55% carbo-
hydrate, 30% fat and15%
protein)
1, 1.5 and 2 hours mea-
sured
Data not reported ade-
quately
yes
Pagano 1995 Standard breakfast, with
125 g fruit juice, 75 g ham
and 80 g white bread (590
kcal, 44% carbohydrates,
41% lipids, 15% protein)
0.5, 1,2 and 3 hours mea-
sured and reported, 0.5, 1,
and 3 hours measured
2 hour glucose, 0.5, 1 and
3 hours not reported ade-
quately
yes (not with respect to
glibencamide)
Rosenthal 2002 Standard breakfast: 80g
bread, 20 g low fat spread,
25 g marmalade, 20 g
cheese (45%), 1 egg
1 hour measured and re-
ported
1 hour glucose & insulin yes
Rybka 1999 Unclear 1 hour measured Data not reported ade-
quately
unclear
Salman 2001 Breakfast which was pre-
pared by an experienced
1.5 hours measured and
reported
1.5 hours glucose, insulin
& c-peptide
no
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dietician according to in-
dividual needs
Santeusanio 1993 Mixed meal test, consist-
ing 440 calories, as 30%
protein, 20% lipid and
50% carbohydrate
1, 2 and 3 hours measured
and reported (0.5 hours
not reported)
1 hour (2 hours value
in sensitivity analysis) glu-
cose & insulin
unclear
Scott 1999 Standardised breakfast
meal (1.6 MJ)
1 and 2 hours measured Data not reported ade-
quately
unclear
Segal 1997 Standardised break-
fast test meal (372 kcal;
49% carbohydrate, 40%
fat, 11% protein)
1 and 2 hour measured Data not reported ade-
quately
unclear
Spengler 1992 Standard breakfast: 80 g,
20 g low fat spread, 25 g
marmelade, 20 g cheese, 1
egg
1 hour measured Data not reported ade-
quately
yes
Takami 2002 No post-load test
Van de Laar 2004a 75 grams Oral Glucose
Tolerance Test
1 hour mesured and re-
ported
1 hour glucose & insulin no
Zheng 1995 ’meal’ 1 hour measured and re-
ported
1 hour glucose & insulin unclear
WH A T ’ S N E W
Last assessed as up-to-date: 29 April 2003.
Date Event Description
31 October 2008 Amended Converted to new review format.
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1 September 2004 Amended We received additional data for the Holman (1999) study on September 1st 2004. The information
is added. (see Table of included studies, comparisons tables and study quality)
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